

# UC San Diego

## UC San Diego Previously Published Works

**Title**

Antibiotics and Bacterial Resistance in the 21st Century

**Permalink**

<https://escholarship.org/uc/item/2zj5q6fs>

**Journal**

Perspectives in Medicinal Chemistry, 6(6)

**ISSN**

1177-391X

**Authors**

Fair, Richard J  
Tor, Yitzhak

**Publication Date**

2014

**DOI**

10.4137/pmc.s14459

Peer reviewed

## Antibiotics and Bacterial Resistance in the 21st Century

Richard J. Fair<sup>1</sup> and Yitzhak Tor<sup>2</sup>

<sup>1</sup>Department for Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Berlin, Germany. <sup>2</sup>Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA.

**ABSTRACT:** Dangerous, antibiotic resistant bacteria have been observed with increasing frequency over the past several decades. In this review the factors that have been linked to this phenomenon are addressed. Profiles of bacterial species that are deemed to be particularly concerning at the present time are illustrated. Factors including economic impact, intrinsic and acquired drug resistance, morbidity and mortality rates, and means of infection are taken into account. Synchronously with the waxing of bacterial resistance there has been waning antibiotic development. The approaches that scientists are employing in the pursuit of new antibacterial agents are briefly described. The standings of established antibiotic classes as well as potentially emerging classes are assessed with an emphasis on molecules that have been clinically approved or are in advanced stages of development. Historical perspectives, mechanisms of action and resistance, spectrum of activity, and preeminent members of each class are discussed.

**KEYWORDS:** antibiotics, antibiotic resistance mechanisms, drug-resistant bacteria, novel antibiotic targets

**CITATION:** Fair and Tor. Antibiotics and Bacterial Resistance in the 21st Century. *Perspectives in Medicinal Chemistry* 2014;6:25–64 doi: 10.4137/PMC.S14459.

**RECEIVED:** April 25, 2014. **RESUBMITTED:** June 24, 2014. **ACCEPTED FOR PUBLICATION:** June 24, 2014.

**ACADEMIC EDITOR:** Daniel J Canney, Editorial Board member

**TYPE:** Review

**FUNDING:** The authors thank the US National Institutes of Health for generous financial support (grant no.: GM069773 to YT).

**COMPETING INTERESTS:** Authors disclose no potential conflicts of interest.

**COPYRIGHT:** © the authors, publisher and licensee Libertas Academica Limited. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.

**CORRESPONDENCE:** Richard.Fair@mpikg.mpg.de; ytor@ucsd.edu

This paper was subject to independent, expert peer review by a minimum of two blind peer reviewers. All editorial decisions were made by the independent academic editor. All authors have provided signed confirmation of their compliance with ethical and legal obligations including (but not limited to) use of any copyrighted material, compliance with ICMJE authorship and competing interests disclosure guidelines and, where applicable, compliance with legal and ethical guidelines on human and animal research participants. Provenance: the authors were invited to submit this paper.

### The Rise of Antibiotic Resistance

Antibiotic resistance fast facts

- **30%** – All deaths that were bacterial infection related in pre-antibiotic America<sup>2</sup>
- **\$20 / 1.6€ billion** – Excess healthcare costs of resistant infections in the US/EU<sup>3–5</sup>
- **8 / 2.5 million** – Excess hospital days caused by resistant infections in the US / EU<sup>3–5</sup>
- **30%** – Antimicrobial component of pharmaceutical budgets in the US<sup>6</sup>
- **1.6%** – Antibiotic allotment of all drugs in development by major pharmaceutical companies<sup>7</sup>
- **4** – Multinational pharmaceutical companies with antibiotics divisions<sup>11</sup>
- **\$1.1 billion** – Cost of unnecessarily prescribed antibiotics in the US<sup>3,4</sup>
- **48%** – Proportion of US hospitals that have adopted stewardship policies<sup>23</sup>

- **36%** – People that correctly answered that antibiotics do not kill viruses in an EU survey<sup>31</sup>
- **24.6 million** – Pounds of antibiotics used non-therapeutically on animals in the US per year in early 2000's<sup>33</sup>
- **300,000** – Pounds of streptomycin (**24**) and oxytetracycline (**40**) sprayed on produce in the US in 1996<sup>42</sup>

Bacterial resistance to antibiotics has been a recognized reality almost since the dawn of the antibiotic era, but only within the past twenty years has the emergence of dangerous, resistant strains occurred with a disturbing regularity. This escalating evolution of resistance coupled with a diminished antibiotic pipeline has led some to claim that a post-antibiotic era is eminent.<sup>1</sup> Given that the three main causes of death in pre-antibiotic America were tuberculosis, pneumonia, and gastrointestinal infections, which combined accounted for 30% of all deaths, this is a frightening prospect.<sup>2</sup> Though we are still far from that scenario becoming reality, the trend in



the antibiotics field has decidedly been negative for some time now. The annual impact of resistant infections is estimated to be \$20 billion in excess health care costs and 8 million additional hospital days in the United States (US)<sup>3,4</sup> and over 1.6€ billion and 2.5 million additional hospital days in the European Union (EU).<sup>5</sup> Antimicrobials currently account for over 30% of hospital pharmacy budgets in the US.<sup>6</sup>

### Diminished Pharmaceutical Investment

A flagging interest in antibiotics by the pharmaceutical industry is one factor that has contributed to an increased occurrence of hard to treat bacterial infections. In 2004 for example, only 1.6% of drugs in clinical development by the world's 15 largest drug companies were antibiotics. This reduced output of antibiotics has several causes.<sup>7</sup> Antibiotics regimens are typically administered for very limited durations making them far less profitable than drugs used to treat chronic ailments. Further, newly approved drugs for most other ailments are immediately prescribed, whereas new antibiotics are typically held in reserve and only prescribed for infections that more established antibiotics can't treat. This policy helps delay the emergence of resistant strains, but it also limits initial investment return. A market saturated with generic competitors and the inevitable growth of bacterial resistance exacerbates this profit disparity as compared to other drugs in the long term.

Regulatory hurdles have also muted the interest of major pharmaceutical companies. The tolerance of adverse side effects has recently been decreased for many drug classes, including antibiotics. Approval requirements during clinical trials have escalated in most cases from demonstration of noninferiority to superiority, and at times a lack of clear trial guidelines for antibiotics, in particular, have stifled development.<sup>8</sup> Pharmaceutical companies are presented with a paradox wherein federal agencies issue calls for antibiotic development while concomitantly other federal agencies enact policies limiting the appeal of that very development.

These factors have made investment in antibiotics development too high risk, and with the cost at an estimated \$1.7 billion per drug, with too little potential reward for many large pharmaceutical companies.<sup>9,10</sup> A metric called net present value (NPV) has been developed for pharmaceutical companies to determine the best avenues of investment at a given time. NPV is a risk-adjusted measure of the projected future revenues of a drug discounting initial development investment and other projected future expenses. A characteristic NPV for an injectable antibiotic may be around 100, which is somewhat unattractive compared to a typical cancer drug, around 300, or a neuroscience drug around 720.<sup>9</sup>

Since 1998 AstraZeneca, GlaxoSmithKline, Merck, Johnson & Johnson, and Pfizer/Wyeth have been the only major pharmaceutical companies to develop an antibiotic past phase I clinical trials.<sup>11</sup> Sanofi Aventis, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Proctor and Gamble, Roche, and Wyeth have all greatly curtailed, eliminated, or spun off their

antibiotic R&D divisions.<sup>6</sup> In fact, as of 2013 there are only four multinational pharmaceutical companies with antibiotics divisions left.<sup>11</sup> No government agency has ever successfully discovered and developed an antibiotic and there have been no indications that any will contribute the resources necessary for such an endeavor anytime in the near future.<sup>6</sup> As a consequence much of what is currently being done in antibiotic development in the western world is done in small pharmaceutical companies, biotech entities, and academic institutions. A number of large pharmaceutical companies still play a central role in antibiotic development in Japan, however.<sup>11-13</sup>

Policies have recently been enacted and incentives offered in an effort to reverse this exodus from antibiotic R&D. Agencies including the World Health Organization (WHO), the European Center for Disease Prevention and Control (ECDC), the Infectious Diseases Society of America (IDSA), and even the US Congress have gotten involved.<sup>5,8,11,14-16</sup> In the 111th congress the Generating Antibiotic Incentives Now (GAIN) Act and the Strategies to Address Antimicrobial Resistance (STAAR) Act were introduced.<sup>17</sup> In 2011 the US government gave \$94 million in government funding for the development of the structurally novel antibiotic candidate, Anacor's GSK-052 (though it's clinical trials were subsequently halted in 2012) and also \$67 million for Teatrphase's TP-434 (eravacycline **44**), a next generation fluorocycline currently in phase III trials.<sup>11</sup> Even the FDA has recently publically acknowledged that there is an antibiotic crisis.<sup>18,19</sup>

### Chronic Clinical Over-prescription and Public Misconceptions

The other factor fueling antibiotic resistance is the evolution and dissemination of resistance factors within bacterial populations. There are a plethora of means by which humans have inadvertently accelerated the evolution of bacterial resistance. The over prescription of antibiotics by doctors for symptoms that in many cases may not be caused by bacteria has historically been one such problematic policy. In recent years steps have been taken to limit antibiotic over prescription, however. In surveys of doctor's visits in 1995 compared to 2005, the percentage that resulted in antibiotic prescriptions decreased universally for symptoms including ear infections, colds, bronchitis, sore throats, and sinusitis.<sup>3,4</sup> Despite these positive trends the Center for Disease Control and Prevention (CDC) recently estimated that approximately 50% of antibiotics are still prescribed unnecessarily in the US at a yearly cost of \$1.1 billion.<sup>3,4</sup>

Antibiotic stewardship programs are becoming more commonplace in hospital settings and have been correlated in many cases to significant reductions in some strains of resistant bacteria.<sup>20-22</sup> Despite these successes only 48% of US hospitals have adopted stewardship policies to date and numbers are unquestionably even lower in the majority of developing countries.<sup>23</sup> Varied methodologies in measuring antibiotic consumption in US hospitals has been an undermining factor even



where stewardship policies are enacted, though.<sup>24</sup> Along with overall reductions to antibiotic usage, cycling usage between antibiotic classes, using combination therapies, and avoiding use of broad spectrum and last resort antibiotics whenever possible, have also been implemented as strategies to avoid the evolutionary pressure that accelerates resistance.<sup>25</sup>

Overly long or improper treatment regimens may also in some cases exert unnecessary evolutionary pressure on bacteria.<sup>26</sup> This can lead to acquired drug resistance in which a minority resistant bacterial phenotype can find themselves in a less competitive, and therefore more advantageous environment as a phenotypically sensitive majority is killed off.<sup>6</sup> Outpatient antibiotic use has been directly tied to macrolide resistance in *Streptococcus pyogenes* and penicillin resistance in *Streptococcus pneumoniae*.<sup>27,28</sup> More restrictive policies regarding outpatient regimens have resulted in the decline of certain resistant isolates in both Finland and France.<sup>29,30</sup>

A lack of public knowledge about antibiotics has also led to their overuse. In a 2009 European survey, of those who had taken antibiotics within the last year, 20% claimed to have taken them for influenza, a viral malady, and only 36% of those surveyed answered correctly that antibiotics do not kill viruses.<sup>31</sup> This particular variety of misuse is especially problematic in countries where antibiotics can be obtained without prescriptions.<sup>32</sup> Europe has instituted an Antibiotics Awareness Day annually on November 18th in an effort to raise public knowledge.<sup>23</sup>

### Misuse by the Food Industry

The use of antibiotics in animal feed stocks has also exacerbated the spread of resistance. Especially egregious is their use for non-curative reasons such as prophylaxis, metaphylaxis, and growth promotion which by one estimate accounted for 25–50% of all antibiotic consumption in the early 2000s.<sup>25</sup> Other assessments within the US during the same time period estimated agricultural use to be much greater at 24.6 million pounds of antibiotics being given to animals for non-therapeutic purposes, 2 million pounds being used therapeutically on animals, and 3 million pounds being used in humans per year.<sup>33</sup> Antibiotic use for growth promotion has been banned in the European Union (EU) since 2003<sup>34</sup> and finally in 2012 the FDA banned the use of antibiotics in livestock without a veterinary prescription.<sup>35</sup> There are still many countries where this practice remains unlegislated, however.

There is strong evidence that the use of fluoroquinolones in food animals has led to the emergence of fluoroquinolone resistant *E. coli*,<sup>36,37</sup> *Salmonella*, and *Campylobacter*.<sup>38</sup> The emergence of vancomycin resistant *Enterococci* (VRE) in Europe was tied to the use of the glycopeptide avoparcin in food animals.<sup>39</sup> Avoparcin was banned in the EU in 1997, which resulted in a reduction in VRE there,<sup>40</sup> but many members of critical antibiotic classes are still used for veterinary purposes. In a survey by the European Medicines Agency there was actually an increase in veterinary sales of fluoroquinolones and

fourth generation cephalosporins from 2005 to 2009.<sup>41</sup> The food industry's use of antibiotics has not been strictly limited to livestock either. In the US, in 1996 for example, 300,000 pounds of the aminoglycoside streptomycin (**24**), and oxytetracycline were sprayed prophylactically on apples and pears.<sup>42</sup> Waste runoff containing resistant bacteria or antibiotics from large corporate farms or agro-industrial plants is also a concern.<sup>23</sup> This serves as a mobile means of exposure to antibiotics and the terrestrial locale provides an ideal environment for dissemination of resistance elements from pathogenic bacteria and potentially from soil bacteria as well.<sup>23</sup>

### Human Independent Resistance

Though there is undoubtedly a significant human contribution to the evolution of bacterial resistance, there is also resistance that has occurred in nature absent human interference.<sup>43</sup> Resistances to first in class antibiotics such as penicillin G (**4**) and streptomycin (**24**), discovered during the golden age of antibiotics, were observed shortly after their initial isolation.<sup>44</sup> Though this is not always the case, this phenomenon is typical when examining the antibiotic arsenal as a whole.<sup>42</sup> With the advent of cloning and sequencing it was possible to trace  $\beta$ -lactamases to a large number of homologous, but distinct genes that were transferred vertically and horizontally throughout many microbial communities, directly between bacteria and indirectly mediated by the many bacteriophages that infect them.<sup>45</sup> Resistance genes can associate in clusters and be transferred together as well.<sup>46</sup> This kind of genetic diversity couldn't have arisen in the time frame since penicillin's discovery and indeed phylogenetic analysis suggested a more ancient root evolution of these enzymes.<sup>47</sup>

Resistance elements have even been found in bacterial DNA that was isolated for 30,000 years in permafrost.<sup>48</sup> Estimates based on the genetic divergence of antibiotic biosynthetic genes have suggested that some antibiotics could have evolved hundreds of millions of years ago.<sup>49</sup> Taken together this evidence suggests that bacteria have likely had a very long time to evolve resistance to many, if not all, natural product antibiotics, and therefore, resistance is highly likely to exist long before their discovery by man. Most soil bacteria exhibit some form of antibiotic resistance and many of them exhibit many resistance mechanisms even to antibiotics that they do not naturally produce.<sup>50</sup> It could be argued that these samples could be contaminated in a variety of ways including antibiotic runoff. However, this evidence is also supported by a number of studies that have found antibiotic resistant (in some cases highly resistant), commensal bacteria on both humans and animals from remote locales that have never been exposed to antibiotics through unnatural means.<sup>51</sup> Evolution of bacterial resistance to antibiotics is therefore a natural process and would exist even absent human mismanagement.

Human use (and misuse) of antibiotics has clearly put unnatural selective pressure on bacteria, which has accelerated their evolutionary process to the detriment of everyone. To



address this problem, faster development of new antibiotics and more responsible use of currently antibiotics are clearly necessary.

## Emergent Bacterial Threats

Bacterial threats fast facts

- **20%** – Proportion of people that are persistent carriers of *S. aureus*<sup>52</sup>
- **\$3 billion** – Annual healthcare costs associated with MRSA in US<sup>62</sup>
- **19,000** – Deaths per year caused by MRSA in the US<sup>62</sup>
- **61%** – Vancomycin (**52**) resistance rate of *E. faecium* in the US<sup>5</sup>
- **40%** – *S. pneumoniae* strains resistant to penicillin<sup>75,76</sup>
- **50%** – Chance of contracting *C. difficile* with > 4 week hospital stays<sup>80</sup>
- **1.3 million** – Worldwide deaths caused by TB per year<sup>90</sup>
- **\$483,000** – Average cost of XDR-TB treatment<sup>92–93</sup>
- **30%** – Increase in carbapenem resistant *A. baumannii* strains from 1995–2004<sup>129</sup>
- **30%** – Quinolone resistance rate for *Enterobacter*<sup>138</sup>
- **700,000** – *N. gonorrhoeae* infections in the US per year<sup>3,4</sup>
- **15.5%** – HAI incidence rate in developing countries<sup>144</sup>

There are many species of dangerous gram-positive and gram-negative bacteria. A sampling of some of the most problematic pathogens and their most alarming resistances are reviewed (Table 1). In the 1990s resistant gram positive bacteria materialized as a major threat with methicillin (MRSA) and vancomycin (VRSA) resistant *Staphylococcus aureus*, VRE, penicillin resistant *Streptococcus pneumoniae*, and multi-drug resistant (MDR) *Clostridium difficile* dominating the headlines.

### *Staphylococcus aureus* (MRSA, VISA, and VRSA).

*S. aureus* is a gram positive, facultative anaerobic pathogen with both hospital and community acquired strains. Though traditionally opportunistic, many *S. aureus* strains are now aggressively pathogenic.<sup>42</sup> It is the most common skin bacterium with 60% of humans being intermittent carriers and 20% being persistent carriers, chronically harboring at least one strain.<sup>52</sup>

*S. aureus* has evolved an arsenal of extracellular proteins and defense factors unassociated with antibiotic resistance. These include hemolysins, proteases, hyaluronidase, collagenase and an enterotoxin that causes gastroenteritis. Approximately 25% of strains express the exotoxin toxic shock syndrome toxin (TSST-1), and in 5% of strains the exotoxin Panton-Valentine leukocidin (PVL), which causes necrotic hemorrhagic pneumonia.<sup>53–56</sup> PVL is encoded by a bacteriophage now found commonly in community acquired MRSA (CA-MRSA).<sup>57</sup> These toxins have made effective protein translation inhibiting antibiotics particularly desirable in the treatment of some *S. aureus* strains.<sup>58</sup> Additionally, the pigment that gives this bacterium its golden color is staphyloxanthin, a carotenoid, antioxidant, virulence factor that aids in immune system evasion.<sup>59,60</sup>

*S. aureus* also frequently causes chronic infections by forming biofilms. It is the leading cause of chronic infections associated with indwelling medical devices.<sup>61</sup> Methicillin (**5**) resistance is also highly prevalent and though numbers can vary widely by country, its incidence is high in almost all countries where such data exists, and it is the single most commonly observed drug resistance in both the US and Europe.<sup>5,6</sup> MRSA was recently estimated to be responsible for 60–89% of nosocomial infections leading to 19,000 deaths and over \$3 billion in health care costs per year in the United States.<sup>8,17,62–64</sup> It was reported in 2009 that MRSA infections kill more people in US hospitals than HIV/AIDS and tuberculosis combined.<sup>58</sup>  $\beta$ -lactam resistance in MRSA is primarily due to expression of the *mecA* gene which encodes the low affinity penicillin binding protein (PBP 2a).<sup>65</sup>

The glycopeptides, vancomycin (**52**) and teicoplanin (**55**), are common treatments for MRSA, however, resistance has now developed towards them as well. Vancomycin intermediate *S. aureus* (VISA), which is also usually insensitive to teicoplanin (**55**), evolved a less permeable cell wall that traps these antibiotics.<sup>66</sup> VISA was first isolated in 1996 in Japan, but has since been encountered globally.<sup>42</sup> VRSA was first reported in 2002 and is far less common.<sup>67</sup> It is caused primarily by an acquired resistance from the VRE *vanA* gene, which alters the terminal sequence of cell wall precursors, making them poor substrates for vancomycin (**52**) and teicoplanin (**55**).<sup>66</sup> VISA and VRSA strains are not strictly opportunistic, making them even more dangerous.<sup>68</sup>

### Resistant *Enterococci* Including VRE

Resistant *Enterococci* are primarily comprised of two species, *E. faecalis* and *E. faecium*, both of which are gram-positive, facultative anaerobic, opportunistic pathogens. *Enterococci* are particularly environmentally tolerant with the ability to withstand a wide range of temperatures and pHs, as well as high salt concentration.<sup>69</sup> They are also capable of colonizing a wide range of locales including the gut, skin, and inanimate surfaces. Both have high levels of resistance rates (30–50%) against the aminoglycosides gentamicin (**25**) and streptomycin (**24**).<sup>70</sup> *E. faecium* is usually inherently resistant to  $\beta$ -lactam antibiotics also, making it particularly difficult to treat when it develops vancomycin resistance, which it much more commonly does than *E. faecalis*.<sup>69</sup> The streptogramin combination, quinupristin (**69**) / dalfopristin (**70**) is an effective treatment for *E. faecium*, but is ineffective against *E. faecalis*.<sup>71</sup>

Some VRE isolates express enterococcal surface protein, which allows for the production of thicker, more drug resistant biofilms. Like VRSA, these traits make VRE common in healthcare-associated infections (HAIs), and particularly in the colonization of indwelling medical devices.<sup>72</sup> Vancomycin resistance in *E. faecium* is common in the US at 61% in 2002, however, this resistance is far less common in the EU.<sup>5,23</sup> Though VRE is known to produce several resistance genes, the most common form of vancomycin resistance, as with VRSA, is *vanA*.<sup>65</sup>

**Table 1.** Emergent bacterial threats.

BACTERIUM	GRAM STAIN	RESPIRATION	PROBLEMATIC RESISTANCES
<i>Staphylococcus aureus</i>	+	Facultative anaerobe	$\beta$ -lactams, glycopeptides
<i>Enterococci</i>	+	Facultative anaerobe	$\beta$ -lactams, glycopeptides, aminoglycosides
<i>Streptococcus pneumoniae</i>	+	Aerotolerant anaerobe	$\beta$ -lactams, macrolides, quinolones
<i>Clostridium difficile</i>	+	Obligate anaerobe	$\beta$ -lactams, quinolones
<i>Mycobacterium tuberculosis</i>	+	Aerobe	Rifamycins, quinolones, aminoglycosides
<i>Escherichia coli</i>	-	Facultative anaerobe	$\beta$ -lactams, quinolones, aminoglycosides
<i>Pseudomonas aeruginosa</i>	-	Facultative anaerobe	All classes except polymyxins
<i>Acinetobacter</i>	-	Facultative anaerobe	All classes
<i>Klebsiella pneumoniae</i>	-	Facultative anaerobe	$\beta$ -lactams, quinolones, aminoglycosides
<i>Enterobacter</i>	-	Facultative anaerobe	$\beta$ -lactams, quinolones
<i>Neisseria gonorrhoeae</i>	-	Aerobe	$\beta$ -lactams, quinolones, tetracyclines, macrolides

***Streptococcus pneumoniae.*** *S. pneumoniae* is a gram-positive, aerotolerant, anaerobic, opportunistic pathogen. It is the leading cause of bacterial pneumonia, but it can also cause otitis media, sinusitis, and meningitis among other pathologies.<sup>73</sup> It has a polysaccharide capsule that makes it naturally resistant to phagocytes. It also produces hydrogen peroxide to kill other bacteria.<sup>74</sup> Approximately 40% of strains are no longer susceptible to penicillin, and its penicillin resistance often correlates with resistances to macrolides, sulfamides, older tetracyclines, and early generation cephalosporins.<sup>75,76</sup> Even absent  $\beta$ -lactam resistance, macrolide resistances caused by upregulated efflux encoded by *mef* or *erm* genes is increasing in *S. pneumoniae*.<sup>77</sup> Resistance to the third-generation fluoroquinolone, levofloxacin (**60**), has also been observed recently.<sup>78</sup> Though resistance isn't as prevalent as in some other gram-positive pathogens, the pathologies associated with *S. pneumoniae* infection make the prospects of increased resistance worth particular consideration.


***Clostridium difficile.*** *C. difficile* is a gram-positive, obligate anaerobic, spore forming opportunistic pathogen. Spores are highly environmentally tolerant and are resistant to heat, changes in pH, alcohol based hand sanitizers, and many traditional cleaning products that don't contain bleach.<sup>79</sup> *C. difficile* can be community acquired, but has a particularly high rate of acquisition in hospitals. Patients hospitalized for over four weeks have an approximately 50% chance of contracting *C. difficile*.<sup>80</sup> It is probably best known for causing antibiotic associated diarrhea. This pathology results when *C. difficile* is contracted and antibiotics that it is resistant to kill all other bacteria in the gastrointestinal tract. This subsequently causes *C. difficile* overgrowths as they spread to inhabit these now vacant niches. It produces an enterotoxin (toxin A) and a cytotoxin (toxin B) which play a role in the resultant symptoms and can lead to colitis, as well as life threatening complications.<sup>81</sup> Prophylactic cephalosporin use in surgeries has been linked to this condition and their use for this purpose is now restricted in certain at risk patient

populations.<sup>42</sup> In 2005 a hypervirulent strain of fluoroquinolone resistant *C. difficile* emerged and quickly spread across North America.<sup>82,83</sup> As serious *C. difficile* infections rarely emerge without the use of antibiotics, eliminating unnecessary usage becomes especially important with the advent of resistant strains of this pathogen.

### A New Wave of Resistant Gram Negative Infections

These gram-positive threats are still widespread and destructive, accounting for the majority of bacteria-related deaths in the United States by a significant margin (Fig. 1).<sup>4</sup> In recent years, however, resistance rates have stabilized or decreased for many of them, including MRSA and VRE, according to the European Antimicrobial Resistance Surveillance Network (EARS-Net).<sup>15</sup> Unfortunately, within the past ten years, as antibiotic development has focused on these threats,<sup>84</sup> drug resistant tuberculosis and a wave of new gram-negative strains just as perilous as their gram-positive counterparts have evolved. At least one analysis has suggested that the resistant gram-negatives may now be even more costly than gram-positives, MRSA included.<sup>85</sup> Also, in a European survey a compilation of some of the most common gram-negative infections were found to slightly outnumber common gram-positive infections.<sup>5</sup> In some ways the new resistant gram-negative pathogens are even more worrying, as their more difficult to penetrate outer membranes and higher prevalence of efflux pumps make them naturally resistant to many antibiotics. Carbapenem resistant gram negative strains, particularly *Enterobacteriaceae* (CRE), are becoming increasingly common place. The main gram-negative threats are multi- (MDR) and pan- (PDR) drug resistant *Escherichia coli*, *Pseudomonas aeruginosa*, *Acinetobacter*, *Klebsiella pneumoniae*, *Enterobacter*, and most recently *Neisseria gonorrhoeae*.<sup>86,87</sup>

***Mycobacterium tuberculosis* (MDR-TB and XDR-TB).** *Mycobacterium tuberculosis* is a highly aerobic, pathogenic bacterium that is the main cause of tuberculosis (TB). Though it doesn't typically gram stain because of a high lipid content



**Figure 1.** Deaths caused by select bacteria in the United States.

in its cell wall, it is classified as gram-positive because of the lack of an outer membrane present in gram-negative bacteria. This atypical cell wall protects it from macrophage digestion and gives it an inherent resistance to many antibiotics.<sup>88,89</sup> An estimated one third of the world's population is infected with latent TB. Many will not have the disease progress to an active state, however enough do to make TB unquestionably one of the greatest bacterial threats.<sup>90</sup> TB is second only to HIV/AIDS as the greatest killer worldwide due to a single infectious agent with 1.3 million deaths from 8.6 million new infections in 2012 largely in developing countries.<sup>90</sup> MDR-TB, resistant to the first line combination therapy of rifamycin, isoniazid, and pyrazinamide is becoming fairly commonplace with about 450,000 people in the world developing cases in 2012. Of those cases 9.6% are estimated to be extensively drug resistant (XDR-TB), which is further resistant to at least one second-line fluoroquinolone and aminoglycoside.<sup>90,91</sup> XDR-TB sometimes requires a two-year course of antibiotics at a staggering average cost of \$483,000 and can be fatal even with proper treatment.<sup>3,4,92,93</sup>

### Resistant *Escherichia coli*

*E. coli* are gram-negative, facultative anaerobes that are most commonly commensal, but can also be pathogenic. Pathogenic strains can produce potentially deadly toxins including enterohemorrhagic verotoxin (Shiga-like toxin), which causes hemolytic-uremic syndrome and renal failure.<sup>94</sup> This toxin was originally gained from a prophage.<sup>95</sup>

Traditionally *E. Coli* has been one of the most widely antibiotic susceptible of the *Enterobacteriaceae* family. Recently, though, horizontal gene transfer has allowed for the rise of highly resistant strains.<sup>96</sup> *E. coli* resistance is worrying because they are the most common gram-negative bacterial infections in humans and occurrence of strains with extended spectrum  $\beta$ -lactamases (ESBLs) conferring resistance to third generation cephalosporins has been steadily rising in Europe.<sup>5</sup> ESBL positive strains in bacteraemias have also shown high cross resistance to fluoroquinolones (>80%) and gentamicin (25)

(>40%).<sup>96</sup> Although still fairly uncommon, *E. coli* on multiple continents have also acquired the New Delhi Metallo- $\beta$ -lactamase-1 (NDM-1) enzyme from *K. pneumoniae*, which confers a broad resistance to all  $\beta$ -lactams including carbapenems with the exception of the monobactam, aztreonam (18).<sup>97-100</sup> Fluoroquinolone resistance is also common among *E. coli*.<sup>97-100</sup> Bacteria overexpressing *FomA* and *FomB* plasmidic genes are capable of inactivating fosfomycin through phosphorylation.<sup>103</sup> *E. coli* are also the most commonly zoonotic pathogens discussed herein. *E. coli* O157:H7, an enterohemorrhagic strain, has been associated with many zoonotic outbreaks and incidences of food borne illness including a 1999 outbreak in the US that infected at least 127 people.<sup>104</sup> Another enterohemorrhagic strain, *E. coli* O104:H4, infected over 3,800 people in Germany in 2011 causing 54 fatalities.<sup>105</sup>

### MDR *Pseudomonas Aeruginosa*

*P. aeruginosa* is a gram-negative, facultative anaerobic, opportunistic pathogen. It is the most common cause of chronic lung infections in cystic fibrosis (CF) patients.<sup>106</sup> These strains are frequently highly resistant and it is no longer uncommon to see CF related infections that are resistant to all antibiotics except polymyxins.<sup>107,108</sup> *P. aeruginosa* employs a type III secretion system to extrude a host of potent cytotoxins directly into host cells.<sup>109</sup> It has a high environmental tolerance especially with respect to nutritional requirements and has been known to survive in such diverse environments as jet fuel and disinfectant.<sup>110</sup> *P. aeruginosa* naturally has a host of siderophores (Fe<sup>3+</sup> carriers) and pigments that allow it to evade the innate immune system. Additionally it has particularly discriminating outer membrane porins that make its outer membrane impermeable and thus naturally resistant to many antibiotics, and a high propensity to form biofilms that can increase resistances to antibiotics 100 to 1000 fold.<sup>111,112</sup>

Further antibiotic resistance occurs thorough a wide variety of mechanisms. Some strains have acquired a variety of  $\beta$ -lactamases including ESBLs, *K. pneumoniae* carbapenemase (KPC), and metallo- $\beta$ -lactamases (MBLs).<sup>113</sup> *P. aeruginosa* also has an extremely comprehensive efflux pump



systems. Mutations resulting in loss of the OprD porin coupled with upregulation of MexEF-OprN efflux pumps result in resistance to carbapenems and fluoroquinolones. MexCD-OprJ upregulation also results in resistance to fluorquinolones and some  $\beta$ -lactams. MexAB-OprM upregulation confers resistance to sulfonamides,  $\beta$ -lactams, cephalosporins, fluoroquinolones, macrolides, novobiocin, tetracycline (**39**), chloramphenicol (**30**), and some detergents. MexXY-OprM results in aminoglycoside efflux.<sup>114</sup> Fluoroquinolone resistance can also occur through DNA gyrase and topoisomerase IV mutations. While rare, mutations to both are found in many persistent infections.<sup>115</sup> Pan-resistant *P. aeruginosa* susceptible only to polymyxins strains have been isolated. In one case the isolated strain produced AmpC  $\beta$ -lactamases, decreased OprD porin expression, and upregulation of MexXY efflux.<sup>116</sup> Another strain produced an MBL, AmpC  $\beta$ -lactamase, and two aminoglycoside acetylating enzymes (AACs).<sup>117</sup>

### MDR *Acinetobacter*

Resistant *P. aeruginosa* and *Acinetobacter* could be especially dangerous in the long term because of their intrinsic resistance to some gram-negative antibiotics and their ready acquisition of DNA from other bacteria ensuring the spread of additional resistances.<sup>111,118</sup> In a survey of select European countries they currently have the highest resistance rates to both carbapenems and aminoglycosides, two traditionally last resort antibiotics.<sup>101,102</sup> *P. aeruginosa* resistance has been stabilizing in the US, while unfortunately *Acinetobacter* resistance has been increasing.<sup>119</sup> The mortality rate for the latter is notably higher as well.<sup>120</sup>

The most common resistant *Acinetobacter* species is *A. baumannii*, a gram-negative, facultative anaerobic, opportunistic pathogen. This bacterium is also colloquially referred to as "Iraqibacter" because of its rapid emergence as a problem pathogen in wounded soldiers during the Iraq war. Many gram-negative bacteria are known for environmental persistence and *Acinetobacter* are particularly adept. With especially thick cell walls that protect them from dry conditions and high tolerance to temperature, pH, and nutrient changes, they are capable of surviving for up to 5 months on inanimate objects.<sup>121–123</sup> *A. baumannii* is naturally resistant to many antibiotics due to both poor membrane penetration and active efflux pumps as well.<sup>121</sup> Overexpression of the AdeABC efflux pump causes broad resistances to cephalosporins, fluoroquinolones, and tigecycline (**46**), the first member of a new tetracycline subclass called glycylcyclines. The AbeM efflux pump leads to aminoglycoside and fluoroquinolone resistance.<sup>124</sup> More specific efflux pumps, Tet(A) and Tet(B) for tetracyclines and CmlA for chloramphenicol also exist.<sup>96a</sup> Further hindering uptake, 30% of *A. baumannii* isolates produce an exopolysaccharide capable of forming biofilms.<sup>125</sup> It also expresses a powerful, epithelial cell targeting cytotoxin that aids in its colonization.<sup>126</sup>

MDR *A. baumannii* has two main modes of resistance. The first is the aforementioned efflux pumps, which also impart resistance to ammonia based disinfectants.<sup>121</sup> The second is a

variety of  $\beta$ -lactamases including ESBLs and carbapenemases including imipenem MBLs and oxacillinases (OXAs).<sup>127</sup> These antibiotic resistances factors coupled with *Acinetobacter* natural resistances have combined to produce *A. baumannii* strains with resistance to all known antibiotics including colistin (**71**).<sup>121</sup> MDR *Acinetobacter* are also already particularly common with greater than 60% of all hospital acquired *Acinetobacter* strains resistant to multiple drugs including carbapenems.<sup>128</sup> Moreover this resistance emerged over a remarkably short time period with a greater than 30% increase in carbapenem resistant *A. baumannii* strains from 1995 and 2004, which coincides closely with the rapid spread of OXAs.<sup>129</sup> During the same time period resistance to the aminoglycoside amikacin (**28**), the quinolone ciprofloxacin (**59**), and the  $\beta$ -lactam /  $\beta$ -lactamase inhibitor combination piperacillin (**9**)-tazobactam (**21**) also increased steadily.<sup>124</sup> MDR *Acinetobacter* and *Klebsiella* are so dangerous that their outbreaks have resulted in hospital ward closures on multiple occasions.<sup>130,131</sup>

### MDR and Pan-drug-resistant *Klebsiella pneumoniae*

*K. pneumoniae* is a gram-negative, facultative anaerobic, primarily opportunistic bacterium that can be nosocomial or community acquired. Community acquired *K. pneumoniae* most commonly causes pneumonia, like *S. pneumoniae*, there are a variety of other pathologies it can cause as well and only about 5% of pneumonia cases are caused by *K. pneumoniae*. This bacterium has a thick polysaccharide capsule that acts as an antiphagocytic factor,<sup>132</sup> and was the first species that *qnr* quinolone resistance genes were isolated from.<sup>133</sup>

This species also commonly acquires MDR determinants, and in particular an impressive array of  $\beta$ -lactamases. Most worrying are ESBLs, KPC, and most recently NDM-1. The latter two have caused multiple epidemics and even more troublingly are capable propagation to other species.<sup>97,127,134</sup> Carbapenem resistances are a serious problem since carbapenems were highly resistant to most other  $\beta$ -lactamases prior to the advent of KPC and were often used as drugs of last resort for serious gram-negative infections.<sup>113</sup> NDM-1 genes have commonly been found on plasmids and since the first identification of NDM-1 in 2007, producer strains have quickly spread around the world.<sup>87,100</sup> NDM-1 producing strains are typically highly resistant with other resistance mechanisms commonly including ESBLs, AAC AMEs and ribosomal methylases for aminoglycoside resistance, and fluoroquinolone resistant topoisomerase mutations, among others. The majority of these strains are only susceptible to the glycylcycline tigecycline (**46**) and the polymyxin colistin (**71**).<sup>87,135</sup> Pan-resistant strains have even been reported.<sup>136</sup> Though NDM-1 producing strains have so far remained relatively rare,<sup>100</sup> their rapid globalization coupled with their extreme resistance profiles warrants close monitoring in years to come.

### $\beta$ -lactam and Quinolone Resistant *Enterobacter*

*Enterobacter* is a genus of gram-negative, facultative anaerobic, opportunistic pathogens. They are mainly known to exhibit





antibiotic resistance through expression of an extensive variety of ESBLs and carbapenemases including, KPC, OXA, and several MBLs.<sup>137</sup> They are also the pathogen to most commonly have *qnr* quinolone resistance genes at over 30% occurrence in isolates.<sup>138</sup> Their outlook is less grim than some of the aforementioned pathogens, however. Colistin (**71**), tigecycline (**46**), amikacin (**28**), and some fluoroquinolones remain effective treatment options even for most MDR strains.

### Resistant *Neisseria Gonorrhoeae*

*N. gonorrhoeae* is a gram-negative, aerobic, fastidious, sexually transmitted pathogen. It has several methods of avoiding the immune system including Opa proteins that bind immune cell receptors to prevent a response and antigenic variation, which prevents the host from developing immunological memory against them.<sup>139</sup> Like *E. coli*, *N. gonorrhoeae* has traditionally been an easy to treat pathogen, but progressive accumulation of resistance mechanisms has gradually led to highly resistant strains. Penicillin and ciprofloxacin resistances acquired by plasmid, are now widespread, with resistances to the commonly used macrolide azithromycin (**32**) and some cephalosporin becoming increasingly common.<sup>140,141</sup> High level tetracycline resistance via TetM efflux proteins is also common.<sup>142</sup> Most recently a MDR *N. gonorrhoeae* strain with high level resistances to the third-generation cephalosporins cefixime and ceftriaxone has been identified as well.<sup>128</sup> MDR *N. gonorrhoeae* is particularly worrying as this bacterium is community acquired and very commonly pathogenic, infecting 700,000 per year in the United States alone.<sup>3,4</sup>

### Hospital Acquired Infections

Bacteria are responsible for approximately 90% of all HAIs.<sup>128</sup> HAIs are a major problem in the industrialized world having 5% and 7.1% incidence rates in the US and the EU, respectively.<sup>143,144</sup> In developing countries, where sterile practices are less stringent, the problem is much worse, with an estimated 15.5% incidence.<sup>144</sup> Additionally, the often immunocompromised patients that these infections target obviously have higher mortality rates than those with healthy immune systems. The risk of fatality associated with infections caused by resistant bacteria as compared to antibiotic sensitive bacteria is much higher as well. In most cases this is not because of any increased virulence, but rather because of prolonged bacterial exposure due to delayed, or a lack of an appropriate therapy.<sup>6,145</sup>

### The Search for New Antibacterial Agents

The number of new antibacterial agents has decreased steadily in the United States over the last several decades.<sup>8,146</sup> Historically there has been a higher chance of success with the development of compounds that belong to already established antibiotic classes.<sup>147</sup> Developmental risks are lower because of already proven microbiological assays to determine efficacy, known toxicological issues, and established regulatory routes for approval.<sup>148</sup> Some scaffolds have been used particularly


extensively. Between 1981 and 2005 cephalosporins, penicillins, quinolones, and macrolides accounted for 73% of all new antibiotics.<sup>149</sup>

There is also a lack of diversity in the cellular target of all known antibiotics. Almost all clinically used antibiotics inhibit DNA, RNA, protein, or cell wall synthesis, and there are less than twenty-five molecular targets that account for their activity. Approximately half of all antibiotics target the cell wall.<sup>150</sup> In some cases structurally distinct antibiotics, even from separate gene clusters, are known to bind the same sites.<sup>151,152</sup> Comparative analysis of bacterial genomes has indicated that there are around 300 essential, highly conserved proteins that could potentially be new, broad spectrum drug targets.<sup>153–157</sup> Though studies have recently begun to identify many antibacterial agents with novel molecular targets, activity is insufficient for many of these to be developed without further modification.

The development of new antibiotics in existing classes is an absolutely essential exercise that has been encouraged even by the IDSA, a principal entity in the push for new scaffold development.<sup>11</sup> However, new antibiotics that conform to established classes are often subject to at least some of the same resistances observed in previous members of the class. It is therefore also necessary to develop new antibiotic classes. There have only been six first in class antibiotics with totally novel scaffolds approved since the 1960s and all of these have been introduced in the past fifteen years, a thirty year innovation gap (Fig. 2). It is worth noting that all of these were developed to combat gram-positive pathogens including *M. tuberculosis* and they all have very little or no activity against gram-negatives. The innovation gap remains for novel antibiotics with potent gram-negative activity.

The new first in class antibiotics introduced for human use are the streptogramin combination quinupristin (**69**) / dalbapristin (**70**) in 1999, the oxazolidinone linezolid (**74**) in 2000, the lipopeptide daptomycin (**79**) in 2003, the pleuromutilin retapmulin (**81**) in 2007, the macrolactone fidaxomicin (**83**) in 2011, and the diarylquinoline bedaquiline (**84**) in 2012. Linezolid (**74**) and bedaquiline (**84**) are fully synthetic molecules while the others are natural products. Though they were only recently developed for approval these molecules or their leads were all discovered much earlier with the exception of the diarylquinolines. Streptogramins were discovered in the 1960s, the leads for linezolid in the 1970s, daptomycin (**79**) in the 1980s, pleuromutilins were isolated in the 1950s, and macrolactones similar to fidaxomicin were found in the 1970s.<sup>12</sup>

The early successes of many of these newer antibiotic classes suggest that scaffolds originally discarded during the heyday of antibiotic discovery because of liabilities such as narrow activity spectrum, like fidaxomicin (**83**) and bedaquiline (**84**), or higher toxicity, like the recently resurrected polymyxins, may need to be revisited given the desperate situation we are experiencing. It has even been argued that species-specific antibiotics may offer some significant advantages.<sup>62</sup>



**Figure 2.** Timeline of first clinical introduction of antibiotic classes.

**Notes:** Classes targeting the cell wall or membrane are highlighted in blue. Classes targeting the ribosome are highlighted in green.

Their cellular targets are less likely to overlap with those of eukaryotic cells or mutualistic gut bacteria. Also, resistance will likely be slower to develop, as resistance genes would likely have to originate in the target species since there would be no evolutionary pressure to produce resistance determinants in bacteria that are naturally resistant to the compound.

In response to this lack of innovation the IDSA issued the  $10 \times '20$  initiative in 2010 that calls for the development of 10 novel, effective antibiotics by 2020.<sup>158</sup> A 2013 update showed little progress towards that goal though and in a 2011 survey of all potential antibiotics in clinical trials only two out of the twenty one had totally novel scaffolds.<sup>11,12</sup> There is a particular need for antibiotics effective against gram-negative pathogens as they comprise most of the currently emerging threats and the majority of recently developed antibiotics are not effective against them.<sup>5,6</sup> According to the IDSA, of the drugs currently in clinical trials there is in particular a deficiency in antibiotics that have good activity against MBL producing gram-negatives and broad activity against *Acinetobacter* strains.<sup>11</sup>

### Semi-synthetic Approaches

Improved biophysical techniques have garnered a wealth of information about cellular targets and binding modes of many established antibiotics frequently making the rational design of semi-synthetic analogs of natural products a fruitful exercise. Precursor directed biosynthesis, mutasynthesis, and chemoenzymatic approaches are also increasingly being investigated to diversify certain established scaffolds.<sup>159</sup> These modifications, implemented to circumvent bacterial resistance mechanisms, have allowed many scaffolds to continue to be useful long after clinical resistance has become predominant to early members of the classes.

The majority of the antibiotics introduced within the last 30 years are semi-synthetically derived. There are now semi-synthetic members of most antibiotic classes that are founded on natural products and there are many examples of highly utilized or extremely promising antibiotics that

are semi-synthetically derived. These include the  $\beta$ -lactams meropenem (**14**) and tazobactam (**21**), the aminoglycoside amikacin (**28**), the macrolide azithromycin (**32**), the tetracycline tigecycline (**46**), the rifamycin rifampicin (**47**), the glycopeptide telavancin (**53**), and the streptogramin combination quinupristin (**69**) / dalbapristin (**26**).<sup>149</sup>

### Synthetic Development

Given the length of time bacteria as a whole have likely had to develop resistance to many natural product antibiotics coupled with the apparent ease with which many resistance genes are disseminated, developing totally synthetic antibiotics would appear to be an attractive strategy. To date, however, synthetic antibiotics are still extremely rare with the sulfa drugs, quinolones, oxazolidinones, and diarylquinolines being the only examples. They are outnumbered two to one by natural product antibiotics and their semi-synthetic derivatives,<sup>42,160</sup> with development over the past few decades focused especially on the latter.<sup>149</sup> Historically all synthetic classes, with the exception of diarylquinolines, were originally discovered outside of traditional antibiotic discovery programs. Sulfa drugs were originally developed as dyes, the first quinolone was an intermediate in the synthesis of chloroquine, a malaria drug, and oxazolidinones were originally developed to treat foliage diseases in plants.<sup>62</sup>

Without a doubt one of the greatest challenges to finding new synthetic scaffolds is the issue of bacterial cell penetration. This is particularly true of gram-negatives, which are naturally resistant to many antibiotics because of outer membranes that keep many amphipathic drugs out as well as inner membranes and highly active efflux pumps that often recognize highly hydrophilic molecules.<sup>161,162</sup> The difficulties of prokaryotic uptake often mean that antibiotics have to be administered at concentrations two to three orders of magnitude higher than therapeutics prescribed for most other diseases. This can impact the therapeutic window and lead to additional toxicity concerns.<sup>163</sup>



The majority of antibiotics do not strictly adhere to the Lipinski rules, a series of soft rules governing the likelihood of a compound's oral bioavailability and "drug like" character. In fact, several major antibiotic classes routinely break all of them. Notably, these rules were designed in the context of treating eukaryotic maladies. The establishment of a similar set of rules for antibacterials would greatly aid in antibiotics rational design and in the formation of compound libraries better suited for antibiotic screening purposes. There are no rules that have been routinely applied as of yet; however, some insights have started to be noted. Relatively hydrophilic compounds with masses below 600 Da tend to have good penetrance probably because of their ability to pass through outer membrane porins.<sup>164,165</sup> MDR efflux pumps tend to recognize cations and hydrophobic compounds particularly well, whereas anions are generally not recognized.<sup>166–168</sup> The inclusion of atoms not usually found in nature like boron and fluorine have had successes, possibly again because of efflux pump evasion.<sup>169</sup> Fluoroquinolones, at this point probably the most successful fully synthetic antibiotics, adhere to all of these observations.

Screening for synthetic leads has not conventionally been a successful method of discovery. Major high throughput synthetic screens and rational design campaigns of synthetic molecules have failed utterly in many cases to identify a single antibiotic.<sup>170</sup> The wide spread failure of cell free target based screens in particular, which were an industry standard, has been implicated as one of the primary reasons for many major pharmaceutical companies movement away from antibiotics development.<sup>170–171</sup> Most scaffolds found at major pharmaceutical companies are optimized more for human eukaryotic targets and are not up to the disparate challenges associated with prokaryotic cellular uptake and evasion of rampant bacterial efflux mechanisms, particularly in gram-negative bacteria. Therefore target based screens of synthetic molecules will often lead to hits with high potency, but no real world utility.<sup>43,62</sup> This is a drawback that rational design of synthetic molecules suffers from as well.<sup>163</sup> Whole cell screens do not suffer from this disadvantage though.

Taking note of fact that all current synthetic antibiotics were originally discovered for other purposes, whole cell screens of libraries originally created by non-antibiotics programs have been done recently. These have been used to identify some promising new leads.<sup>172,173</sup> Many hits on whole cell screens may exhibit narrow or even genus specific activity, as in the case of bedaquiline (**84**) though, which notably is the only synthetic, clinically approved antibiotic to our knowledge that was discovered by high throughput screens actually designed to identify antibiotics.<sup>163</sup> For some particularly hard to treat pathogens this may be acceptable at this point though.

Taking whole cell screens a step further, in vivo screens have also gained some interest with the rationalization that metabolically activated prodrugs, like sulfonamides, may be overlooked in traditional in vitro screens. Using animal

models would of course be prohibitive in any large screening process for obvious reasons. However, *Caenorhabditis elegans*, a nematode, can be infected with human pathogens to making it a passable model organism for in vivo screens. Screens using *C. elegans* have had hits, including some that have no in vitro activity.<sup>174,175</sup>

Diversity oriented synthesis based approaches have been used to create promising totally synthetic molecules that more closely mimic microbial natural products.<sup>176</sup> Combinatorial chemistry can be done to create libraries around known privileged scaffolds. Another approach is to do unbiased diversity oriented synthesis. This approach, coupled with subsequent SAR, has been used to find promising antibiotic candidates.<sup>177,178</sup>

### Natural Product Development

Natural products are a historically successful and still a very much viable option as new antibiotics. During the "golden age" of antibiotics many of the current antibiotic classes were discovered by systematic screening methods of *Streptomyces* introduced by Selman Waksman in the 1940s. There is reason to believe that many natural products are still as yet undiscovered. One recent estimate puts the number of discovered antibiotics as only 10% of the total from screened bacterial strains and only 1% from all microbes.<sup>179</sup> Approximately two thirds of natural product antibiotics are isolated from terrestrial soil actinomycetes.<sup>180,181</sup> Multiple classes of antibiotics are even known to be encountered within the same gene clusters.<sup>182</sup> Finding a useable antibiotic in the milieu of compounds produced by these organisms is no easy feat though, especially given that the most commonly produced antibacterial molecules for these particular bacteria have all likely been already identified. It was recently estimated that with current technology  $10^7$  actinomycete strains would have to be screened to discover the next novel antibiotics class.<sup>49</sup> Given that a strain collection at a large pharmaceutical company may be around 50,000 isolates, this is no longer a feasible approach.<sup>163</sup>

Exploration of bacteria from other ecological niches has recently yielded many promising new lead compounds, however. The producers of these include deep sea sediment actinomycetes,<sup>183</sup> marine sponges and seaweeds (though these seem to actually be made by colonizing bacteria),<sup>184</sup> bacterial symbionts of insects, ascidians, fungi,<sup>186–189</sup> and myxobacteria.<sup>190</sup>

With the colossal advances in gene sequencing technology within last several decades, genomic prospecting has also begun. Genomic sequencing has in several cases identified silent operons that code for secondary metabolites within *Streptomyces*, some of which are not currently known to produce antimicrobial compounds.<sup>191,192</sup> The proper conditions for realizing expression of these potential antibiotics in cultures can be difficult as antibiotic production may depend on a variety of factors including proper concentration of quorum sensing factors, which may be difficult to replicate.<sup>193–195</sup> Methods of



manipulating these silent operons represent an active area of research. These approaches have thus far never realized more than the identification of several lead compounds per year though.<sup>192, 196–199</sup>

Natural products screens have been touted over synthetic molecule screens both for the obviously superior number of compounds available and the fact that natural products have already been “prescreened” by evolution.<sup>163</sup> It has traditionally been an often used approach, with whole cell empirical screening being the method of discovery of the majority of antibiotics used today.<sup>171</sup> Whole cell screening does not aid in identification of mode of action, however, and this approach can be expensive. It is made even more so in the realm of natural products screening, particularly for antibiotics, as many antibiotic producing bacteria are difficult to culture (an estimated 99% of microbial species are uncultured).<sup>200, 201</sup>

Even more importantly, in current screens, many hits are actually previously discovered compounds. This is because of the pervasiveness of lateral transfer of antibiotic producing genes amongst terrestrial soil bacteria. One study estimated that 1 in 100 actinomycetes produce streptomycin (**24**), 1 in 250 tetracycline (**39**), 1 in 66,000 vancomycin (**52**), and 1 in 200,000 erythromycin (**31**).<sup>49</sup> This phenomenon is not strictly limited to actinomycetes either.<sup>202–206</sup> Some members of the same antibiotic subclass can even be produced by extremely disparate organisms. Cephalosporins, for example, are produced by actinomycetes, proteobacteria, and fungi.<sup>207, 208</sup> Several methods have been developed to alleviate the problem of rediscovery. One strategy is to use strains resistant to commonly “rediscovered” antibiotics in the screening process.

This has been done with wild type MRSA and with MDR *E. faecium*, which led to the discovery of many new promising compounds.<sup>209, 210</sup>

Target based natural products screens offer a useful counterpoint to whole cell screening. Target based screens do not suffer from all the drawbacks that these screens have when applied to synthetic molecules. Recently, several bioinformatics based, genome screening approaches have been used with some success.<sup>211–213</sup> It was previously mentioned that through genomic screening it has been estimated that there are hundreds of potential broad spectrum targets that no antibiotics have ever been developed for. Screens developed for these targets have the advantage that there are no false positives caused by already discovered antibiotics. Also, drugs developed for these targets may have less initial bacterial resistance than targets that already have selective pressure from many current antibiotics.

Hybrids of whole cell and cell free target based assays now exist as well. Whole cell reporter assays or whole cell target-based assays employ either cells or conditions that are engineered to report specific molecular events at sub-bactericidal concentrations, unlike traditional whole cell screens that simply look at cell death upon introduction of a compound or isolate. Antisense technology has also been used successfully to identify promising natural products. One particularly interesting discovery made using these techniques was platensimycin and other potent fatty acid biosynthesis inhibitors.<sup>214</sup>

## A History of Established Antibiotic Classes

The following sections present profiles of the major established classes of antibiotics with a focus on new or exceptional

**Table 2.** Antibiotics of the 21st century.

CLASS	CLINICALLY INTRODUCED SINCE 2000	IN PHASE II OR III TRIALS
Sulfonamides	None	None
β-lactams	Biapenem ( <b>16</b> ), ceftaroline ( <b>11</b> ), doripenem ( <b>15</b> ), ertapenem	Ceftobiprole, ceftolozane ( <b>12</b> ), razupenem ( <b>17</b> )
Aminoglycosides	None	Plazomicin ( <b>29</b> )
Amphenicols	None	None
Macrolides	Telithromycin ( <b>35</b> )	Cethromycin ( <b>36</b> ), solithromycin ( <b>37</b> )
Tetracyclines	Tigecycline ( <b>46</b> )	Eravacycline ( <b>44</b> ), omadacycline ( <b>45</b> )
Rifamycins	Rifaximin ( <b>51</b> )	None
Glycopeptides	Telavancin ( <b>53</b> )	Dalbavancin ( <b>56</b> ), oritavancin ( <b>54</b> ), ramoplanin ( <b>57</b> )
Quinolones	Balafloxacin, gemifloxacin, pazufloxacin, prulifloxacin	Avarofloxacin ( <b>65</b> ), delafloxacin ( <b>63</b> ), finafloxacin ( <b>66</b> ), JNJ-Q2, levonadifloxacin, nemonoxacin ( <b>64</b> )
Streptogramins	None	None
Polymyxins	None	None
Oxazolidinones	Linezolid ( <b>74</b> )	AZD5847 ( <b>78</b> ), radezolid ( <b>76</b> ), sutezolid ( <b>77</b> ), tedizolid ( <b>75</b> )
Lipopeptides	Daptomycin ( <b>79</b> )	Surotomycin ( <b>80</b> )
Pleuromutilins	Retapmulin ( <b>81</b> )	BC-3781 ( <b>82</b> )
Macrolactones	Fidaxomicin ( <b>83</b> )	None
Diarylquinolines	Bedaquiline ( <b>84</b> )	None



members. What are thought to be emerging classes are also discussed even though some may only have one currently clinically approved member. Discussion of many structurally unique antibiotics has been avoided for brevity. Promising antibiotics in clinical trials are also discussed with a focus primarily on phase II and III candidates (Table 2).

### Sulfonamides

Sulfonamides are a structurally diverse class of antibiotics that all have an aryl sulfonamide moiety in common (Fig. 3). The first sulfonamide discovered was prontosil (**1**) in 1932.<sup>163</sup> Sulfonamides were first used clinically in 1936. They are synthetic antimetabolites that inhibit dihydropteroate synthetase, an enzyme totally absent human cells used in folic acid metabolism. Inhibition of this enzyme ultimately leads to repressed DNA replication and bacteriostatic activity against aerobic gram-positive and negative bacteria. Due to their broad spectrum activity sulfonamides were once popular antibiotics.<sup>215</sup> Increases in resistance, allergic reactions, and rare, but serious side effects including Stevens-Johnson syndrome and blood dyscrasias led to declines in their use many years ago.<sup>216</sup> However, interest has recently been rekindled in the use of sulfamethoxazole (**2**) in a combination therapy with trimethoprim (**3**), a compound that inhibits DNA replication by binding dihydrofolate reductase, another enzyme involved in folic acid metabolism. Trimethoprim (**3**) has been found to have an up to 100 fold synergistic effect in combination with sulfonamides.<sup>42</sup> This combination has good activity against some MRSA strains and evidence has suggested that resistance has actually decreased to these compounds in recent years likely because of many years of infrequent usage.<sup>217,218</sup>


### $\beta$ -lactams

$\beta$ -lactam antibiotics are diverse in their structure, but they share a common four-membered  $\beta$ -lactam ring, which functions as the active pharmacophore for this class. The first  $\beta$ -lactam antibiotic to be discovered was benzylpenicillin (penicillin G) (**4**) in 1928 though it wasn't used clinically until 1938.<sup>163</sup>  $\beta$ -lactams are the class with by far the most FDA approved members. They are also the most populous class on the WHO's list of critically important antibiotics to human medicine. There are 28 members, including antibiotic/ $\beta$ -lactamase inhibitor combinations, from three subclasses:

penicillins, cephalosporins, and carbapenems that are listed as critically important (Table 3).<sup>219</sup> They exhibit antibacterial activity by acting as suicide substrates for penicillin binding proteins (PBPs) (transpeptidases) inhibiting cell wall biosynthesis, specifically maintenance of peptidoglycan. This leads to cell stress responses that result in cell lysis.<sup>220</sup> Many currently used  $\beta$ -lactams have very broad spectrum activity against most aerobic and anaerobic gram-positive and negative bacteria as well as low toxicity profiles making them popular first line antibiotics.<sup>42</sup> Resistance to older members of this class, especially the penicillin subclass, has proliferated dramatically though.

Resistance usually occurs via hydrolysis of the  $\beta$ -lactam ring mediated by a wide range of  $\beta$ -lactamases. These enzymes have been divided into four classes by the Ambler classification system: class A (KPCs and most ESBLs), class B (MBLs), class C (AmpC  $\beta$ -lactamases), and class D (OXAs). Class A includes many enzymes that can hydrolyze penicillins and cephalosporins as well as some that can hydrolyze monobactams and KPCs that are capable of hydrolyzing carbapenems.<sup>221</sup> The ESBLs from this class are plasmid mediated which has aided in their intra- and interspecies diffusion.<sup>222</sup> MBLs use divalent cations such as zinc as cofactors. Many are encoded in class 1 integrons, typically on gene cassettes also coding for aminoglycoside modifying enzymes (AMEs), found on transposons facilitating their spread.<sup>223</sup> MBLs inactivate many  $\beta$ -lactams including carbapenems and there are no currently improved inhibitors for them, but they have no activity against aztreonam (**18**), a monobactam.<sup>224</sup> AmpC  $\beta$ -lactamases are typically chromosomally encoded. AmpC and other class C  $\beta$ -lactamases can inactivate many  $\beta$ -lactams including aztreonam (**18**) with preferential activity against cephalosporins, but they have no activity against carbapenems.<sup>221,225</sup> Many OXAs are encoded on integrons.<sup>226–229</sup> Class D which is solely comprised of OXAs can hydrolyze cephalosporins and aztreonam (**18**) and some have carbapenemase activity as well.<sup>221,230</sup> Though their activity isn't as great as MBLs they are the most commonly found  $\beta$ -lactamase in *Acinetobacter*, which makes them particularly problematic.<sup>222</sup>

Altered PBPs, especially in *Streptococci*, also occur.<sup>231</sup> Methicillin (**5**) and other  $\beta$ -lactam resistances in MRSA are caused by production of low affinity PBP2a in greater than 90% of isolates.<sup>232</sup> Likewise in *S. pneumoniae* resistance to  $\beta$ -lactams is commonly caused by expression of a variety of



**Figure 3.** Sulfonamides and trimethoprim (**3**).

**Note:** The sulfonamide moiety is highlighted in blue.


**Table 3.** Critically important antibiotics.

CLASS OR SUBCLASS	PRIMARY TARGET	WHO CRITICALLY IMPORTANT MEMBERS <sup>219</sup>
Penicillins	Penicillin binding proteins	Penicillin G ( <b>4</b> ) and V, ampicillin ( <b>7</b> ), ampicillin ( <b>7</b> ) / sulbactam ( <b>22</b> ), amoxicillin ( <b>8</b> ), amoxicillin ( <b>8</b> ) / clavulanate, piperacillin ( <b>9</b> ), piperacillin ( <b>9</b> ) / tazobactam ( <b>21</b> ), azlocillin, carbenicillin, mezlocillin, ticarcillin, ticarcillin / clavulanate
Cephalosporins	Penicillin binding proteins	Cefixime, cefotaxime, cefpodoxime, ceftazidime, ceftizoxime, cefoperazone, cefoperazone / sulbactam ( <b>22</b> ), ceftriaxone, cefepime, ceftiprome, cefoselis
Carbapenems	Penicillin binding proteins	Ertapenem, faropenem, imipenem ( <b>13</b> ), meropenem ( <b>14</b> )
Aminoglycosides	30S ribosomal subunit	Amikacin ( <b>28</b> ), arbekacin, gentamicin ( <b>25</b> ), netilmicin, tobramycin ( <b>27</b> ), streptomycin ( <b>24</b> )
Macrolides	50S ribosomal subunit	Azithromycin ( <b>32</b> ), clarithromycin ( <b>33</b> ), erythromycin ( <b>31</b> ), midecamycin, roxithromycin ( <b>34</b> ), spiramycin, telithromycin ( <b>35</b> )
Tetracyclines	30S ribosomal subunit	Tigecycline ( <b>46</b> )
Rifamycins	RNA polymerase	Rifabutin ( <b>49</b> ), rifampin, rifaximin ( <b>51</b> )
Glycopeptides	Peptidoglycan units	Teicoplanin ( <b>55</b> ), vancomycin ( <b>52</b> )
Quinolones	Topoisomerase II and IV	Cinoxacin, nalidixic acid ( <b>58</b> ), pipemidic acid, ciprofloxacin ( <b>59</b> ), enoxacin, gatifloxacin, gemifloxacin, levofloxacin ( <b>60</b> ), lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, sparfloxacin
Streptogramins	50S ribosomal subunit	Quinupristin ( <b>69</b> ) / dalfopristin ( <b>70</b> ), pristinamycin ( <b>67</b> / <b>68</b> )
Oxazolidinones	50S ribosomal subunit	Linezolid ( <b>74</b> )
Lipopeptides	Cell membrane	Daptomycin ( <b>79</b> )


low affinity PBPs.<sup>42</sup> Efflux by RND and ABC efflux pumps,<sup>233</sup> and outer membrane impermeability<sup>234</sup> can also cause resistance to  $\beta$ -lactams.

Progressive generations of  $\beta$ -lactams have largely advanced through semi-synthetic modification. Within the penicillin subclass (Fig. 4) some early modifications were focused on increasing stability to early penicillinases through the attachment of bulky side chains as in the cases of methicillin (**5**)

and oxacillin (**6**). Other modifications were made to increase spectrum activity, from penicillin G (**4**), which is comparatively narrow spectrum, especially against gram-negatives, as compared to other  $\beta$ -lactams. Examples of this include the aminopenicillins such as ampicillin (**7**) and amoxicillin (**8**), and ureidopenicillins like piperacillin (**9**). Despite dramatic proliferation of resistance to this class many penicillins remain important first line antibiotics.<sup>42</sup>


**Figure 4.** Penicillin subclass  $\beta$ -lactams.

**Note:** The  $\beta$ -lactam moiety is highlighted in blue.




**Figure 5.** Cephalosporin subclass  $\beta$ -lactams.

**Note:** The  $\beta$ -lactam moiety is highlighted in blue.

The first cephalosporin was cephalosporin C (**10**), which was discovered in 1948 (Fig. 5). Early generations of semi-synthetic cephalosporins largely sought to improve pharmacokinetics and increase spectrum of activity against gram-negative pathogens primarily through increased cellular penetration. Later generations have become increasingly focused on combating  $\beta$ -lactam resistance.<sup>42</sup> Now in their fifth generation, excellent safety profiles and increased spectrum of activity have made modern cephalosporins some of the most highly utilized first line antibiotics.


Fifth-generation cephalosporin, ceftaroline (**11**), approved by the FDA in 2010, has shown increased activity against

MRSA, but is no more potent against MDR gram-negatives, likely because it is still susceptible to most ESBLs.<sup>235,236</sup> However, it has shown promise in combination with the  $\beta$ -lactamase inhibitor, tazobactam (**21**), against many resistant strains though this doesn't prevent inactivation via MBLs.<sup>221</sup> Cubist's ceftolozane (**12**), in phase III trials, has shown complimentary activity. It has low activity against MRSA, but is active against many MDR gram-negatives including *E. coli* and *K. pneumoniae* strains, and superior activity against *P. aeruginosa* including strains with AmpC  $\beta$ -lactamases and upregulated efflux.<sup>237</sup> It will also likely be used in combination with tazobactam (**21**), which broadens their range of activity against ESBL producers.<sup>238</sup>



**Figure 6.** Carbapenem subclass  $\beta$ -lactams.

**Note:** The  $\beta$ -lactam moiety is highlighted in blue.




**Figure 7.** Monobactam subclass  $\beta$ -lactams.

**Note:** The  $\beta$ -lactam is moiety highlighted in blue.

Imipenem (13) was the first carbapenem to be identified in 1976 (Fig. 6). Carbapenems show enhanced activity against many anaerobic and gram-negative bacteria as compared to other  $\beta$ -lactams mainly because of their resistance to most ESBLs. Many are susceptible to the various carbapenemases that have more recently evolved though. Imipenem (13) and meropenem (14) resistance has also evolved in *P. aeruginosa* with loss of OprD porins and MexAB-OprM efflux upregulation.<sup>222</sup> Doripenem (15), approved in Japan in 2005 and the US in 2007, is impervious to certain KPCs and OXAs, but it is still susceptible to all MBLs.<sup>239</sup> It shows similar activity against most bacteria as imipenem (13) and is superior to other carbapenems against *P. aeruginosa*, but it notably lacks activity against MRSA.<sup>58,240</sup> Meropenem (14) and biapenem (16) (approved in Japan) have shown activity against some imipenem resistant, MBL producing *P. aeruginosa*.<sup>241</sup> Razupenem (17), a carbapenem in phase II trials, has shown promising activity against ampicillin resistant *E. faecium*.<sup>242</sup>

The first, and currently only FDA approved monobactam, aztreonam (18), was identified in 1981 (Fig. 7). Though it is useful against only gram-negative pathogens, it has the distinction of being the only  $\beta$ -lactam impervious to some of the most dreaded class B  $\beta$ -lactamases.<sup>42,224</sup> Though only in phase I clinical trials, Basilea's BAL30072 (19) is a very promising monobactam, which shows superior activity against MBL producing *P. aeruginosa* and *Acinetobacter*, as well as many KPC producing *Enterobacteriaceae*.<sup>243</sup> It has also showed promising synergistic activity with meropenem (14) against *Acinetobacter*.<sup>244</sup>

Clavulanic acid (20), discovered in 1976, was the first identified  $\beta$ -lactamase inhibitor (Fig. 8). Augmentin, a combination therapy of clavulanic acid (20) and amoxicillin (8), is



**Figure 8.**  $\beta$ -lactamase inhibitors.

**Note:** The  $\beta$ -lactam moiety is highlighted in blue.


still one of the most successful antibiotics on the market. Piperacillin (9) and tazobactam (21) are also a popular combination therapy particularly against some *P. aeruginosa* infections including those producing ESBLs.<sup>222</sup> There has also been some renewed interest in sulbactam (22), which has been used successfully in the past with ampicillin (7) and has recently shown good synergistic activity in combination with meropenem (14) against a wide range of *A. baumannii* strains. Unfortunately this combination isn't yet clinically approved.<sup>245</sup> Avibactam (23) is a newer  $\beta$ -lactamase inhibitor with broad spectrum activity against class A, C, and D  $\beta$ -lactamases.<sup>246</sup> There are quite a few  $\beta$ -lactam inhibitors, both with and without  $\beta$ -lactam structures, that are clinically approved or in clinical trials in combination with  $\beta$ -lactam antibiotics. Many of these have activity against KPC, AmpC, and OXA  $\beta$ -lactamases.<sup>247</sup> There are very few with activity against MBLs, however, and none that are currently clinically approved.<sup>248</sup> Some combinations of inhibitors including ones that have siderophore activity have shown some promise against MBLs though.<sup>221</sup> Tricyclic competitive inhibitors of certain MBLs have also been isolated.<sup>249</sup>

### Aminoglycosides

Aminoglycosides consist of amino-sugars connected through glycosidic bonds typically to a 2-deoxystreptamine (2-DOS) core (Fig. 9). The first aminoglycoside to be discovered was streptomycin (24) in 1943 and it was subsequently used clinically in 1946.<sup>163</sup> They target the 30S ribosomal subunit, most commonly the A-site within the 16S rRNA, leading to mistranslation of proteins. Some aminoglycosides are broad spectrum antibiotics with good activity against some aerobic gram-positive and most gram-negative species as well as *M. tuberculosis*. Their uptake is severely limited under certain anaerobic conditions, so their efficacy can be severely diminished for certain facultative or obligate anaerobes. They are notably the only class of translation inhibiting antibiotics that is broadly bactericidal. The precise mechanism of their bactericidal activity isn't fully understood.<sup>215</sup> Insertion of flawed membrane proteins has been implicated though and this is known to promote further aminoglycoside uptake.<sup>250</sup>

The aminoglycosides suffer from issues of nephrotoxicity and ototoxicity, which in most cases consigns them to the role of antibiotics of last resort rather than first line treatments. Resistance, particularly common in gram-negatives, has also developed through mechanisms including increased efflux by MexXY and ABC transporters, especially in *P. aeruginosa*, and





**Figure 9.** Aminoglycosides.


**Note:** The 2-DOS ring is highlighted in blue.

methylated ribosomal A-sites, which decrease target affinity. Rmt and Arm methylases methylate the N7 position of rRNA G1405 conferring resistance to gentamicin (25) and kanamycin subclasses of aminoglycosides. The less common NpmA enzymes methylate N1 of A1408 causing broad resistance to the aforementioned subclasses as well as the neomycin subclass and apramycin (26).<sup>251–252</sup> The most common resistance mechanism is AMEs, however, consisting of N-acetyltransferases (AAC), O-nucleotidyltransferases (ANT) and O-phosphotransferases (APH). These are often encoded on mobile genetic elements and are readily disseminated between bacterial species via lateral gene transfer.<sup>225</sup>

Streptomycin (24) was successfully used as a first line therapy for TB for many years until a mutation to the 30S ribosomal protein RpsL became commonplace, but it is still sometimes used as a second line therapy for MDR-TB.<sup>253</sup> Gentamicin (25), a natural product of *Micromonospora*, is the most widely used aminoglycoside. It is approved infections caused by *Enterococci*, *Streptococci*, and *P. aeruginosa*. Tobramycin (27) has activity against many gram-negative pathogens, but is primarily used for the treatment of cystic fibrosis and resultant *P. aeruginosa* lung infections.<sup>254</sup> A large

number of aminoglycosides are natural products, but several of the more recently developed members of this class are semi-synthetic. Amikacin (28) is a semi-synthetic designer derivative of kanamycin A clinically introduced in 1976. The L-hydroxyaminobutyramide (HABA) side chain of amikacin (28) blocks many AAC and APH enzymes, which increases its spectrum of activity considerably.<sup>255,256</sup> It is currently used mainly for the treatment of highly drug resistant gram-negative organisms including MBL producers and for MDR-TB.<sup>217,218</sup>

For the last several decades and until recently very little was done to advance new aminoglycosides into the clinic. Plazomicin (29), a very promising new semisynthetic sisomicin derivative from Achaogen, is currently in phase II clinical trials. It was designed with several modifications,



**Figure 10.** Chloramphenicol (30).

including a HABA side chain, to make it resistant to almost all AMEs and have lower toxicity than other aminoglycosides. It exhibits activity against fluoroquinolone and aminoglycoside resistant pathogens as well as many  $\beta$ -lactamase producers.<sup>11</sup> It also shows impressive synergy with daptomycin (**79**) and several  $\beta$ -lactam antibiotics.<sup>257,258</sup> It has good activity against many MRSA strains and carbapenemase producing *Enterobacteriaceae*, including KPC producing *K. pneumoniae*, but most NDM-1 producing isolates show resistance to it along with all other aminoglycosides. This is because these strains also typically produce ArmA and RmtC 16S rRNA methylases.<sup>11,259</sup> It also has lower activity against some *A. baumannii* and *P. aeruginosa* strains than currently used aminoglycosides.<sup>260,261</sup>

### Amphenicols


Amphenicols are a class of phenylpropanoid antibiotics. Chloramphenicol (**30**) was discovered in 1946 and introduced to the clinic in 1948 (Fig. 10).<sup>163</sup> It is the only member of this class FDA approved for human consumption although there are other amphenicols that have been approved for use in other countries and for veterinary purposes. These antibiotics bind the peptidyl transferase center (PTC) of the 50S ribosomal subunit to inhibit the elongation step of translation.

Chloramphenicol (**30**) has fairly broad spectrum bacteriostatic activity against some gram-positive and negative species including anaerobes.<sup>215</sup> They are bactericidal against *H. influenzae*, *N. meningitidis*, and *S. pneumoniae*, however.<sup>262</sup>

Despite their broad spectrum, amphenicols have never been popular first line antibiotics in the developed world largely because of concerns regarding their safety. They are widely used in the developing world because they are inexpensive and readily available, though.<sup>263</sup> Resistance can occur through target modification by the *cfi* gene encodes a methylase that methylates the C8 position of A2503 of the 23S rRNA causing resistance to amphenicols as well as many other PTC targeting antibiotics.<sup>264</sup> Acetyltransferases are also a common resistance mechanism.<sup>265</sup> Efflux of amphenicols is also common with members in all of the major efflux pump families that recognize them.<sup>42,266</sup>

### Macrolides

Macrolides are macrocyclic lactones with deoxy-sugars, usually cladinose or desosamine, appended through glycosidic bonds (Fig. 11). The first macrolide to be discovered was erythromycin (**31**) in 1949 and it was introduced clinically in 1951.<sup>163</sup> Macrolides bind the 50S ribosomal subunit blocking the peptide exit tunnel, inhibiting elongation of translation by causing premature disassociation of peptidyl tRNA from the



**Figure 11.** Macrolides.


**Note:** The cladinose ring is highlighted in blue, desosamine in green.

ribosome.<sup>267</sup> They have fairly broad spectrum antibacterial activity against aerobic and anaerobic gram-positive and some gram-negative bacteria. They are bacteriostatic except at very high concentrations and in select situations, such as azithromycin (**32**), which is bactericidal against *H. influenzae*.<sup>268</sup>

Resistance to macrolides occurs via a variety of target modifications. Methylases encoded by the *erm* gene cause resistance. Mono-methylation of rRNA A2058 and occasionally A2509 in the N6 positions confers resistance many macrolides, but has no effect on the newer ketolide subclass. Di-methylation confers resistance to both macrolides and ketolides, however.<sup>269</sup> A2058G and A2059G mutations cause resistance although the effect is much diminished in ketolides. A2062C confers resistance selectively to 16-membered ring macrolides.<sup>270</sup> Mutations in the ribosomal protein L22 and L4 can also result in resistance.<sup>271,272</sup> Macrolide modifying enzymes also exist.<sup>273</sup> As with many antibiotics, efflux is the main source of resistance, particularly in 14-membered ring macrolides.<sup>42,274,275</sup>

The semi-synthetic members of this class, azithromycin (**32**) and clarithromycin (**33**), showed expanded spectrums of activity, better acid stability, and improved pharmacokinetics as compared to erythromycin (**31**) making them popular first line antibiotics.<sup>42</sup> Azithromycin (**32**) was the most commonly prescribed out-patient antibiotic in the US in 2010.<sup>276</sup> Roxithromycin (**34**) another semi-synthetic macrolide is currently the only other member of this subclass on the US market.

Telithromycin (**35**), a semi-synthetic erythromycin derivative, was the first ketolide identified in 1997 and it is currently the only FDA approved member of this subclass (Fig. 12). Telithromycin (**35**) shows improved activity against many strains with upregulated macrolide efflux and *erm* methylases including *Streptococci* and *S. Aureus* strains.<sup>277</sup> It was partially withdrawn on the US market after rare but serious side effects including blurred vision and liver failure were observed.<sup>278</sup> SAR studies have likely pinpointed the structural origin of this toxicity, however, and ketolides currently in development including Advanced Life Science's



**Figure 12.** Ketolides.

**Note:** The deosamine ring is highlighted in green.



cethromycin (**36**), in post-phase III trials, and Cemptra's solithromycin (**37**), awaiting phase III trials, have sought to remedy this. Cethromycin (**36**) has improved activity against *S. pneumoniae*, but is less effective against erm methylase producers.<sup>279</sup> Solithromycin (**37**) has good activity against many gram-positive and some gram-negative pathogens, including some with erm methylase resistances, but reduced activity against some *S. aureus* strains.<sup>280</sup>

## Tetracyclines

Tetracyclines are an antibiotics class that shares a common octahydro-tetracene skeleton (Fig. 13). The first tetracycline was discovered in 1945 and was named chlortetracycline (**38**). It was introduced clinically in 1952. These antibiotics are broad spectrum, bacteriostatic agents used against aerobic gram-positive and negative bacteria that bind the 30S ribosomal subunit and block aminoacyl tRNA access to the ribosome. Their typically low incidence of severe side effects has made them a first line therapy. Tetracycline resistance is most often due to efflux by SMR, RND, or ABC efflux pumps or by ribosomal modification. A tetracycline inactivating enzyme, TetX, has also been reported.<sup>42,281</sup>

Early members of this class were natural products (tetracycline **39**, oxytetracycline **40**, and demeclocycline **41**), but later members (doxycycline **42** and minocycline **43**) were semi-synthetic.<sup>42</sup> The semisynthetic derivatives have better pharmacokinetic features.<sup>282</sup> Tetracycline has a fluorocycline, eravacycline (**44**), in phase III trials with broad spectrum activity against many MDR pathogens including MRSA, VRE, *C. difficile*, and KPC producing gram-negatives, but it has low activity against *P. aeruginosa* and some *Acinetobacter* strains.<sup>11,283</sup> It circumvents several tetracycline resistance mechanisms including tetracycline specific efflux, tetracycline inactivating enzymes, and ribosomal modification.<sup>11,284</sup> Also, Paratek's omadacycline (**45**), a derivative of minocycline (**43**), has passed phase II clinical trials. It has similar activity in many cases to the glycylicycline, tigecycline (**46**). Like both tigecycline (**46**) and eravacycline (**44**) it has little activity against *P. aeruginosa* though, despite its advantages against many other species including highly resistant *N. gonorrhoeae*.<sup>142, 279</sup>

The only FDA approved glycylicycline, a new tetracycline subclass, is tigecycline (**46**). It is a derivative of minocycline (**43**), which was first identified in 1998 making it the first new tetracycline introduced in 30 years. It overcomes previous




Figure 13. Tetracyclines and the glycylicycline, tigecycline (**46**).


tetracycline resistance mechanisms of ribosomal modification and efflux.<sup>285</sup> It exhibits broad spectrum activity, but most importantly it has good activity against MRSA, VRE, many MDR gram-negatives, including *A. baumannii* and ESBL producing *Enterobacteriaceae*. It notably has low activity against *P. aeruginosa* though. Low blood serum levels and some toxicity are reported disadvantages. Also, efflux pumps have quickly evolved to recognize it, particularly *A. baumannii* AdeABC multi-drug efflux pumps.<sup>286–291</sup>

## Rifamycins


Rifamycins are ansamycin antibiotics possessing macrocyclic structures bridging an aromatic moiety. Rifampicin (47), the first rifamycin, was made as a semi-synthetic derivative of the *Nocardia* natural product rifamycin B (48) in 1957 (Fig. 14).<sup>163</sup> It quickly thereafter introduced to the clinic in 1958. These compounds exert antibacterial activity by binding the  $\beta$ -subunit of RNA polymerase inhibiting transcription.

They are bactericidal against gram-positive bacteria and *M. tuberculosis*. They are bacteriostatic against some gram-negative bacteria, which has been attributed to their relatively lower cellular permeability.<sup>292</sup> Mutations to the  $\beta$ -subunit, most often on the side chains of residues 406 and 411, cause resistance. Efflux by VceB and Acr efflux pumps can also occur.<sup>42</sup>

Rifampicin (47) administered as a combination therapy with isoniazid and pyrazinamide is still a first line treatment for TB infections. Though less commonly used rifabutin (49) and rifapentine (50) are also primarily used for treating TB. These three compounds are all designated as critically important by the WHO largely because of their efficacy and common usage against TB.<sup>219</sup> The emergence of MDR- and more recently XDR-TB strains, which are resistant to these treatments has necessitated an interest in the development of next generation TB therapies, however.<sup>293</sup> Rifaximin (51) is a newer rifamycin approved by the FDA in 2004. Its only antibiotic indication is



**Figure 14.** Rifamycins, including the newly approved rifaximin (51).



**Figure 15.** Vancomycin (52) glycopeptide and derivatives.

for treatment of *E. coli* associated traveler's diarrhea, although its spectrum of activity is considerably broader.<sup>294</sup>

### Glycopeptides

Glycopeptides are macrocyclic peptides with interspersed bridged aromatic moieties and saccharide side chains linked through glycosidic bonds. The first glycopeptide to be discovered was vancomycin (52) in 1952 (Fig. 15). It was then introduced clinically in 1958.<sup>163</sup> In contrast to  $\beta$ -lactams, glycopeptides inhibit cell wall biosynthesis in gram-positive bacteria by binding the terminal D-Ala-D-Ala dipeptide of peptidoglycan units sterically inhibiting their use as substrates for PBPs and transglycosylases. Five vancomycin resistant phenotypes (VanA-E), originating in VRE, have altered peptidoglycan termini with lower affinities for vancomycin (52).<sup>295</sup> VanH, VanR, VanS, and VanX are also proteins involved in the regulation and reprogramming of vancomycin

resistance. Efflux mediated resistance is rare for glycopeptides, but AcrF efflux pumps have been known to cause resistance.<sup>42</sup>

Vancomycin (52) stays free in the periplasm while teicoplanin (55) is membrane anchored by a lipophilic side chain (Fig. 16).<sup>296</sup> Their spectrum of activity and efficacy is generally similar, but its side chain allows teicoplanin (55) to overcome *vanB* encoded resistance that vancomycin (52) is susceptible to.<sup>297</sup> In 2009 telavancin (53), a derivative of vancomycin (52), became the first glycopeptide approved for use in the US since vancomycin (52). It has a secondary mechanism of action, membrane depolarization, similar to daptomycin (79). It has shown particularly good activity against MRSA, resistant *Enterococci*, and activity against biofilm forming bacteria that vancomycin (52) lacks.<sup>298</sup> Oritavancin (54), a derivative of a vancomycin precursor, has had a complicated development, but is currently undergoing




Figure 16. Teicoplanin (55) glycopeptide and derivative.

phase III trials under the management of The Medicines Co. It appears to have a higher affinity for peptidoglycan and has a wider range of activity than vancomycin (52) including activity against VRSA, *S. pneumoniae*, and an impressive 1000 fold greater activity against VRE.<sup>299–301</sup> Durata's dalbavancin (56), a teicoplanin analog, is undergoing phase III clinical trials. It has a significantly higher activity than vancomycin (52) against *Staphylococci*, but is not active against VRE. Its main advantage isn't its increased activity though, but once weekly dosing.<sup>299, 302</sup>

Nanotherapeutics' ramoplanin (57), a structurally similar lipoglycopeptide, isolated from *Actinoplanes*, has also generated a lot of interest and is currently in phase III trials (Fig. 17). Ramoplanin (57) inhibits cell wall biosynthesis, but through a different mechanism than glycopeptides. It inhibits the transglycosylation step by stopping lipid I transformation into lipid II in gram-positive bacteria. It would primarily be used in the treatment of MDR *C. difficile* if approved.<sup>303</sup>


## Quinolones

Quinolone antibiotics possess a quinolone core that typically has a N linked cyclic moiety and various substituents at the C(6) and/or C(7) positions (Fig. 18). Nalidixic acid (58), the first quinolone, was discovered in 1962. It wasn't until 1968 that a quinolone, ciprofloxacin (59), which is a fully synthetic analog of nalidixic acid, was introduced clinically.<sup>163</sup> Quinolones inhibit topoisomerases II (DNA gyrase) and IV

trapping the enzymes in the DNA cleavage stage, ultimately inhibiting DNA synthesis among other things. Modern quinolones are bactericidal and have broad spectrum activity that covers most aerobic gram-positive and negative bacteria, some anaerobic gram-negatives, and *M. tuberculosis*. Most quinolones preferentially target DNA gyrase or topoisomerase IV, though some, particularly later generation compounds, target both equally.<sup>42</sup>

Resistance by target modification commonly occurs by mutations to genes *gyrA* and *parC* in both *P. aeruginosa* and *A. baumannii* as well as the *grrI* gene in *S. aureus*.<sup>225, 304, 305</sup> The plasmid mediated *qnrA* gene, which produces a protein that protects DNA from quinolone binding, has also been found primarily in *Enterobacter* and *Klebsiella*.<sup>306, 307</sup> A number of other Qnr proteins have also been identified in gram-negative bacteria.<sup>308</sup> Fluoroquinolone efflux pumps, which can be intrinsic or acquired, commonly show broad activity against multiple antibiotic classes.<sup>42, 309</sup>

First generation quinolones are rarely used today because of poor biodistribution and spectrum of activity compared to more modern members of this class. Second generation drugs were characterized by expanded activity particularly against aerobic gram-negative bacteria, but were not broadly active against gram-positive bacteria.<sup>310</sup> Ciprofloxacin (59), a standout second generation fluoroquinolone, is still one of the most active quinolones against *P. aeruginosa* and has also garnered a lot of attention for its



**Figure 17.** The lipoglycopeptide ramoplanin (**57**).

activity against extremely virulent bacteria such as *Bacillus anthracis* (anthrax) and *Yersinia pestis* (plague). Some third generation compounds showed improved activity against gram-positives. Levofloxacin (**60**), for example, showed marked improvements against *Streptococcus*.

The fourth generation of quinolones expanded activity even further, especially in their coverage of anaerobic bacteria and bacteria that had developed resistances against this class. Some have also had more issues with toxicity than most second and third generation compounds though.<sup>311</sup> Fourth generation fluoroquinolones, sitafloxacin (**61**) (approved in Japan) and clinafloxacin (**62**), overcome individual target modification resistances because they simultaneously target both DNA gyrase and topoisomerase IV. In some cases they are even active against double mutants in relevant organisms including *S. pneumoniae*, *E. faecium*, and *N. gonorrhoeae*.<sup>312</sup>

Three promising quinolones in development are Rib-X's delafloxacin (**63**), TaiGen's nemonoxacin (**64**), and Furiex's avarofloxacin (**65**), which are all in phase III trials. All have enhanced activity against gram-positive bacteria including *S. pneumoniae* and MRSA strains including some that are ciprofloxacin resistant.<sup>313–316</sup> MerLion's finafloxacin (**66**), also in phase III clinical trials, shows enhanced activity over other quinolones at low pH and has particularly good activity against CA-MRSA and *A. baumannii* including strains with ciprofloxacin resistance.<sup>317,318</sup>

## Streptogramins

Streptogramins are divided into class A and class B based on their structures, which also correlates with their mechanism of

action. Class A streptogramins are 23-membered unsaturated macrocycles containing peptide and lactone bonds. Class B streptogramins are 19-membered depsipeptides (Fig. 11). Streptogramin B was discovered in 1963, but it wasn't until 1999 that members of this class would be used clinically.<sup>163</sup> They are typically administered clinically as pairs of molecules from each class. Pristinamycin (**67** / **68**) itself is a combination of class A and B molecules.

Group A streptogramins bind the 50S ribosomal subunit at the PTC to inhibit initiation and translocation, whereas group B antibiotics bind the peptide exit tunnel to inhibit the elongation stage of translation. They have activity against gram-positive and in select cases gram-negative bacteria, but their overall narrow activity combined with poor aqueous solubility have limited the clinical use of many members of this class. They are usually bacteriostatic when administered alone. When they are administered as combinations of group A and B streptogramins they exhibit bactericidal activity.<sup>215</sup>

Quinupristin (**69**) / dalfopristin (**70**) and pristinamycin (**67** / **68**) both show good bactericidal activity against MRSA, and the former also shows very high activity against vancomycin resistant *E. faecium*, but their activity becomes bacteriostatic in strains that exhibit *erm* methylases.<sup>303</sup> *Erm* methylases, which also produce resistance to macrolides, cause resistance in group B streptogramins.<sup>319</sup> *Cfr* methylases create resistance specifically to group A streptogramins.<sup>320</sup> There are now strains that have an *mfr* operon, which has both *erm* and *cfr* genes. These strains are resistant to all PTC targeting antibiotics.<sup>321</sup>






Figure 18. Select first through fourth generation quinolones.





Figure 19. Class A and B streptogramins.



**Figure 20.** Polymyxins including preclinical polymyxin B analog, NAB739.

## Polymyxins

Polymyxins are cyclic peptides with peptidyl side chains capped with a hydrophobic, saturated alkyl tail (Fig. 20). Polymyxins A–E, natural products of *Bacillus*, were discovered in 1947. Colistin (polymyxin E) (71) has been on the market since 1950. Primarily because of significant nephrotoxicity and neurotoxicity<sup>322</sup> it was infrequently used until recently, when interest was renewed in it and polymyxin B (72), as drugs of last resort. Recent studies have shown that colistin nephrotoxicity may have been overstated possibly because of improper dosing or inferior formulation.<sup>323,324</sup> They have potent broad spectrum activity against most gram-negative bacteria although some strains of *E. Coli*, *Klebsiella*, *Enterobacter*, *M. tuberculosis*, and others have developed resistances.<sup>325–327</sup>

Polymyxins, which are polycationic, displace stabilizing magnesium and calcium ions to electrostatically interact with the anionic lipopolysaccharide (LPS) outer layer of gram-negative cell membranes. This disrupting interaction leads to increased cell membrane permeability, cell leakage, and rapid cell death.<sup>328</sup> Colistin (71) also has the added benefit of having potent anti-endotoxin activity also.<sup>329</sup> Resistance to polymyxins is fairly uncommon, although its frequency varies significantly by bacterial species and by geographic region.<sup>330</sup> Some gram-negative bacteria including *E. coli* and *P. aeruginosa* can exhibit resistance through expression of lower affinity modified LPS. *P. aeruginosa* can also upregulate membrane protein H1, which replaces divalent cations in the LPS, decreasing polymyxin affinity. *K. pneumoniae* increases production of its capsule polysaccharide,

which limits polymyxin penetration to the LPS layer. Also, though not yet known to spread to pathogenic bacteria, strains of *B. polymyxa* are known to produce a degrading colistinase.<sup>284</sup>


Colistin (**71**) is now used in the treatment of MDR gram-negative pathogens with few other treatment options, particularly MDR *Pseudomonas*, *Klebsiella*, and *Acinetobacter* strains including NDM-1 producers.<sup>124</sup> Cubist's CB-182,804 is a polymyxin B analog currently in phase I trials that shows activity against many MDR gram-negative bacteria and even some colistin resistant strains.<sup>331</sup> It was developed to not only have greater activity, but to have a more favorable toxicity profile though no evidence has been shown that this was indeed successful.<sup>332</sup> Polymyxin B analogs with reduced overall positive charge have recently been shown to retain good antibacterial activity, while showing much improved in vitro toxicity profiles. One of these molecules, NAB739 (**73**), is being actively developed in preclinical studies by Northern Antibiotics Ltd.<sup>333–337</sup>

## Oxazolidinones

Oxazolidinone antibiotics have a shared oxazolidinone core with various N-linked aryl and heterocyclic rings and short C(5) side chains (Fig. 21). The first and currently only clinically approved oxazolidinone, linezolid (**74**), was first identified in 1995 and approved by the FDA in 2000, though the roots of this class go back to the 1970s.<sup>338</sup> Oxazolidinones bind the PTC on the 50S ribosomal subunit blocking peptide bond formation to

elicit bacteriostatic activity against gram-positive bacteria and *M. tuberculosis*. Resistance mechanisms to oxazolidinones are still somewhat rare. Target modification of the PTC by the G2576U mutation confers, however, resistance in some *Enterococci* and *S. Aureus* strains.<sup>339</sup> U2500A and U2571C rRNA mutations, mutations to ribosomal proteins L3 and L4, and *cfr* encoded methylation of A2503 are also known to result in resistance.<sup>279</sup> Although still rare, *cfr* methylases have spread to many countries and recently caused serious outbreaks of linezolid resistant *Staphylococci*.<sup>340–343</sup>

Linezolid (**74**) is useful against hard to treat gram-positive infections including those caused by MRSA and VRE.<sup>344,345</sup> Since linezolid's approval, many oxazolidinones in development have been plagued by issues including poor solubility and pharmacokinetics, toxicity, and few improvements to activity. As a result most have failed in early developmental stages.<sup>346</sup> Trius's tedizolid (**75**), in phase III trials, and Rib-X's radezolid (**76**), in phase II trials have shown promise, however. They have both shown broadly improved activity and even activity against a wide range of linezolid resistant *Staphylococci* including MRSA strains.<sup>347</sup> Tedizolid (**75**) was found to have significantly greater activity against a variety of strains known to have point mutations or methylations that normally result in linezolid resistance.<sup>348</sup> The series of compounds that include radezolid (**76**) were designed based on computational models that were created using atomic level structures of linezolid (**74**). It was successfully designed to extend activity to include gram-negatives *H. influenzae* and *Moraxella catarrhalis*.<sup>349,350</sup>



**Figure 21.** Oxazolidinones.

**Note:** The oxazolidinone rings are highlighted in blue.



It also circumvents resistance mutations to L3 and L4, but it doesn't do as well as tedizolid (**75**) against rRNA point mutation resistances, or against *cfr* methylase producers.<sup>299,349,350</sup> Pfizer's sutezolid (**77**) and AstraZeneca's AZD5847 (**78**), both in phase II trials, are being developed for use against MDR- and XDR-TB. Sutezolid (**77**) was designed to be potentially less toxic than linezolid (**74**) and was found to have broadly superior activity against *M. tuberculosis* isolates including those with resistance to isoniazid, rifampicin (**47**), ethambutol, and streptomycin (**24**).<sup>351</sup>


## Lipopeptides

Lipopeptides are cyclic depsipeptides with a peptidyl side chain capped with a saturated alkyl tail. Daptomycin (**79**), discovered in 1985, was the first lipopeptide antibiotic to be identified though it wasn't used clinically until 2003 (Fig. 22).<sup>163</sup> It is currently the only clinically approved member of the lipopeptide class. Lipopeptides work by inserting their lipid tails into the cytoplasmic membrane of gram-positive


bacteria, which depolarizes the membrane leading to potassium efflux. This disrupts the structural integrity of the membrane resulting in cell lysis.

Daptomycin resistance is still rare and the mechanisms of its occurrence are not fully understood. Resistance in *Enterococci* has been linked to genes that alter cell envelope stress response and upregulation of cardiolipin synthase, an enzyme involved in cell membrane homeostasis.<sup>352</sup> *S. aureus* strains with thickened cell walls caused by increased production and D-alanylation of cell wall teichoic acids show daptomycin resistance.<sup>353</sup> Single nucleotide polymorphisms in *S. aureus mprF* and *dltA-D* genes resulting in increased cell wall positive charge are also resistant.<sup>354,355</sup>

Daptomycin (**79**) displays good activity against many drug resistant gram-positive pathogens including MRSA and VRE.<sup>349</sup> Cubist's surotomycin (**80**) is a lipopeptide in phase III trials for the treatment of *C. difficile*. So far it has been found to have a similar cure rate and a lower rate of relapse than vancomycin (**52**), the current standard treatment for this bacterium.<sup>356</sup>



**Figure 22.** Daptomycin (**79**) and surotomycin (**80**), a lipopeptide in clinical development.



**Figure 23.** Retapmulin (81) and the BC-3781 (82), a pleuromutilin in clinical development.

### Pleuromutilins


Pleuromutilins all have a common fused cyclo-octane / pentanone with a bridged cyclohexane ring system. They have a variety of ester linked side chains. Retapmulin (81) became the first clinically approved pleuromutilin in 2007 (Fig. 23), though they were used extensively for several decades in veterinary medicine before that and some were discovered as early as the 1950s. Like many other antibiotics they bind the PTC on the 50S ribosomal subunit and thus inhibit translation. Upregulated *vga* genes that code for ABC efflux transporters confer resistance to pleuromutilins.<sup>357,358</sup> Target modifications including *cfr* mediated methylations, mutations to ribosomal protein L3, and point mutation to the 23S rRNA also cause resistance.<sup>320,359</sup>

Retapmulin (81) has been approved for topical usage against gram-positive bacteria including MRSA, resistant *Streptococci*, and *erm* methylase producers.<sup>320</sup> Nabriva's BC-3781 (82) is currently in phase II trials for non-topical applications. It shows good activity against MRSA, VRE, and macrolide and quinolone resistant *S. pneumoniae*, and has compared favorably to vancomycin (52) in trials.<sup>360,361</sup>

### Macrolactones

Antibacterial macrolactones have unsaturated lactone cores decorated with deoxysugars and aromatic motifs. Macrolactones with antibacterial activity were first discovered in the 1970s, but it wasn't until 2011 that the first and currently only macrolactone, fidaxomicin (83), was approved for clinical use (Fig. 24).<sup>163</sup> Fidaxomicin (83) is an actinomycete natural product that inhibits RNA polymerase in gram-positive and some gram-negative bacteria to elicit bactericidal activity. It has almost no systemic bioavailability though which makes it unsuitable for the treatment of many infections.<sup>362</sup>

Fidaxomicin (83) is a very narrow spectrum antibiotic with approval only for *C. difficile* infections. As *C. difficile* associated diarrhea is a gastrointestinal affliction it has been argued that it's narrow spectrum of activity is actually advantageous because of its low activity against beneficial commensal bacteria, which is thought to help prevent reoccurring infections.<sup>362,363</sup>



**Figure 24.** The macrolactone fidaxomicin (83).


### Diarylquinolines

Antibacterial diarylquinolines consist of a quinoline core with two other aryl groups linked through the C(3) position of the quinoline. Diarylquinolines with antibacterial activity were first discovered in 1997 through whole cell high throughput screening of synthetic molecules for direct antibacterial activity against the *M. tuberculosis* surrogate *M. smegmatis*.<sup>364</sup> Bedaquiline (84), the only clinically approved member of this class was first used in 2012. It inhibits  $F_1F_0$ -ATPase, the proton pump for ATP synthase (Fig. 25).

Like fidaxomicin (83), bedaquiline (84) is a very narrow spectrum antibiotic. It has activity against *Mycobacteria*, and in particular *M. tuberculosis* making it the first new TB drug in more than forty years.<sup>364</sup> It will be used only for MDR-TB and XDR-TB. There was some controversy over its approval though as it was based on clearance of TB from sputum cultures rather than patient mortality.<sup>365</sup>

### Combination Therapies

Taking a note from the drug cocktails used to combat HIV in the successful highly active anti-retroviral therapy (HAART) and the longtime strategy for combating *M. tuberculosis*, the use of antibiotics in combination therapies is becoming an increasingly attractive approach to combat resistance. Synergy can be such a powerful force that even molecules too weakly active on their own to be considered for monotherapies can be administered in combination therapies to great effect.<sup>366</sup> Evidence suggests that some antibiotic producing *Streptomyces* may also naturally employ combination approaches to eliminate



**Figure 25.** The diarylquinoline bedaquiline (84).

competition.<sup>367</sup> There are many combinations of antibiotics that are known to exhibit synergy. Some antibiotics are almost always administered as combination therapies even, such as streptogramins and rifamycins.

An extension of this strategy that is also being pursued is the production of covalently linked hybrids of two antibiotic classes. Actelion's cadazolid (**85**), in phase III trials, is structural hybrid of a fluoroquinolone and an oxazolidinone that primarily inhibits translation in gram-positive bacteria (Fig. 26).<sup>332</sup> It has activity against *C. difficile* strains that are resistant to linezolid (**74**) and moxifloxacin, so it is being developed primarily to combat that pathogen.<sup>368</sup> A hybrid of two cell wall biosynthesis inhibiting classes, Theravance's TD-1792 (**86**), in phase II trials, is a cephalosporin/glycopeptide hybrid.<sup>332</sup> This hybrid principally targets the D-Ala-D-Ala terminus of peptidoglycan units in gram-positive bacteria. It is being developed chiefly as a treatment for MRSA although it also has activity against *C. difficile*.<sup>369,370</sup> The obvious advantage to this approach is the potential added benefit of synergistic secondary antibiotic effects with the administration of a single molecule. One disadvantage that has been noted, however, is that gram-negative activity is commonly lost in hybrid molecules likely because of their bulk, which is prohibitive of uptake.<sup>371</sup>


### New Antibacterial Targets

With the advancements of the last several decades have come the identification of numerous novel potential antibacterial

targets. Though some of these have proven to be dead ends many remain promising. For the sake of brevity only a selection of the most promising targets, chosen based on interest generated in the field and by clinical advancement of compounds targeting them, are discussed in this review.

Symmetric bis-indoles have been identified that function as groove binders of double stranded nucleic acids to inhibit DNA and RNA synthesis and induce a SOS response. Though established antibiotic classes are known to inhibit both DNA and RNA synthesis, this particular mechanism is unprecedented for antibiotics. One compound, MBX-1162 (**87**), is currently in phase I clinical trials and has shown good, broad spectrum activity against gram positive and negative bacteria including problem pathogens such as MDR *A. baumannii*, *K. pneumoniae*, VRE, and MRSA.<sup>372, 373</sup>

Many of the most promising new targets are antibacterial enzymes and one of the most extensively discussed is undoubtedly FtsZ, a highly conserved, GTPase, tubulin homolog that assembles into dynamic contractile ring structures that act as a scaffold for the protein complexes that drive cell division. A host of antibacterial molecules have been recently discovered that target cell division by interfering with FtsZ. Taxanes, such as SB-RA-5001 (**88**), which display anti-cancer properties derived from their stabilization of tubulin structures, are also capable of stabilizing FtsZ ring structures and have shown promising anti-tuberculosis activities.<sup>374</sup> Several structurally unique classes of compounds including benzimidazoles and pteridines possess antibacterial activity based on inhibition of FtsZ polymerization.<sup>375–378</sup> Benzamides, such as PC190723 (**89**), cause FtsZ to polymerize




**Figure 26.** Potential combination therapies.

**Notes:** Cadazolid (**85**), a quinolone (blue) and oxazolidinone (red) combination. TD-1792 (**86**), a glycopeptide (blue) and  $\beta$ -lactam (red) combination.

into non-functional, hyperstable polymers in *Staphylococci*.<sup>379,380</sup> Several classes of aryl tricyclic heterocycles have also shown good activity against gram positive bacteria including MRSA and VRE also through a polymerization stimulating mechanism of action.<sup>381–384</sup> Many disparate classes of molecules have also been found, among other functions, to inhibit the GTPase activity of FtsZ, a function that is essential to the dynamic nature of FtsZ

superstructures.<sup>377,385–391</sup> Acyldepsipeptides have been discovered that activate ClpP peptidase. The dysregulated peptidase causes uncontrolled degradation of FtsZ. These molecules show broad spectrum activity against a wide range of gram positive bacteria.<sup>392–394</sup>

Given the success of antibiotics that target protein synthesis it is unsurprising that other efforts have focused on



**Figure 27.** Antibiotic candidates with novel targets.

**Notes:** MBX-1162 (**87**) is a double stranded nucleic acid groove binder. SB-RA-5001 (**88**) and PC190723 (**89**) target FtsZ. BB-83698 (**90**), LBM415 (**91**), and GSK1322322 (**92**) target peptide deformylase. Abyssomycin C (**93**) blocks p-aminobenzoic acid formation in the tetrahydrofolate biosynthetic pathway. Platensimycin (**94**) targets FabF and platencin (**95**) is a dual FabF / FabH inhibitor. GSK2251052 (**96**) inhibits leucyl-tRNA synthetase.



enzymes involved in post-translational peptide modification. Peptide deformylase, a highly conserved metalloprotease that hydrolyzes the terminal *N*-formyl group present in all bacterial peptides, is a target that has garnered attention for many years now. Significant research efforts have led to many diverse inhibitors of this enzyme, but they have met with limited success for a variety of reasons.<sup>395, 396</sup> Disappointingly, two compounds, BB-83698 (**90**) and LBM415 (**91**), were even advanced to phase I trials before clinical development was discontinued.<sup>397, 398</sup> A hydrazide, GSK1322322 (**92**), has recently advanced to phase II clinical trials for the treatment of gram positive infections, however, keeping hope alive that this target may see a fully developed antibiotic.<sup>399</sup>

Numerous efforts at generating new antibiotics have been focused on biosynthetic enzymes. In 2004 the first of a family of spirotetronate-polyketides, abyssomycin C (**93**), was isolated from a marine strain of actinomycetes.<sup>400</sup> These molecules, like sulfonamides, are tetrahydrofolate synthesis inhibitors. Their antibacterial activity is derived, however, from blocking formation of *p*-aminobenzoic acid rather than its conversion to dihydropteroate, an unprecedented mechanism of action. The potency of these molecules against highly resistant *S. aureus* strains has made them attractive lead compounds, however their cytotoxicity has thus far stifled their advancement towards clinical usage.<sup>401, 402</sup>

Fatty acid biosynthesis inhibitors have also recently generated quite a bit of interest in the antibiotics field. Like inhibiting tetrahydrofolate synthesis, targeting fatty acid synthesis is not in itself novel with FabI [enoyl-acyl carrier protein (ACP) reductase] as an established target for the antibiotics isoniazid and triclosan. However, other enzymes in this biosynthetic pathway remain unexploited. FabF [ $\beta$ -ketoacyl-acyl carrier protein (ACP) synthase II] in particular has recently received significant attention<sup>403–410</sup> largely due to the 2006 discovery of platensimycin (**94**) and its subsequent identification as a FabF inhibitor through an RNA antisense based assay.<sup>411, 412–413</sup> This molecule has shown potent activity against broad spectrum of gram positive bacteria by blocking the malonyl-ACP binding site of FabF.<sup>412</sup> Even more promising is a synergistic dual inhibitor of FabF and FabH ( $\beta$ -ketoacyl-ACP synthase III), platencin (**95**).<sup>414, 415</sup> Though these compounds are both promising, their pharmacokinetics is not optimal and both remain only in pre-clinical stages.<sup>416</sup>

The vast majority of antibiotic candidates with untried targets have shown promise only against gram positive bacteria. The 2-keto-3-deoxy-D-manno-octulosonic acid (Kdo) biosynthetic pathway is one target that could have an impact against gram negative bacteria, however. This monosaccharide is an essential component of the LPS layer of the bacterial outer membrane, but intriguingly is not present among mammalian carbohydrates. Unfortunately, though *in vitro* inhibitors of many steps in this pathway have been synthesized, they have thus far all lacked *in vivo* activity. In some cases this is because of insufficient bioavailability, but in many others it is cellular permeability which is likely the challenge as it is often the case when targeting gram negative pathogens.<sup>417–424</sup>

The target currently closest to potentially achieving clinical validation is likely leucyl-tRNA synthetase. Benzoxaborole compounds have been found to inhibit protein synthesis by binding the terminal adenosine ribose of this enzyme. One of these compounds, GSK2251052 (AN3365) (**96**), has good activity against a broad spectrum of gram positive and negative bacteria. It advanced to phase II clinical trials where its development has currently stalled.<sup>425, 426</sup> Another benzoxaborole has advanced to phase III trials for the treatment of fungal infections and mupirocin, an isoleucyl-tRNA synthetase inhibitor, has been an exemplary topical antibiotic suggesting that it may only be a matter of time until an antibiotic with this target is approved.<sup>427</sup>

## Conclusions and Outlook

Many years of stagnant development and the alarming rise of bacterial resistance fueled by irresponsible policies and practices has created an undeniably dangerous quandary for the field of antibiotics research. Recent efforts by diverse groups including scientists, medical doctors, and even in some cases politicians, have shed light on this predicament, however. The approval of five new classes of antibiotics since the turn of the century to combat the emergent resistant gram-positive pathogens of the 1990s was a step in the right direction. Advances in scientific technology have provided the tools necessary for the discovery of new antibiotic classes and the improvement of already established ones to combat the largely unchecked rise of resistant gram-negative pathogens. It remains to be seen whether these encouraging developments will flower with increases in funding and the backing of major pharmaceutical companies into an antibiotic renaissance or if they will wilt, paving the way for a dreaded “post-antibiotic” era.

## Glossary

**Actinomycetes:** Soil bacteria that produce the majority of currently identified natural product antibiotics. In particular, the genus *Streptomyces* has historically been a prolific source of antibacterial agents.

**Aerobic Bacteria:** All aerobic bacteria require oxygen for growth. Microaerophiles require some oxygen for growth, however they are harmed by high concentrations of it.

**Anaerobic Bacteria:** Bacteria that do not require oxygen for growth. Obligate anaerobes are incapable of growing in oxygenated environments. Aerotolerant anaerobes can grow in oxygenated environments, but are incapable of utilizing oxygen. Facultative anaerobes are capable of utilizing oxygen for growth, but are also capable of surviving in oxygen free environments.

**Bactericidal Agent:** An agent that is capable of killing bacteria. These can be antiseptics, disinfectants, or antibiotics.

**Bacteriostatic Agent:** An agent that stops bacteria from reproducing while not harming them otherwise. Unlike bactericidal agents they are not capable of killing bacteria on their own.

**Biofilm:** A sessile community of microorganisms that adhere to a surface. Some biofilm forming bacteria produce





exopolysaccharide sheaths that make them dramatically less susceptible to antibiotics and other environmental toxins.

**Center for Disease Control and Prevention (CDC):** An agency of the United States Department of Health and Human Services that is in charge of monitoring and maintaining the health safety of its residents in regard to both non-communicable and communicable disease.

**Commensal Bacteria:** Bacteria that benefit from their host environment without causing harm to the host. These bacteria are non-pathogenic.

**Cytotoxin:** Substances that are toxic to cells. They can induce cell death through apoptosis or necrosis or they can simply reduce cell viability.

**Efflux Pump:** Protein or glycoprotein complexes located in the cell membrane that are responsible for energy-dependent, active transport of toxins out of cells. These structures play a major role in bacterial antibiotic resistance. Bacterial efflux pumps are categorized by five sub-families: Major facilitator superfamily (MFS), ATP-binding cassette superfamily (ABC), small multi-drug resistance family (SMR), resistance-nodulation cell-division superfamily (RND), and multi-antimicrobial extrusion protein family (MATE).

**Endotoxin:** Toxins that are not secreted by bacteria, but rather are a part of their cellular membrane and are released only upon its degradation. These toxins are most often lipopolysaccharides.

**Enterobacteriaceae:** A family of gram-negative bacteria that includes many non-pathogenic species as well as many problem pathogens including *Klebsiella*, *Shigella*, *Enterobacter*, *Salmonella*, *E. coli*, and *Y. pestis*.

**Enterotoxin:** Protein exotoxins that target the intestines.

**Exotoxin:** A broad term referring to any toxin that is secreted by the bacteria. Many exotoxins are highly potent and can be potentially lethal to humans.

**Food and Drug Administration (FDA):** An agency of the United States Department of Health and Human Services that regulates food, drugs, and cosmetic products. One of the duties of the FDA within the context of pharmaceuticals is the approval of new drugs for public consumption.

**Gram-negative Bacteria:** Bacteria that have a lipopolysaccharide / protein outer cell membrane and an inner cell membrane with a peptidoglycan layer sandwiched between the two. Their outer cell membrane does not retain Gram stain allowing them to be differentiated from gram-positive bacteria.

**Gram-positive Bacteria:** Bacteria that have a thick peptidoglycan cell wall surrounding their cell membrane which is capable of retaining Gram stain.

**Infectious Diseases Society of America (IDSA):** An association based in the United States that represents health care professionals and scientists from around the world that specialize in infectious diseases. The society promotes research, education, and initiatives related to this field.

**Methylase:** Otherwise known as methyltransferases, these enzymes are highly relevant in many aspects of biology and medicine. In the context of antibiotics they are a common bacterial resistance mechanism. Bacteria utilize them to modify drug targets with methyl groups thereby decreasing the affinity of the antibiotic.

**Nosocomial Infection:** Also referred to as hospital acquired infections (HAIs), these infections occur in hospital associated environments.

**Opportunistic Pathogen:** A microorganism that is normally commensal, but can become pathogenic in hosts with compromised immune systems.

**Penicillin-binding Proteins:** A large group of proteins essential for cell wall biogenesis that are all characterized by their ability to irreversibly bind  $\beta$ -lactam antibiotics.

**Peptidoglycan:** A polymeric saccharide and amino acid structure. In a cross linked form it is the primary constituent of the cell wall of bacteria. Gram positive bacteria have a thick peptidoglycan layer outside of their cell membrane. Gram negative bacteria have a much thinner peptidoglycan layer located between an inner and an outer cell membrane.

**Porin:** Beta-barrel, transmembrane, transport proteins that allow small to medium sized molecules to pass through cell membranes.

**Structure-activity Relationship (SAR):** The relationship between the chemical structure of a molecule and its biological activity. Medicinal chemists probe this relationship by manipulating functional groups or even larger portions of a molecule and then observing the changes to biological activity that result.

**World Health Organization (WHO):** An agency of the United Nations with a focus on international public health. The WHO monitors and advises on all aspects of public health including trends in communicable diseases.

**Zoonotic Infection:** A disease transmitted from animals to humans. These infections can occur via contact with living animals or through the consumption of foods that are either products of animals or have been contaminated by animals.

## Acknowledgements

The authors would like to thank Dr. Lisa McCoy for editorial assistance.

## Author Contributions

Wrote the first draft of the manuscript: RJF. Contributed to the writing of the manuscript: RJF, YT. Agree with manuscript results and conclusions: RJF, YT. Jointly developed the structure and arguments for the paper: RJF, YT. Made critical revisions and approved final version: RJF, YT. Both authors reviewed and approved of the final manuscript.

## REFERENCES

1. Appelbaum PC, 2012 and Beyond: Potential for the Start of a Second Pre-antibiotic Era? *J Antimicrob Chemother.* 2012;67(9):2062–8.



2. Center for Disease Control and Prevention. Achievements in Public Health, 1900–1999: Control of Infectious Diseases. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4829a1.htm>. Accessed December 20, 2013.
3. Center for Disease Control and Prevention. World Health Day: Media Fact Sheet. Available at: [http://www.cdc.gov/media/releases/2011/f0407\\_antimicrobialresistance.pdf](http://www.cdc.gov/media/releases/2011/f0407_antimicrobialresistance.pdf). Accessed December 20, 2013.
4. Center for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. Available at: <http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf>. Accessed March 19, 2014.
5. European Medicine Agency. The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. Available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Report/2009/11/WC500008770.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Report/2009/11/WC500008770.pdf). Accessed: December 20, 2013.
6. Sipahi OR. Effects of Antibiotic Resistance on Industrial Antibiotic R&D. *Expert Rev Anti Infect Ther.* 2008;6(4):523–39.
7. Shlaes DM. *Antibiotics: The Perfect Storm*. The Netherlands: Springer; 2010.
8. Spellberg B, Guidos R, Gilbert D, et al. The Epidemic of Antibiotic-resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America. *Clin Infect Dis* 2008;46(2):155–64.
9. Projan SJ. Why is Big Pharma Getting out of Antibacterial Drug Discovery? *Curr Opin Microbiol.* 2003;6(5):427–30.
10. Power E. Impact of Antibiotic Restrictions: The Pharmaceutical Perspective. *Clin Microb Infect.* 2006;12(Suppl. 5):25–34.
11. Boucher HW, Talbot GH, Benjamin Jr DK, et al. 10x'20 Progress—Development of New Drugs Active Against Gram-negative Bacilli: An Update from the Infectious Diseases Society of America. *Clin Infect Dis.* 2013;56(12):1685–94.
12. (a) Jabes D. The antibiotic R&D Pipeline: An Update. *Curr Opin in Microbiol.* 2011;14(5):564–9.
13. Moellering RC. Discovering New Antimicrobial Agents. *Int J Antimicrob Agents.* 2011;37(1):2–9.
14. WHO: Department of Communicable Disease Surveillance and Response. WHO Global Strategy for Containment of Antimicrobial Resistance. Available at: [http://www.who.int/csr/resources/publications/drugresist/en/EGlobal\\_Strat.pdf](http://www.who.int/csr/resources/publications/drugresist/en/EGlobal_Strat.pdf). Accessed: December 20, 2013.
15. European Centre for Disease Prevention and Control. Communication from the Commission to the European Parliament and the Council. Action plan against the rising threats from Antimicrobial Resistance. Available at: [http://ec.europa.eu/dgs/health\\_consumer/docs/communication\\_amr\\_2011\\_748\\_en.pdf](http://ec.europa.eu/dgs/health_consumer/docs/communication_amr_2011_748_en.pdf). Accessed: December 20, 2013.
16. Nathan C. Antibiotics at the Crossroads. *Nature.* 2004;431(7011):899–902.
17. Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS. Combating Antimicrobial Resistance: Policy Recommendations to Save Lives. *Clin Infect Dis.* 2011;52(Suppl. 5):S397–428.
18. The Wall Street Journal. FDA Chief Focuses on Antibiotic Resistance. Available at: <http://online.wsj.com/article/SB10001424052748703735804575536411612671060.html>. Accessed December 20, 2013.
19. Brookings Institution. Facilitating Antibacterial Drug Development 2012. Available at: <http://www.brookings.edu/events/2012/05/09-antibacterialdrug-development>. Accessed December 20, 2013.
20. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable Impact of a Multidisciplinary Antibiotic Management Program Conducted During 7 Years. *Infect Control Hosp Epidemiol.* 2003;24(9):699–706.
21. Yong MK, Buising KL, Cheng AC, Thursky KA. Improved Susceptibility of Gram-negative Bacteria in an Intensive Care Unit Following Implementation of a Computerized Antibiotic Decision Support System. *J Antimicrob Chemother.* 2010;65(5):1062–9.
22. Fishman N. Antimicrobial Stewardship. *Am J Med.* 2006;119(6 Suppl. 1):S53–61.
23. Pendleton JN, Gorman SP, Gilmore BF. Clinical Relevance of the ESKAPE Pathogens. *Expert Rev Anti Infect Ther.* 2013;11(3):297–308.
24. Jacob JT, Gaynes RP. Emerging Trends in Antibiotic use in US Hospitals: Quality, Quantification and Stewardship. *Expert Rev Anti Infect Ther.* 2010;8(8):893–902.
25. Palumbi SR. *Science*, Humans as the World's Greatest Evolutionary Force. 2001;293(5536):1786–90.
26. Rice LB. The Maxwell Finland Lecture: For the Duration-rational Antibiotic Administration in an Era of Antimicrobial Resistance and *Clostridium difficile*. *Clin Infect Dis* 2008;46(4):491–6.
27. Seppala H, Klaukka T, Lehtonen R, Nenonen E, Huovinen P. Outpatient use of Erythromycin: Link to Increased Erythromycin Resistance in Group A Streptococci. *Clin Infect Dis.* 1995;21(6):1378–85.
28. Goossens H, Ferech M, Vander SR, Elseviers M. Outpatient Antibiotic use in Europe and Association with Resistance: A Cross-national Database Study. *Lancet.* 2005;365(9459):579–87.
29. Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K. The Effect of Changes in the Consumption of Macrolide Antibiotics on Erythromycin Resistance in Group A Streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. *N Engl J Med.* 1997;337(7):441–6.
30. Anonymous, Recent trends in Antimicrobial Resistance among Streptococcus pneumoniae and Staphylococcus aureus Isolates: The French Experience. *Euro Surveill.* 2008;13(46):19035.
31. Special Eurobarometer 338 'Antimicrobial Resistance', 2009. Survey Commissioned by the Directorate-General for Health and Consumers and Coordinated by the Directorate-General Communication ('Research and Political Analysis' Unit). Available at: [http://ec.europa.eu/public\\_opinion/index\\_fr.htm](http://ec.europa.eu/public_opinion/index_fr.htm). Accessed December 20, 2013.
32. Kunin CM. Resistance to Antimicrobial Drugs: A Worldwide Calamity. *Ann Intern Med.* 1993;118(7):557–61.
33. Gorbach SL. Antimicrobial use in Animal Feed: Time to Stop. *N Engl J Med.* 2001;345(16):1202–3.
34. Official Journal of the European Union. Regulation (EC) No. 1831/2003 of the European Parliament and of The Council of 22 September 2003 on Additives for use in Animal Nutrition. Available at: <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:268:0029:0043:EN:PDF>. Accessed: December 20, 2013.
35. FDA News Release. FDA Takes Steps to Protect Public Health. Available at: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm299802.htm>. Accessed: December 20, 2013.
36. Qin X, Razia Y, Johnson JR, et al. Ciprofloxacin-resistant Gram-negative Bacilli in the Fecal Microflora of Children. *Antimicrob Agents Chemother.* 2006;50(10):3325–9.
37. van den Bogaard AE, London N, Driessen C, Stobberingh EE. Antibiotic Resistance of Faecal Escherichia coli in Poultry, Poultry Farmers and Poultry Slaughterers. *J Antimicrob Chemother.* 2001;47(6):763–71.
38. Mead PS, Slutsker L, Dietz V, McCaig LF, Bresee JS, Shapiro C. Food-related Illness and Death in the United States. *Emerg Infect Dis.* 1999;5(5):607–25.
39. Wegener HC, Aarestrup FC, Jensen LB, Hammerum AM, Bager F. Use of Antimicrobial Growth Promoters in Food Animals and Enterococcus faecium Resistance to Therapeutic Antimicrobial Drugs in Europe. *Emerg Infect Dis.* 1999;5(3):329–35.
40. Wegener HC. Antibiotics in Animal Feed and their Role in Resistance Development. *Curr Opin Microbiol.* 2003;6(5):439–45.
41. European Medicines Agency. Trends in the Sales of Veterinary Antimicrobial Agents in Nine European Countries. Reporting period: 2005–2009. Available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Report/2011/09/WC500112309.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/09/WC500112309.pdf). Accessed: December 20, 2013.
42. Walsh C. *Antibiotics: Actions, Origins, Resistance*. American Society for Microbiology (ASM) Press: Washington, DC, 2003.
43. Wright GD, Poinar H. Antibiotic Resistance is Ancient: Implications for Drug Discovery. *Trends in Microbiol.* 2012;20(4):157–9.
44. Davies J, Davies D. Origins and Evolution of Antibiotic Resistance. *Microbiol Mol Biol Rev.* 2010;74(3):417–33.
45. Lyon BR, Skurray R. Antimicrobial Resistance of Staphylococcus aureus: Genetic Basis. *Microbiol Rev.* 1987;51(1):88–134.
46. Schaack S, Gilbert C, Feschotte C. Promiscuous DNA: Horizontal Transfer of Transposable Elements and why it Matters for Eukaryotic Evolution. *Trends Ecol Evol.* 2010;25(9):537–46.
47. Hall BG, Barlow M. Structure-based Phylogenies of the Serine Beta-lactamases. *J Mol Evol.* 2003;57(3):255–60.
48. D'Costa VM, King CE, Kalan L, et al. Antibiotic Resistance is Ancient. *Nature.* 2011;477(7365):457–61.
49. Baltz RH. Antibiotic Discovery from Actinomycetes: Will a Renaissance Follow the Decline and Fall? *SIM News.* 2005;55:186–96.
50. D'Costa VM, McGrann KM, Hughes DW, Wright GD. Sampling the Antibiotic Resistome. *Science.* 2006;311(5759):374–7.
51. Pallecchi L, Bartoloni A, Paradisi F, Rossolini GM. Antibiotic Resistance in the Absence of Antimicrobial Use: Mechanisms and Implications. *Expert Rev Anti Infect Ther.* 2008;6(5):725–32.
52. Kluytmans J, van Belkum A, Verbrugh H. Nasal Carriage of Staphylococcus aureus: Epidemiology, Underlying Mechanisms, and Associated Risks. *Clin Microbiol Rev.* 1997;10(3):505–20.
53. Boubaker K, Diebold P, Blanc DS, et al. Panton-Valentine Leukocidin and Staphylococcal Skin Infections in Schoolchildren. *Emerging Infect Dis.* 2004;10(1):121–4.
54. Parsonnet J, Hansmann MA, Delaney ML, et al. Prevalence of Toxic Shock Syndrome Toxin 1-Producing Staphylococcus aureus and the Presence of Antibodies to this Superantigen in Menstruating Women. *J. Clin. Microbiol.* 2005;43(9):4628–34.
55. Lina G, Piémont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine Leukocidin-producing Staphylococcus aureus in Primary Skin Infections and Pneumonia. *Clin Infect Dis.* 1999;29(5):1128–32.
56. Vandenesch F, Naimi T, Enright MC, et al. Community-acquired Methicillin-resistant Staphylococcus aureus Carrying Panton-Valentine Leukocidin Genes: Worldwide Emergence. *Emerging Infect Dis.* 2003;9(8):978–84.
57. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus Strains Carrying the Gene for Panton-Valentine Leukocidin and Highly Lethal Necrotising Pneumonia in Young Immunocompetent Patients. *Lancet.* 2002;359(9308):753–9.



58. Boucher HW, Talbot GH, Bradley JS, et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. *Clin Infect Dis*. 2009;48(1):1–2.
59. Liu GY, Essex A, Buchanan JT, et al. Staphylococcus aureus Golden Pigment Impairs Neutrophil Killing and Promotes Virulence Through its Antioxidant Activity. *J Exp Med*. 2005;202(2):209–15.
60. Clauditz A, Resch A, Wieland KP, Peschel A, Götz F. Staphyloxanthin Plays a Role in the Fitness of Staphylococcus aureus and its Ability to Cope with Oxidative Stress. *Infect Immun*. 2006;74(8):4950–3.
61. Costerton JW, Stewart PS, Greenberg EP. Bacterial Biofilms: A Common Cause of Persistent Infections. *Science*. 1999;284(5418):1318–22.
62. Fischbach MA, Walsh CT. Antibiotics for Emerging Pathogens. *Science*. 2009;325(5944):1089–93.
63. Klevens RM, Morrison MA, Nadle J, et al. Invasive Methicillin-resistant Staphylococcus aureus Infections in the United States. *JAMA*. 2007;298(15):1763–71.
64. Talbot GH, Bradley J, Edwards Jr JE, Gilbert D, Scheld M, Bartlett JG. Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. *Clin Infect Dis*. 2006;42(5):657–68.
65. Smith A. *Bacterial resistance to antibiotics*. In: *Hugo and Russell's Pharmaceutical Microbiology*. Denyer SP, Hodges NA, Gorman SP (Eds). Blackwell Science Ltd, Oxford, UK, 2007.
66. Appelbaum PC. Reduced Glycopeptide Susceptibility in Methicillin-resistant Staphylococcus aureus (MRSA). *Int J Antimicrob Agents*. 2007;30(5):398–408.
67. Chang S, Sievert DM, Hageman JC, et al. Infection with Vancomycin-resistant Staphylococcus aureus Containing the vanA Resistance Gene. *N Engl J Med*. 2003;348(14):1342–47.
68. Department of Health, Standing Medical Advisory Committee, Sub-Group on Antimicrobial Resistance. The Path of Least Resistance. Available at: <http://antibiotic-action.com/wp-content/uploads/2011/07/Standing-Medical-Advisory-Committee-The-path-of-least-resistance-1998.pdf>. Accessed: December 20, 2013.
69. Fisher K, Phillips C. The Ecology, Epidemiology and Virulence of Enterococcus. *Microbiology*. 2009;155(6):1749–57.
70. Livermore DM. Future Directions with Daptomycin. *J Antimicrob Chemother*. 2008;62 Suppl(3):iii41–9.
71. Arias CA, Contreras GA, Murray BE. Management of Multidrug-resistant Enterococcal Infections. *CMI*. 2010;16(6):555–62.
72. van Wamel WJ, Hendrick AP, Bonten MJ, Top J, Posthuma G, Willems RJ. Growth Condition-dependent Esp Expression by Enterococcus faecium Affects Initial Adherence and Biofilm Formation. *Infect Immun*. 2007;75(2):924–31.
73. Zinner SH. The Search for New Antimicrobials: Why we Need New Options. *Expert Rev Anti Infect Ther*. 2005;3(6):907–13.
74. Regev-Yochay G, Trzcinski K, Thompson CM, Malley R, Lipsitch M. Interference Between Streptococcus pneumoniae and Staphylococcus aureus: In vitro Hydrogen Peroxide-mediated Killing by Streptococcus pneumoniae. *J Bacteriol*. 2006;188(13):4996–5001.
75. Jacobs MR. Streptococcus pneumoniae: Epidemiology and Patterns of Resistance. *Am J Med*. 2004;117 Suppl(3A):S3–15.
76. Karchmer AW. Increased Antibiotic Resistance in Respiratory Tract Pathogens: PROTEKT US--An Update. *Clin Infect Dis*. 2004;39 Suppl(3):S142–50.
77. Edelstein PH. Pneumococcal Resistance to Macrolides, Lincosamides, Ketolides, and Streptogramin B Agents: Molecular Mechanisms and Resistance Phenotypes. *Clin Infect Dis*. 2004;38 Suppl(4):S322–7.
78. von Gottberg A, Klugman KP, Cohen C, et al. Emergence of Levofloxacin-nonsusceptible Streptococcus pneumoniae and Treatment for Multidrug-resistant Tuberculosis in Children in South Africa: A Cohort Observational Surveillance Study. *Lancet*. 2008;371(9618):1108–13.
79. Barth H, Aktories K, Popoff MR, Stiles BG. Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins. *Microbiol Mol Biol Rev*. 2004;68(3):373–402.
80. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by Hospitalized Patients: Evidence for Colonized New Admissions as a Source of Infection. *J Infect Dis*. 1992;166(3):561–7.
81. Planche T, Aghaizu A, Holliman R, Riley P, Poloniecki J, Breathnach A, Krishna S. Diagnosis of Clostridium difficile Infection by Toxin Detection Kits: A Systematic Review. *Lancet Infect Dis*. 2008;8(12):777–84.
82. Pepin J, Saheb N, Coulombe MA, et al. Emergence of Fluoroquinolones as the Predominant Risk Factor for Clostridium difficile-Associated Diarrhea: A Cohort Study During an Epidemic in Quebec. *Clin Infect Dis*. 2005;41(9):1254–60.
83. McDonald LC, Killgore GE, Thompson A, et al. An Epidemic, Toxin Gene-variant Strain of Clostridium difficile. *N Engl J Med*. 2005;353(23):2433–41.
84. Loffler CA, MacDougall C. Update on Prevalence and Treatment of Methicillin-resistant Staphylococcus aureus Infections. *Exp Rev Anti Infect Ther*. 2007;5(6):961–81.
85. Daxboeck F, Budic T, Assadian O, Reich M, Koller W. Economic Burden Associated with Multi-resistant Gram-negative Organisms Compared with that for Methicillin-resistant Staphylococcus aureus in a University Teaching Hospital. *J Hosp Infect*. 2006;62(2):214–8.
86. Arias CA, Murray BE. Antibiotic-resistant Bugs in the 21st Century--A Clinical Super-challenge. *N Engl J Med*. 2009;360(5):439–43.
87. Kumarasamy KK, Toleman MA, Walsh TM, et al. Emergence of a New Antibiotic Resistance Mechanism in India, Pakistan, and the UK: A Molecular, Biological, and Epidemiological Study. *Lancet Infect Dis*. 2010;10(9):597–602.
88. Flynn JL, Chan J. Immune Evasion by Mycobacterium tuberculosis: Living with the Enemy. *Curr Opin Immunol*. 2003;15(4):450–5.
89. Niederweis M, Danilchanka O, Huff J, Hoffmann C, Engelhardt H. Mycobacterial Outer Membranes: In Search of Proteins. *Trends in Microbiol*. 2010;18(3):109–16.
90. World Health Organization. Tuberculosis Fact Sheet. Available at: <http://www.who.int/mediacentre/factsheets/fs104/en/index.html>. Accessed: December 20, 2013.
91. Anonymous. Extensively Drug-resistant Tuberculosis (XDR-TB): Recommendations for Prevention and Control. *Wkly Epidemiol Rec*. 2006;81(45):430–2.
92. Dorman SE, Chaisson RE. From Magic Bullets Back to the Magic Mountain: The Rise of Extensively Drug-resistant Tuberculosis. *Nat Med*. 2007;13(3):295–8.
93. Kim DH, Hee J, Park SK, et al. Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis. *Am J Respir Crit Care Med*. 2008;178(10):1075–82.
94. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. *Nat Rev Microbiol*. 2004;2(2):123–40.
95. O'Brien AD, Newland JW, Miller SF, Holmes RK, Smith HW, Formal SB. Shiga-like Toxin-converting Phages from Escherichia coli Strains that Cause Hemorrhagic Colitis or Infantile Diarrhea. *Science*. 1984;226(4675):694–6.
96. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R. Non-susceptibility Trends among Enterobacteriaceae from Bacteraemias in the UK and Ireland, 2001–06. *J Antimicrob Chemother*. 2008;62(Suppl 2):ii41–54.
97. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. Emergence of Metallo- $\beta$ -lactamase NDM-1 Producing Multidrug-resistant Escherichia coli in Australia. *Antimicrob Agents Chemother*. 2010;54(11):4914–6.
98. Solé M, Pitart C, Roca I, et al. First Description of an Escherichia coli Strain Producing NDM-1 Carbapenemase in Spain. *Antimicrob Agents Chemother*. 2011;55(9):4402–04.
99. Pfeifer Y, Witte W, Holfelder M, Busch J, Nordmann P, Poirel L. NDM-1 Producing Escherichia coli in Germany. *Antimicrob Agents Chemother*. 2011;55(3):1318–9.
100. Nordmann P, Poirel L, Toleman MA, Walsh TA. Does Broad-spectrum  $\beta$ -lactam Resistance due to NDM-1 Herald the End of the Antibiotic Era for Treatment of Infections Caused by Gram-negative Bacteria? *J Antimicrob Chemother*. 2011;66(4):689–92.
101. Souli M, Galani I, Giamarellou H. Emergence of Extensively Drug-resistant and Pandrug-resistant Gram-negative Bacilli in Europe. *Euro Surveill*. 2008;13(47):pii=19045.
102. Rodloff AC, Leclercq R, Debbia EA, Canton R, Oppenheim BA, Dowzicky MJ. Comparative Analysis of Antimicrobial Susceptibility among Organisms from France, Germany, Italy, Spain and the UK as Part of the Tigecycline Evaluation and Surveillance Trial. *Clin Microbiol Infect*. 2008;14(4):307–14.
103. Kobayashi S, Kuzuyama T, Seto H. Characterization of the fomA and fomB Gene Products from Streptomyces wedmorensis, which Confer Fosfomycin Resistance on Escherichia coli. *Antimicrob Agents Chemother*. 2000;44(3):647–650.
104. New York State Department of Health. Health Commissioner Releases E. coli Outbreak Report. Available at: <http://www.health.ny.gov/press/releases/2000/ecoli.htm>. Accessed December 20, 2013.
105. Frank C, Werber D, Cramer JP, et al. Epidemic Profile of Shiga-toxin Producing Escherichia coli O104:H4 Outbreak in Germany. *N Engl J Med*. 2011;365(19):1771–80.
106. Hart CA, Winstanley C. Persistent and Aggressive Bacteria in the Lungs of Cystic Fibrosis Children. *Br Med Bull*. 2002;61:81–96.
107. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High Frequency of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Lung Infection. *Science*. 2000;288(5469):1251–4.
108. Henrichfreise B, Wiegand I, Pfister W, Wiedemann B. Resistance Mechanisms of Multiresistant Pseudomonas aeruginosa Strains from Germany and Correlation with Hypermutation. *Antimicrob Agents Chemother*. 2007;51(11):4062–70.
109. Lee VT, Smith RS, Tummeler B, Lory S. Activities of Pseudomonas aeruginosa Effectors Secreted by the Type III Secretion System in vitro and During Infection. *Infect Immun*. 2005;73(3):1695–705.
110. Adair FW, Gefic SG, Gelzer J. Resistance of Pseudomonas to Quaternary Ammonium Compounds. I. Growth in Benzalkonium Chloride Solution. *Appl Microbiol*. 1969;18(3):299–302.
111. Nikaido H. Molecular Basis of Bacterial Outer Membrane Permeability Revisited. *Microbiol Mol Biol Rev*. 2003;67(4):593–656.
112. Fothergill JL, Winstanley C, James CE. Novel Therapeutic Strategies to Counter Pseudomonas aeruginosa Infections. *Expert Rev Anti Infect Ther*. 2012;10(2):219–35.
113. Bush K. Alarming  $\beta$ -lactamase-mediated Resistance in Multidrug-resistant Enterobacteriaceae. *Curr Opin Microbiol*. 2010;13(5):558–64.



114. Livermore DM. Multiple Mechanisms of Antimicrobial Resistance in *Pseudomonas aeruginosa*: Our Worst Nightmare? *Clin Infect Dis*. 2002;34(5):634–40.
115. Morero NR, Monti MR, Argaraña CE. Effect of Ciprofloxacin Concentration on the Frequency and Nature of Resistant Mutants Selected from *Pseudomonas aeruginosa* mutS and mutT Hypermutators. *Antimicrob Agents Chemother*. 2011;55(8):3668–76.
116. Deplano A, Denis O, Poirel L, et al. Struelens MJ, Molecular Characterization of an Epidemic Clone of Panantibiotic-resistant *Pseudomonas aeruginosa*. *J Clin Microbiol*. 2005;43(3):1198–204.
117. Lolans K, Queenan AM, Bush K, Sahud A, Quinn JP. First Nosocomial Outbreak of *Pseudomonas aeruginosa* Producing an Integron-borne Metallo-beta-lactamase (VIM-2) in the United States. *Antimicrob Agents Chemother*. 2005;49(8):3538–40.
118. Crespo MP, Woodford N, Sinclair A, et al. Outbreak of Carbapenem-resistant *Pseudomonas aeruginosa* Producing VIM-8, a Novel Metallo-beta-lactamase, in a Tertiary Care Center in Cali, Colombia. *J Clin Microbiol*. 2004;42(11):5094–101.
119. Kallen AJ, Srinivasan A. Current Epidemiology of Multidrug-resistant Gram-negative Bacilli in the United States. *Infect Control Hosp Epidemiol*. 2010;31Suppl(1):S51–4.
120. Abbo A, Carmeli Y, Navon-Venezia S, Siegman-Igra Y, Schwaber MJ. Impact of Multi-drug-resistant *Acinetobacter baumannii* on Clinical Outcomes. *Eur J Clin Microbiol Infect Dis*. 2007;26(11):793–800.
121. Vila J, Marti S, Sánchez-Céspedes J. Porins, Efflux Pumps and Multidrug Resistance in *Acinetobacter baumannii*. *J Antimicrob Chemother*. 2007;59(6):1210–5.
122. Kramer A, Schwabke I, Kampf G. How Long do Nosocomial Pathogens Persist on Inanimate Surfaces? A Systematic Review. *BMC Infect Dis*. 2006;6:130.
123. Houang ET, Sormunen RT, Lai L, Chan CY, Leong AS. Effect of Desiccation on the Ultrastructural Appearances of *Acinetobacter baumannii* and *Acinetobacter lwoffii*. *J Clin Pathol*. 1998;51(10):786–8.
124. Gootz TD, Marra A. *Acinetobacter baumannii*: An Emerging Multidrug-resistant Threat. *Expert Rev Anti Infect Ther*. 2008;6(3):309–25.
125. Joly-Guillou ML. Clinical Impact and Pathogenicity of *Acinetobacter*. *Clin Microbiol Infect*. 2005;11(11):868–73.
126. Choi CH, Lee EY, Lee Park YC, et al. Outer Membrane Protein 38 of *Acinetobacter baumannii* Localizes to the Mitochondria and Induces Apoptosis of Epithelial Cells. *Cell Microbiol*. 2005;7(8):1127–38.
127. Queenan AM, Bush K. Carbapenemases: The Versatile Beta-lactamases. *Clin Microbiol Rev*. 2007;20(3):440–58.
128. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant Pathogens Associated with Healthcare-associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. *Infect Control Hosp Epidemiol*. 2013;34(1):1–4.
129. Munoz-Price LS, Weinstein RA. *Acinetobacter* Infection. *N Engl J Med*. 2008;358(12):1271–81.
130. Macrae MB, Shannon KP, Rayner DM, Kaiser AM, Hoffman PN, French GL. A Simultaneous Outbreak on a Neonatal Unit of Two Strains of Multiply Antibiotic Resistant *Klebsiella pneumoniae* Controllable only by Ward Closure. *J Hosp Infect*. 2001;49(3):183–92.
131. Fontana C, Favaro M, Minelli S, et al. *Acinetobacter baumannii* in Intensive Care Unit: A Novel System to Study Clonal Relationship among the Isolates. *BMC Infect Dis*. 2008;8(8):79.
132. Podschun R, Ullmann U. *Klebsiella* spp. as Nosocomial Pathogens: Epidemiology, Taxonomy, Typing Methods, and Pathogenicity Factors. *Clin Microbiol Rev*. 1998;11(4):589–603.
133. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone Resistance from a Transferable Plasmid. *Lancet*. 1998;351(9105):797–9.
134. Yong D, Toleman MA, Giske CG, et al. Characterization of a New Metallo-beta-lactamase Gene, bla(NDM-1), and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in *Klebsiella pneumoniae* Sequence Type 14 from India. *Antimicrob Agents Chemother*. 2009;53(12):5046–54.
135. Hawser SP, Bouchillon SK, Hoban DJ, Badal BD, Hsueh PR, Paterson DL. Emergence of High Levels of Extended-spectrum Beta-lactamase-producing Gram-negative Bacilli in the Asia-Pacific Region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007. *Antimicrob Agents Chemother*. 2009;53(8):3280–4.
136. Elemam A, Rahimian J, Mandell W. Infection with Panresistant *Klebsiella pneumoniae*: A Report of 2 Cases and a Brief Review of the Literature. *Clin Infect Dis*. 2009;49(2):271–4.
137. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early Dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian Hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006–2007. *Antimicrob Agents Chemother*. 2011;55(3):1274–8.
138. Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. Prevalence in the United States of aac(6)-Ib-cr Encoding a Ciprofloxacin-modifying Enzyme. *Antimicrob Agents Chemother*. 2006;50(11):3953–5.
139. Stern A, Brown M, Nickel P, Meyer TF. Opacity Genes in *Neisseria gonorrhoeae*: Control of Phase and Antigenic Variation. *Cell*. 1986;47(1):61–71.
140. Yokoi S, Deguchi T, Ozawa T, et al. Threat to Cefixime Treatment for Gonorrhea. *Emerg Infect Dis*. 2007;13(8):1275–7.
141. Palmer HM, Young H, Winter A, Dave J. Emergence and Spread of Azithromycin-resistant *Neisseria gonorrhoeae* in Scotland. *J Antimicrob Chemother*. 2008;62(3):490–4.
142. Livermore DM. Has the Era of Untreatable Infections Arrived? *J Antimicrob Chemother*. 2009;64Suppl(1):i29–36.
143. Centers for Disease Control and Prevention. Healthcare-associated Infections (HAIs) – The Burden. Available at: <http://www.cdc.gov/HAI/burden.html>. Accessed December 20, 2013.
144. Allegranzi B, Bagheri Nejad S, Combescure C, et al. Burden of Endemic Health-care-associated Infection in Developing Countries: Systematic Review and Meta-analysis. *Lancet*. 2011;377(9761):228–41.
145. Paphitou NI. Antimicrobial Resistance: Action to Combat the Rising Microbial Challenges. *Int J Antimicrob Agents*. 2013;42S:S25–8.
146. Rice LB. Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE. *J Infect Dis*. 2008;197(8):1079–81.
147. Silver LL. Challenges of Antibacterial Discovery. *Clin Microbiol Rev*. 2011;24(1):71–109.
148. Andes D, Anon J, Jacobs MR, Craig WA. Application of Pharmacokinetics and Pharmacodynamics to Antimicrobial Therapy of Respiratory Tract Infections. *Clin Lab Med*. 2004;24(2):477–502.
149. Newman DJ, Cragg GM. Natural Products as Sources of New Drugs over the Last 25 Years. *J Nat Prod*. 2007;70(3):461–77.
150. Singh SB, Barrett JF. Empirical Antibacterial Drug Discovery-Foundation in Natural Products. *Biochem Pharmacol*. 2006;71(7):1006–15.
151. Hansen JL, Moore PB, Steitz TA. Structures of Five Antibiotics Bound at the Peptidyl Transferase Center of the Large Ribosomal Subunit. *J Mol Biol*. 2003;330(5):1061–75.
152. Moore PB, Steitz TA. The Ribosome Revealed. *Trends Biochem Sci*. 2005;30(6):281–3.
153. Akerley BJ, Rubin EJ, Novick VL, Amaya K, Judson N, Mekalanos JJ. A Genome-scale Analysis for Identification of Genes Required for Growth or Survival of *Haemophilus influenzae*. *Proc Natl Acad Sci USA*. 2002;99(2):966–71.
154. Hutchison CA, Peterson SN, Gill SR, et al. Global Transposon Mutagenesis and a Minimal *Mycoplasma* Genome. *Science*. 1999;286(5447):2165–9.
155. Ji Y, Zhang B, Van SF, et al. Identification of Critical Staphylococcal Genes using Conditional Phenotypes Generated by Antisense RNA. *Science*. 2001;293(5538):2266–9.
156. Kobayashi K, Ehrlich SD, Albertini A, et al. Essential *Bacillus subtilis* Genes. *Proc Natl Acad Sci USA*. 2003;100(8):4678–83.
157. Forsyth RA, Haselbeck RJ, Ohlsen KL, et al. A Genome-wide Strategy for the Identification of Essential Genes in *Staphylococcus aureus*. *Mol Microbiol*. 2002;43(6):1387–400.
158. Infectious Diseases Society of America. The 10x '20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020. *Clin Infect Dis*. 2010;50(8):1081–3.
159. Witting K, Smith RD. Discovery of Antibacterials and Other Bioactive Compounds from Microorganisms-evaluating Methodologies for Discovery and Generation of Non-ribosomal Peptide Antibiotics. *Curr Drug Targets*. 2011;12(11):1547–59.
160. Clardy J, Fischbach MA, Walsh CT. New Antibiotics from Bacterial Natural Products. *Nat Biotechnol*. 2006;24(12):1541–50.
161. Lomovskaya O, Lewis K. Emr, an *Escherichia coli* Locus for Multidrug Resistance. *Proc Natl Acad Sci USA*. 1992;89(18):8938–42.
162. Li XZ, Nikaido H. Efflux-mediated Drug Resistance in Bacteria. *Drugs*. 2004;64(2):159–204.
163. Lewis K. Platforms for Antibiotic Discovery. *Nat Rev Drug Disc*. 2013;12(5):371–87.
164. O'Shea R, Moser HE. Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery. *J Med Chem*. 2008;51(10):2871–8.
165. Silver LL. Are Natural Products Still the Best Source for Antibacterial Discovery? The bacterial entry factor. *Expert Opin Drug Discov*. 2008;3(5):487–500.
166. Hsieh PC, Siegel SA, Rogers B, Davis D, Lewis K. Bacteria Lacking a Multidrug Pump: A Sensitive Tool for Drug Discovery. *Proc Natl Acad Sci USA*. 1998;95(12):6602–6.
167. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. Synergy in a Medicinal Plant: Antimicrobial Action of Berberine Potentiated by 5'-Methoxyhydrocarpin, a Multidrug Pump Inhibitor. *Proc Natl Acad Sci USA*. 2000;97(4):1433–7.
168. Lewis K, Ausubel FM. Prospects for Plant-derived Antibacterials. *Nature Biotech*. 2006;24(12):1504–7.
169. Rock FL, Mao W, Yaremchuk A, et al. An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site. *Science*. 2007;316(5832):1759–61.
170. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for Bad Bugs: Confronting the Challenges of Antibacterial Discovery. *Nature Rev Drug Discov*. 2007;6(1):29–40.
171. Singh SB, Young K, Miesel L. Screening Strategies for Discovery of Antibacterial Natural Products. *Expert Rev Anti Infect Ther*. 2011;9(8):589–613.



172. Boguski MS, Mandl KD, Sukhatme VP. Drug Discovery. Repurposing with a Difference. *Science*. 2009;324(5933):1394–5.
173. Andries K, Verhasselt P, Guillemont J, et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis. *Science*. 2005;307(5707):223–7.
174. Moy TI, Ball AR, Anklesaria Z, Casadei G, Lewis K, Ausubel FM. Identification of Novel Antimicrobials using a Live-animal Infection Model. *Proc Natl Acad Sci USA* 2006;103(27):10414–9.
175. O'Rourke EJ, Conery AL, Moy TI. Whole-animal High-throughput Screens: The *C. elegans* Model. *Methods Mol Biol*. 2009;486:57–75.
176. Galloway WRJD, Bender A, Welch M, Spring DR. The Discovery of Antibacterial Agents using Diversity-oriented Synthesis. *Chem Commun*. 2009;18:2446–62.
177. Robinson A, Thomas GL, Spandl RJ, Welch M, Spring DR. Gemmacin B: Bringing Diversity Back into Focus. *Org Biomol Chem*. 2008;6(16):2978–81.
178. Wyatt EE, Galloway WRJD, Thomas GL, et al. Identification of an Anti-MRSA Dihydrofolate Reductase Inhibitor from a Diversity-oriented Synthesis. *Chem Commun*. 2008;40:4962–4.
179. Watve MG, Tickoo R, Jog MM, Bhole BD. How Many Antibiotics are Produced by the Genus Streptomyces? *Arch Microbiol*. 2001;176(5):386–90.
180. Weber T, Welzel K, Pelzer S, Vente A, Wohlleben W. Exploiting the Genetic Potential of Polyketide Producing Streptomyces. *J Biotechnol*. 2003;106(2–3):221–32.
181. Baltz RH. Genetic Manipulation of Antibiotic-producing Streptomyces. *Trends Microbiol*. 1998;6(2):76–83.
182. Fischbach MA. Antibiotics from Microbes: Converging to Kill. *Curr Opin Microbiol*. 2009;12(5):520–7.
183. Bister B, Bischoff D, Ströbele M, et al. *Angew Chem Int Ed*. 2004;43(19):2574–6.
184. Laport MS, Santos OC, Muricy G. Marine Sponges: Potential Sources of New Antimicrobial Drugs. *Curr Pharm Biotechnol*. 2009;10(1):86–105.
185. Burgess JG, Jordan EM, Bregu M, Mearns-Spragg A, Boyd KG. Microbial Antagonism: A Neglected Avenue of Natural Products Research. *J. Biotechnol*. 1999;70(1–3):27–32.
186. Donia MS, Ravel J, Schmidt EW. A Global Assembly Line for Cyanobactins. *Nat Chem Biol*. 2008;4(6):341–3.
187. Partida-Martinez LP, Hertweck C. Pathogenic Fungus Harbours Endosymbiotic Bacteria for Toxin Production. *Nature*. 2005;437(7060):884–8.
188. Piel J. Metabolites from Symbiotic Bacteria. *Nat Prod Rep*. 2009;26(3):338–62.
189. Scott JJ, Oh DC, Yuceer MC, Klepzig KD, Clardy J, Currie CR. Bacterial Protection of Beetle-fungus Mutualism. *Science*. 2008;322(5898):63.
190. Wenzel SC, Muller R. The Biosynthetic Potential of Myxobacteria and their Impact in Drug Discovery. *Curr Opin Drug Discov Dev*. 2009;12(2):220–30.
191. Bentley SD, Chater KF, Cerdeño-Tarraga AM, et al. Complete Genome Sequence of the Model Actinomycete *Streptomyces coelicolor* A3(2). *Nature*. 2002;417(6885):141–7.
192. Ikeda H, Ishikawa J, Hanamoto A, et al. Complete Genome Sequence and Comparative Analysis of the Industrial Microorganism *Streptomyces avermitilis*. *Nature Biotechnol*. 2003;21(5):526–31.
193. Ohnishi Y, Kameyama S, Onaka H, Horinouchi S. The A-factor Regulatory Cascade Leading to Streptomycin Biosynthesis in *Streptomyces griseus*: Identification of a Target Gene of the A-factor Receptor. *Mol Microbiol*. 1999;34(1):102–11.
194. Khoklov AS, Tovarova II, Borisova LV, et al. The A-factor, Responsible for Streptomycin Biosynthesis by Mutant Strains of *Actinomyces streptomycini*. *Dokl Akad Nauk SSSR*. 1967;177(1):232–5.
195. Horinouchi S. A Microbial Hormone, A-factor, as a Master Switch for Morphological Differentiation and Secondary Metabolism in *Streptomyces griseus*. *Front Biosci*. 2002;7:d2045–57.
196. Baltz RH. Streptomyces and Saccharopolyspora Hosts for Heterologous Expression of Secondary Metabolite Gene Clusters. *J Ind Microbiol Biotechnol*. 2010;37(8):759–72.
197. Gomez-Escribano JP, Bibb MJ. Engineering *Streptomyces coelicolor* for Heterologous Expression of Secondary Metabolite Gene Clusters. *Microb Biotechnol*. 2011;4(2):207–15.
198. Komatsu M, Uchiyama T, Omura S, Cane DE, Ikeda H. Genome-minimized Streptomyces Host for the Heterologous Expression of Secondary Metabolism. *Proc Natl Acad Sci USA*. 2010;107(6):2646–51.
199. Baltz RH. Strain Improvement in Actinomycetes in the Postgenomic Era. *J Ind Microbiol Biotechnol*. 2011;38(6):657–66.
200. Rappe MS, Giovannoni SJ. The Uncultured Microbial Majority. *Annu Rev Microbiol*. 2003;57:369–94.
201. Schloss PD, Handelsman J. Status of the Microbial Census. *Microbiol Mol Biol Rev*. 2004;68(4):686–91.
202. Freiberg C, Brunner NA, Schiffer G, et al. Identification and Characterization of the First Class of Potent Bacterial Acetyl-CoA Carboxylase Inhibitors with Antibacterial Activity. *J Biol Chem*. 2004;279(25):26066–73.
203. Needham J, Kelly MT, Ishige M, Andersen RJ. Andrimid and Moiramides A–C, Metabolites Produced in Culture by a Marine Isolate of the Bacterium *Pseudomonas fluorescens*: Structure Elucidation and Biosynthesis. *J Org Chem*. 1994;59(8):2058–63.
204. Fredenhagen A, Tamura SY, Kenny PT, et al. Andrimid, a New Peptide Antibiotic Produced by an Intracellular Bacterial Symbiont Isolated from a Brown Planthopper. *J Am Chem Soc*. 1987;109(14):4409–11.
205. Long RA, Rowley DC, Zamora E, Liu J, Bartlett DH, Azam F. Antagonistic Interactions among Marine Bacteria Impede the Proliferation of *Vibrio cholerae*. *Appl Environ Microbiol*. 2005;71(12):8531–36.
206. Jin M, Fischbach MA, Clardy J. A Biosynthetic Gene Cluster for the Acetyl-CoA Carboxylase Inhibitor Andrimid. *J Am Chem Soc*. 2006;128(33):10660–1.
207. Liras P, Martin JF. Gene Clusters for Beta-lactam Antibiotics and Control of their Expression: Why have Clusters Evolved, and from where did they Originate? *Int Microbiol*. 2006;9(1):9–19.
208. Liras P, Rodriguez-Garcia A, Martin JF. Evolution of the Clusters of Genes for Beta-lactam Antibiotics: A Model for Evolutionary Combinatorial Assembly of New Beta-lactams. *Int Microbiol*. 1998;1(4):271–8.
209. Haste NM, Perera VR, Maloney KN, et al. Activity of the Streptogramin Antibiotic Etamycin Against Methicillin-resistant *Staphylococcus aureus*. *J Antibiot (Tokyo)*. 2010;63(5):219–24.
210. Li W, Leet JE, Ax HA, et al. Nocathiacins, New Thiazolyl Peptide Antibiotics from *Nocardia* sp. I. Taxonomy, Fermentation and Biological Activities. *J Antibiot (Tokyo)*. 2003;56(3):226–31.
211. Challis GL. Genome Mining for Novel Natural Product Discovery. *J Med Chem*. 2008;51(9):2618–28.
212. McAlpine JB. Advances in the Understanding and use of the Genomic Base of Microbial Secondary Metabolite Biosynthesis for the Discovery of New Natural Products. *J Nat Prod*. 2009;72(3):566–72.
213. Banskota AH, McAlpine JB, Sørensen D, et al. Genomic Analyses Lead to Novel Secondary Metabolites. Part 3. ECO-0501, a Novel Antibacterial of a New Class. *J Antibiot (Tokyo)*. 2006;59(9):533–42.
214. Wang J, Soisson SM, Young K, et al. *Nature* 2006;441(7091):358–61.
215. Kohanski MA, Dwyer DJ, Collins JJ. How Antibiotics Kill Bacteria: From Targets to Networks. *Nat Rev Microbiol*. 2010;8(6):423–35.
216. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole Compared with Vancomycin for the Treatment of *Staphylococcus aureus* Infection. *Ann Intern Med*. 1992;117(5):390–8.
217. Jemni L, Hmouda H, Letaief A. Efficacy of Trimethoprim-sulfamethoxazole Against Clinical Isolates of Methicillin-resistant *Staphylococcus aureus*: A Report from Tunisia. *Clin Infect Dis*. 1994;19(1):202–3.
218. Huovinen P. Resistance to Trimethoprim-sulfamethoxazole. *Clin Infect Dis*. 2001;32(11):1608–14.
219. Collignon P, Powers JH, Chiller TM, Aidara-Kane A, Aarestrup FM. World Health Organization Ranking of Antimicrobials According to their Importance in Human Medicine: A Critical Step for Developing Risk Management Strategies for the use of Antimicrobials in Food Production Animals. *Clin Infect Dis*. 2009;49(1):132–41.
220. Tomasz A. The Mechanism of the Irreversible Antimicrobial Effects of Penicillins: How the Beta-lactam Antibiotics Kill and Lyse Bacteria. *Annu Rev Microbiol*. 1979;33:113–37.
221. Bassetti M, Ginocchio F, Mikulska M, Taramasso L, Giacobbe DR. Will New Antimicrobials Overcome Resistance among Gram-negatives? *Expert Rev Anti Infect Ther*. 2011;9(10):909–22.
222. Torres JA, Villegas MV, Quinn JP. Current Concepts in Antibiotic-resistant Gram-negative Bacteria. *Expert Rev Anti Infect Ther*. 2007;5(5):833–43.
223. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: The Quiet Before the Storm? *Clin Microbiol Rev*. 2005;18(2):306–25.
224. Nordmann P, Poirel L. Emerging Carbapenemases in Gram-negative Aerobes. *Clin Microbiol Infect*. 2002;8(6):321–31.
225. Bonomo RA, Szabo D. Mechanisms of Multidrug Resistance in Acinetobacter Species and *Pseudomonas aeruginosa*. *Clin Infect Dis*. 2006;43(Suppl(2)):S49–56.
226. Navia MM, Ruiz J, Vila J. Characterization of an Integron Carrying a New Class D Beta-lactamase (OXA-37) in *Acinetobacter baumannii*. *Microb Drug Resist*. 2002;8(4):261–5.
227. Vila I, Navia M, Ruiz J, Casals C. Cloning and Nucleotide Sequence Analysis of a Gene Encoding an OXA-derived Beta-lactamase in *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 1997;41(12):2757–9.
228. Poirel L, Gerome P, De Champs C, Stephanazzi J, Naas T, Nordmann P. Integron-located oxa-32 Gene Cassette Encoding an Extended-spectrum Variant of OXA-2 Beta-lactamase from *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2002;46(2):566–9.
229. Poirel L, Girlich D, Naas T, Nordmann P. OXA-28, an Extended-spectrum Variant of OXA-10 Beta-lactamase from *Pseudomonas aeruginosa* and its Plasmid- and Integron-located Gene. *Antimicrob Agents Chemother*. 2001;45:447.
230. Naas T, Nordmann P, OXA-type Beta-lactamases. *Curr Pharm Des*. 1999;5(11):865–79.
231. Hakenbeck R, Grebe T, Zahner D, Stock JB. Beta-lactam Resistance in *Streptococcus pneumoniae*: Penicillin-binding Proteins and Non-penicillin-binding Proteins. *Mol Microbiol*. 1999;33(4):673–8.
232. Chambers HF. Methicillin Resistance in Staphylococci: Molecular and Biochemical Basis and Clinical Implications. *Clin Microbiol Rev*. 1997;10(4):781–91.



233. Mazzariol A, Cornaglia G, Nikaido H. Contributions of the AmpC Beta-lactamase and the AcrAB Multidrug Efflux System in Intrinsic Resistance of Escherichia coli K-12 to Beta-lactams. *Antimicrob. Agents Chemother.* 2000;44(5):1387-90.
234. Hancock RE. The Bacterial Outer Membrane as a Drug Barrier. *Trends Microbiol.* 1997;5(1):37-42.
235. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A Randomized, Double-blind Trial Comparing Ceftobiprole Medocaril with Vancomycin Plus Ceftazidime for the Treatment of Patients with Complicated Skin and Skin-structure Infections. *Clin Infect Dis.* 2008;46(5):647-55.
236. El Solh A. Ceftobiprole: A New Broad Spectrum Cephalosporin. *Expert Opin Pharmacother.* 2009;10(10):1675-86.
237. Takeda S, Nakai T, Wakai T, Ikeda F, Hatano K. In vitro and in vivo Activities of a New Cephalosporin, FR264205, Against Pseudomonas aeruginosa. *Antimicrob Agents Chemother.* 2007;51(3):826-30.
238. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam Against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains having Various Resistance Phenotypes. *Antimicrob Agents Chemother.* 2011;55(5):2390-4.
239. Queenan AM, Shang W, Flamm R, Bush K. Hydrolysis and Inhibition Profiles of Beta-lactamases from Molecular Classes A to D with Doripenem, Imipenem, and Meropenem. *Antimicrob. Agents Chemother.* 2010;54(1):565-9.
240. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and Safety of Intravenous Infusion of Doripenem Versus Imipenem in Ventilator-associated Pneumonia: A Multicenter, Randomized Study. *Crit Care Med.* 2008;36(4):1089-96.
241. Fujimura S, Nakano Y, Sato T, Shirahata K, Watanabe A. Relationship Between the Usage of Carbapenem Antibiotics and the Incidence of Imipenem-resistant Pseudomonas aeruginosa. *J Infect Chemother.* 2007;13(3):147-50.
242. Livermore DM, Mushtaq S, Warner M. Activity of the Anti-MRSA Carbapenem Razupenem (PTZ601) Against Enterobacteriaceae with Defined Resistance Mechanisms. *J Antimicrob Chemother.* 2009;64(2):330-5.
243. Page MG, Dantier C, Desarbre E. In vitro Properties of BAL30072, a Novel Siderophore Sulfactam with Activity Against Multiresistant Gram-negative Bacilli. *Antimicrob Agents Chemother.* 2010;54(6):2291-302.
244. Russo TA, Page MG, Beanan JM, et al. In vivo and in vitro Activity of the Siderophore Monosulfactam BAL30072 Against Acinetobacter baumannii. *J Antimicrob Chemother.* 2011;66(4):867-73.
245. Kiffer CRV, Sampaio JLM, Sinto S, et al. In vitro Synergy Test of Meropenem and Sulfactam Against Clinical Isolates of Acinetobacter baumannii. *Diagn Microbiol Infect Dis.* 2005;52(4):317-22.
246. Ehmann DE, Jahic H, Ross PL, et al. Kinetics of Avibactam Inhibition Against Class A, C, and D  $\beta$ -lactamases. *J Biol Chem.* 2013;288(39):27960-71.
247. Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the Clinical Pipeline in 2013. *J Antibio (Tokyo).* 2013;66(10):571-91.
248. Bassetti M, Righi E, Viscoli C. Novel Beta-lactam Antibiotics and Inhibitor Combinations. *Expert Opin Investig Drugs.* 2008;17(3):285-96.
249. Payne DJ, Hueso-Rodríguez JA, Boyd H, et al. Identification of a Series of Tricyclic Natural Products as Potent Broad-spectrum Inhibitors of Metallo-beta-lactamases. *Antimicrob Agents Chemother.* 2002;46(6):1880-6.
250. Davis BD, Chen LL, Tai PC. Misread Protein Creates Membrane Channels: An Essential Step in the Bactericidal Action of Aminoglycosides. *Proc Natl Acad Sci USA.* 1986;83(16):6164-8.
251. Wachino J, Shibayama K, Kurokawa H, et al. Novel Plasmid-mediated 16S rRNA m1 A1408 Methyltransferase, NpmA, Found in a Clinically Isolated Escherichia coli Strain Resistant to Structurally Diverse Aminoglycosides. *Antimicrob Agents Chemother.* 2007;51(12):4401-9.
252. Wachino J, Arakawa Y. Exogenously Acquired 16S rRNA Methyltransferases Found in Aminoglycoside-resistant Pathogenic Gram-negative Bacteria: An Update. *Drug Resist Updat.* 2012;15(3):133-48.
253. Gillespie SH. Evolution of Drug Resistance in Mycobacterium tuberculosis: Clinical and Molecular Perspective. *Antimicrob Agents Chemother.* 2002;46(2):267-74.
254. Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of Aminoglycosides: Indications, Pharmacokinetics and Monitoring for Toxicity. *Int Med J.* 2011;41(6):441-9.
255. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: Activity and Resistance. *Antimicrob Agents Chemother.* 1999;43(4):727-37.
256. Kawaguchi H, Naito T, Nakagawa S, Fujisawa K. BB-K 8, a New Semisynthetic Aminoglycoside Antibiotic. *J Antibio (Tokyo).* 1972;25(12):695-708.
257. Lin G, Ednie LM, Appelbaum PC. Antistaphylococcal Activity of ACHN-490 Tested Alone and in Combination with Other Agents by Time-kill Assay. *Antimicrob Agents Chemother.* 2010;54(5):2258-61.
258. Pankuch GA, Lin G, Kubo A, Armstrong ES, Appelbaum PC, Kosowska-Shick K. Activity of ACHN-490 Tested Alone and in Combination with Other Agents Against Pseudomonas aeruginosa. *Antimicrob Agents Chemother.* 2011;55(5):2463-5.
259. Livermore DM, Mushtaq S, Warner M, et al. Activity of Aminoglycosides, Including ACHN-490, Against Carbapenem-resistant Enterobacteriaceae Isolates. *J Antimicrob Chemother.* 2011;66(1):48-53.
260. Landman D, Kelly P, Bäcker M, et al. Antimicrobial Activity of a Novel Aminoglycoside, ACHN-490, Against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. *J Antimicrob Chemother.* 2011;66(2):332-4.
261. Landman D, Babu E, Shah N, et al. Activity of a Novel Aminoglycoside, ACHN-490, Against Clinical Isolates of Escherichia coli and Klebsiella pneumoniae from New York City. *J Antimicrob Chemother.* 2010;65(10):2123-7.
262. Rahal Jr JJ, Simberloff MS. Bactericidal and Bacteriostatic Action of Chloramphenicol Against Meningeal Pathogens. *Antimicrob Agents Chemother.* 1979;16(1):13-8.
263. Falagas ME, Kopterides P. Old Antibiotics for Infections in Critically Ill Patients. *Curr Opin Crit Care.* 2007;13(5):592-7.
264. Kehrenberg C, Schwarz S, Jacobsen L, Hansen LH, Vester B. A New Mechanism for Chloramphenicol, Florfenicol and Clindamycin Resistance: Methylation of 23S Ribosomal RNA at A2503. *Mol Microbiol.* 2005;57(4):1064-73.
265. Murray IA, Shaw WV. O-Acetyltransferases for Chloramphenicol and Other Natural Products. *Antimicrob Agents Chemother.* 1997;41(1):1-6.
266. Arcangioli MA, Leroy-Setrin S, Martel JL, Chaslus-Dancla E. A New Chloramphenicol and Florfenicol Resistance Gene Flanked by Two Integron Structures in Salmonella typhimurium DT104. *FEMS Microbiol Lett.* 1999;174(2):327-32.
267. Tenson T, Lovmar M, Ehrenberg M. The Mechanism of Action of Macrolides, Lincosamides and Streptogramin B Reveals the Nascent Peptide Exit Path in the Ribosome. *J Mol Biol.* 2003;330(5):1005-14.
268. Goldstein FW, Emirian MF, Coutrot A, Acar JF. Bacteriostatic and Bactericidal Activity of Azithromycin Against Haemophilus influenzae. *J Antimicrob Chemother.* 1990;25Suppl(A):25-8.
269. Liu MF, Douthwaite S. Activity of the Ketolide Telithromycin is Refractory to Erm Monomethylation of Bacterial rRNA. *Antimicrob Agents Chemother.* 2002;46(6):1629-33.
270. Depardieu F, Courvalin P. Mutation in 23S rRNA Responsible for Resistance to 16-membered Macrolides and Streptogramins in Streptococcus pneumoniae. *Antimicrob Agents Chemother.* 2001;45(1):319-23.
271. Wittmann HG, Stöffler G, Apirion D, et al. Biochemical and Genetic Studies on Two Different Types of Erythromycin Resistant Mutants of Escherichia coli with Altered Ribosomal Proteins. *Mol Gen Genet.* 1973;127(2):175-89.
272. Canu A, Malbrun B, Coquemont M, Davies TA, Appelbaum PC, Leclercq R. Diversity of Ribosomal Mutations Conferring Resistance to Macrolides, Clindamycin, Streptogramin, and Telithromycin in Streptococcus pneumoniae. *Antimicrob Agents Chemother.* 2002;46(1):125-31.
273. Chesneau O, Tsvetkova K, Courvalin P. Resistance Phenotypes Conferred by Macrolide Phosphotransferases. *FEMS Microbiol Lett.* 2007;269(2):317-22.
274. Clancy J, Petitpas J, Dib Hajj F, et al. Molecular Cloning and Functional Analysis of a Novel Macrolide-resistance Determinant, mefA, from Streptococcus pyogenes. *Mol Microbiol.* 1996;22(5):867-79.
275. Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE. Efflux-mediated Aminoglycoside and Macrolide Resistance in Burkholderia pseudomallei. *Antimicrob Agents Chemother.* 1999;43(3):465-470.
276. Hicks LA, Taylor Jr. TH, Hunkler RJ. U.S. Outpatient Antibiotic Prescribing, 2010. *N Engl J Med.* 2013;368(15):1461-2.
277. Hoban DJ. Prevalence and Characterization of Macrolide Resistance in Clinical Isolates of Streptococcus pneumoniae and Streptococcus pyogenes from North America. *J Chemother.* 2002;14Suppl(3):25-30.
278. Echols RM. Understanding the Regulatory Hurdles for Antibacterial Drug Development in the Post-Ketek World. *Ann NY Acad Sci.* 2011;1241:153-61.
279. Sutcliffe JA. Antibiotics in Development Targeting Protein Synthesis. *Ann NY Acad Sci.* 2011;1241:122-52.
280. Putnam SD, Sader HS, Farrell DJ, Biedenbach DJ, Castanheira M. Antimicrobial Characterisation of Solithromycin (CEM-101), a Novel Fluoroketolide: Activity Against Staphylococci and Enterococci. *Int J Antimicrob Agents.* 2011;37(1):39-45.
281. Roberts MC. Update on Acquired Tetracycline Resistance Genes. *FEMS Microbiol Lett.* 2005;245(2):195-203.
282. Agwuh KN, MacGowan A. Pharmacokinetics and Pharmacodynamics of the Tetracyclines Including Glycylcyclines. *J Antimicrob Chemother.* 2006;58(2):256-65.
283. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, Against Hospital and Community Pathogens. *Antimicrob Agents Chemother.* 2013;57(11):5548-58.
284. Grossman TH, Starosta AL, Fyfe C, et al. Target- and Resistance-based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic. *Antimicrob Agents Chemother.* 2012;56(5):2559-64.
285. Jones CH, Peterson PJ. Tigecycline: A review of Preclinical and Clinical Studies of the First-in-class Glycylcycline Antibiotic. *Drugs Today.* 2005;41(10):637-59.
286. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo Antibacterial Activities of a Novel Glycylcycline, the 9-t-Butylglyclamido Derivative of Minocycline (GAR-936). *Antimicrob Agents Chemother.* 1999;43(4):738-44.
287. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and Safety of Tigecycline for the Treatment of Infectious Diseases: A Meta-analysis. *Lancet Infect Dis.* 2011;11(11):834-44.



288. Hornsey M, Ellington MJ, Doumith M, Hudson S, Livermore DM, Woodford N. Tigecycline Resistance in *Serratia marcescens* Associated with Up-regulation of the SdeXY-HasF Efflux System also Active Against Ciprofloxacin and Cefpirome. *J Antimicrob Chemother.* 2010;65(3):479–82.
289. Ruzin A, Immermann FW, Bradford PA. RT-PCR and Statistical Analyses of adeABC Expression in Clinical Isolates of *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* Complex. *Microb Drug Res Mech* 2010;16(2):87–9.
290. Horiyama T, Nikaido E, Yamaguchi A, Nishino K. Roles of *Salmonella* Multidrug Efflux Pumps in Tigecycline Resistance. *J Antimicrob Chemother.* 2011;66(1):105–10.
291. Peleg AY, Adams J, Paterson DL. Tigecycline Efflux as a Mechanism for Nonsusceptibility in *Acinetobacter baumannii*. *Antimicrob Agents Chemother.* 2007;51(6):2065–9.
292. Sensi P. History of the Development of Rifampin. *Rev Infect Dis.* 1983;5Suppl(3):S402–6.
293. Almeida Da Silva PE, Palomino JC. Molecular Basis and Mechanisms of Drug Resistance in *Mycobacterium tuberculosis*: Classical and New Drugs. *J Antimicrob Chemother.* 2011;66(7):1417–30.
294. Lichtenstein GR, Rifaximin: Recent Advances in Gastroenterology and Hepatology. *Gastroenterol Hepatol (NY).* 2007;3(6):474–83.
295. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant Enterococci. *Clin Microbiol Rev.* 2000;13(4):686–707.
296. Cooper MA, Williams DH. Binding of Glycopeptide Antibiotics to a Model of a Vancomycin-resistant Bacterium. *Chem Biol.* 1999;6(12):891–9.
297. Kahne D, Leimkuhler C, Lu W, Walsh C. Glycopeptide and Lipoglycopeptide Antibiotics. *Chem Rev.* 2005;105(2):425–48.
298. Show JP, Seroogy J, Kaniga K, Higgins DL, Kit M, Barriere S. Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy Subjects. *Antimicrob Agents Chemother.* 2005;49(1):195–201.
299. Pace JL, Yang G. Glycopeptides: Update on an Old Successful Antibiotic Class. *Biochem Pharmacol.* 2006;71(7):968–80.
300. Barrett JF, Oritavancin. Eli Lilly & Co. *Curr Opin Investig Drugs.* 2001;2(8):1039–44.
301. Mercier RC, Hrebickova L, Oritavancin: A New Avenue for Resistant Gram-positive Bacteria. *Expert Rev Anti Infect Ther.* 2005;3(3):325–32.
302. Lin G, Credito K, Ednic LM, Appelbaum PC. Antistaphylococcal Activity of Dalbavancin, an Experimental Glycopeptide. *Antimicrob Agents Chemother.* 2005;49(2):770–2.
303. Giamarellou H, Treatment Options for Multidrug-resistant Bacteria. *Expert Rev Anti Infect Ther.* 2006;4(4):601–18.
304. Lambert PA. Mechanisms of Antibiotic Resistance in *Pseudomonas aeruginosa*. *J R Soc Med.* 2002;95Suppl(41):22–6.
305. Hooper DC. Mechanisms of Action and Resistance of Older and Newer Fluoroquinolones. *Clin Infect Dis.* 2000;31Suppl(2):S24–8.
306. Robicsek A, Sahn DF, Strahilevitz J, Jacoby GA, Hooper DC. Broader Distribution of Plasmid-mediated Quinolone Resistance in the United States. *Antimicrob Agents Chemother.* 2005;49(7):3001–3.
307. Nordmann P, Poirel L. Emergence of Plasmid-mediated Resistance to Quinolones in Enterobacteriaceae. *J Antimicrob Chemother.* 2005;56(3):463–9.
308. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. Plasmid-mediated Quinolone Resistance: a Multifaceted Threat. *Clin Microbiol Rev.* 2009;22(4):664–89.
309. Poole K. Efflux-mediated Resistance to Fluoroquinolones in Gram-negative Bacteria. *Antimicrob Agents Chemother.* 2000;44(9):2233–41.
310. Oliphant CM, Green GM. Quinolones: A Comprehensive Review. *Am Fam Physician.* 2002;65(3):455–64.
311. Ambrose PG, Owens Jr RC, Quintiliani R, Nightingale CH. New Generations of Quinolones: With Particular Attention to Levofloxacin. *Conn Med.* 1997;61(5):269–72.
312. Poole K. Overcoming Antimicrobial Resistance by Targeting Resistance Mechanisms. *J Pharm Pharmacol.* 2001;53(3):283–94.
313. Lemaire S, Tulkens PM, Van BF. Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-gram-positive Fluoroquinolones Moxifloxacin and Delafloxacin Against *Staphylococcus aureus*. *Antimicrob Agents Chemother.* 2011;55(2):649–58.
314. Lauderdale TL, Shiar YR, Lai JF, Chen HC, King CH. Comparative in vitro Activities of Nemonoxacin (TG-873870), a Novel Nonfluorinated Quinolone, and Other Quinolones Against Clinical Isolates. *Antimicrob Agents Chemother.* 2010;54(3):1338–42.
315. Morrow BJ, He W, Amslem KM, et al. In vitro Antibacterial Activities of JNJ-Q2, a New Broad-spectrum Fluoroquinolone. *Antimicrob Agents Chemother.* 2010;54(5):1955–64.
316. Morrow BJ, Abbanat D, Baum EZ, et al. Antistaphylococcal Activities of the New Fluoroquinolone JNJ-Q2. *Antimicrob Agents Chemother.* 2011;55(12):5512–21.
317. Higgins PG, Stubbings W, Wisplinghoff H, Seifert H. Activity of the Investigational Fluoroquinolone Finafloxacin Against Ciprofloxacin-sensitive and -Resistant *Acinetobacter baumannii* Isolates. *Antimicrob Agents Chemother.* 2010;54(4):1613–5.
318. Merlion Pharmaceuticals. Finafloxacin. Available at: <http://www.merlion-pharma.com/?q=node/16>. Accessed December 20 2013.
319. Roberts MC. Update on Macrolide-lincosamide-streptogramin, Ketolide, and Oxazolidinone Resistance Genes. *FEMS Microbiol Lett.* 2008;282(2):147–59.
320. Long KS, Poehlgaard J, Kehrenberg C, Schwarz S, Vester B. The Cfr rRNA Methyltransferase Confers Resistance to Phenicol, Lincosamides, Oxazolidinones, Pleuromutins, and Streptogramin A Antibiotics. *Antimicrob Agents Chemother.* 2006;50(7):2500–5.
321. Smith LK, Mankin AS. Transcriptional and Translational Control of the mlr Operon, which Confers Resistance to Seven Classes of Protein Synthesis Inhibitors. *Antimicrob Agents Chemother.* 2008;52(5):1703–1712.
322. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse Effects of Sodium Colistimethate. Manifestations and Specific Reaction Rates During 317 Courses of Therapy. *Ann Intern Med.* 1970;72(6):857–68.
323. Ouderkirk JP, Nord JA, Turett GS, Kislak JW, Polymyxin B. Nephrotoxicity and Efficacy Against Nosocomial Infections Caused by Multiresistant Gram-negative Bacteria. *Antimicrob Agents Chemother.* 2003;47(8):2659–62.
324. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin Treatment in Patients with ICU-acquired Infections Caused by Multiresistant Gram-negative Bacteria: The Renaissance of an Old Antibiotic. *Clin Microbiol Infect.* 2005;11(2):115–21.
325. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of Colistin as an Agent Against Multi-resistant Gram-negative Bacteria. *Int J Antimicrob Agents.* 2005;25(1):11–25.
326. Rastogi N, Potar MC, David HL. Antimycobacterial Spectrum of Colistin (Polymyxin E). *Ann Inst Pasteur Microbiol.* 1986;137 A(1):45–53.
327. Gales AC, Jones RN, Sader HS. Global Assessment of the Antimicrobial Activity of Polymyxin B Against 54,731 Clinical Isolates of Gram-negative Bacilli: Report from the SENTRY Antimicrobial Surveillance Programme (2001–2004). *Clin Microbiol Infect.* 2006;12(4):315–21.
328. Schindler M, Osborn MJ. Interaction of Divalent Cations and Polymyxin B with Lipopolysaccharide. *Biochemistry.* 1979;18(20):4425–30.
329. Senturk S. Evaluation of the Anti-endotoxic Effects of Polymyxin-E (Colistin) in Dogs with Naturally Occurred Endotoxic Shock. *J Vet Pharmacol Ther.* 2005;28(1):57–63.
330. Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to Polymyxins: Mechanisms, Frequency and Treatment Options. *Drug Resist Update.* 2010;13(4–5):132–8.
331. Quale J, Shah N, Kelly P, et al. Activity of Polymyxin B and the Novel Polymyxin Analogue CB-182,804 Against Contemporary Gram-negative Pathogens in New York City. *Microb Drug Res.* 2012;18(2):132–6.
332. Shapiro S. Speculative Strategies for New Antibacterials: All Roads should not Lead to Rome. *J Antibiot (Tokyo).* 2013, 66(7):371–86.
333. Vaara M, Fox J, Loidl G, et al. Novel Polymyxin Derivatives Carrying only Three Positive Charges are Effective Antibacterial Agents. *Antimicrob Agents Chemother.* 2008;52(9):3229–36.
334. Ali FE, Cao G, Poudyal A, et al. Pharmacokinetics of Novel Antimicrobial Cationic Peptides NAB 7061 and NAB 739 in Rats Following Intravenous Administration. *J Antimicrob Chemother.* 2009;64(5):1067–70.
335. Mingeot-Leclercq MP, Tulkens PM, Denamur S, Vaara T, Vaara M. Novel Polymyxin Derivatives are Less Cytotoxic than Polymyxin B to Renal Proximal Tubular Cells. *Peptides.* 2012;35(2):248–52.
336. Vaara M, Vaara T. The Novel Polymyxin Derivative NAB739 is Remarkably less Cytotoxic than Polymyxin B and Colistin to Human Kidney Proximal Tubular Cells. *Int J Antimicrob Agents.* 2013;41(3):292–3.
337. Vaara M, Sader HS, Rhomberg PR, Jones RN, Vaara T. Antimicrobial Activity of the Novel Polymyxin Derivative NAB739 Tested Against Gram-negative Pathogens. *J Antimicrob Chemother.* 2013;68(3):636–9.
338. Fugitt RB, Luckenbaugh RW. 1978. Patent 4,128,654.
339. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid Resistance in a Clinical Isolate of *Staphylococcus aureus*. *Lancet.* 2001;358(9277):207–08.
340. Shaw KJ, Barbachyn MR. The Oxazolidinones: Past, Present, and Future. *Ann NY Acad Sci.* 2011;1241:48–70.
341. Morales G, Picazo JJ, Baos E, et al. Resistance to Linezolid is Mediated by the cfr Gene in the First Report of an Outbreak of Linezolid-resistant *Staphylococcus aureus*. *Clin Infect Dis.* 2010;50(6):821–5.
342. Seral C, Saenz Y, Algarate S, et al. Nosocomial Outbreak of Methicillin- and Linezolid-resistant *Staphylococcus epidermidis* Associated with Catheter-related Infections in Intensive Care Unit Patients. *Int J Med Microbiol.* 2011;301(4):354–8.
343. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The Emerging Problem of Linezolid-resistant *Staphylococcus*. *J Antimicrob Chemother.* 2013; 68(1):4–11.
344. Diekema DJ, Jones RN. Oxazolidinone Antibiotics. *Lancet.* 2001;358(9297):1975–82.



345. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the Treatment of Multidrug-resistant, Gram-positive Infections: Experience from a Compassionate-use Program. *Clin Infect Dis*. 2003;36(2):159–68.
346. Bush K. Improving Known Classes of Antibiotics: An Optimistic Approach for the Future. *Curr Opin Pharmacol*. 2012;12(5):527–34.
347. Rodriguez-Avial I, Culebras E, Betriu C, Morales G, Pena I, Picazo JJ. In vitro Activity of Tedizolid (TR-700) Against Linezolid-resistant Staphylococci. *J Antimicrob Chemother*. 2012;67(1):167–9.
348. Shaw KJ, Poppe S, Schaadt R, et al. In vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, Against Linezolid-resistant Strains. *Antimicrob Agents Chemother*. 2008;52(12):4442–7.
349. Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe JA. In vitro Activities of the Rx-01 Oxazolidinones Against Hospital and Community Pathogens. *Antimicrob Agents Chemother*. 2008;52(5):1653–62.
350. Locke JB, Finn J, Hilgers M, et al. Structure-activity Relationships of Diverse Oxazolidinones for Linezolid-resistant Staphylococcus aureus Strains Possessing the *cfi* Methyltransferase Gene or Ribosomal Mutations. *Antimicrob Agents Chemother*. 2010;54(12):5337–43.
351. Alfenaar JWC, van der Laan T, Simons S, et al. Susceptibility of Clinical Mycobacterium tuberculosis Isolates to a Potentially less Toxic Derivate of Linezolid, PNU-100480. *Antimicrob Agents Chemother*. 2011;55(3):1287–9.
352. Davlieva M, Zhang W, Arias CA, Shamoo Y. Biochemical Characterization of Cardiolipin Synthase Mutations Associated with Daptomycin Resistance in Enterococci. *Antimicrob Agents Chemother*. 2013;57(1):289–96.
353. Bertsche U, Yang SJ, Kuehner D, et al. Increased Cell Wall Teichoic Acid Production and D-alanylation are Common Phenotypes Among Daptomycin-resistant Methicillin-resistant Staphylococcus aureus (MRSA) Clinical Isolates. *PLoS One*. 2013;8(6):e67398.
354. Yang SJ, Kreiswirth BN, Sakoulas G, et al. Enhanced Expression of *dltABCD* is Associated with the Development of Daptomycin Nonsusceptibility in a Clinical Endocarditis Isolate of Staphylococcus aureus. *J Infect Dis*. 2009;200(12):1916–20.
355. Yang SJ, Xiong YQ, Dunman PM, et al. Regulation of *mprF* in Daptomycin-nonsusceptible Staphylococcus aureus Strains. *Antimicrob Agents Chemother*. 2009;53(6):2636–7.
356. Cubist Pharmaceuticals. Surotomycin (CB-315). Available at: <http://www.cubist.com/products/cdad>. Accessed December 20 2013.
357. Kadlec K, Pomba CF, Couto N, Schwarz S. Small Plasmids Carrying *vga(A)* or *vga(C)* Genes Mediate Resistance to Lincosamides, Pleuromutilins and Streptogramin A Antibiotics in Methicillin-resistant Staphylococcus aureus ST398 from Swine. *J Antimicrob Chemother*. 2010;65(12):2692–3.
358. Schwendener S, Perreten V. New Transposon Tn6133 in Methicillin-resistant Staphylococcus aureus ST398 Contains *vga(E)*, a Novel Streptogramin A, Pleuromutilin, and Lincosamide Resistance Gene. *Antimicrob Agents Chemother*. 2011;55(10):4900–4.
359. Miller K, Dunsmore CJ, Colin WG, Chopra I. Linezolid and Tiamulin Cross-resistance in Staphylococcus aureus Mediated by Point Mutations in the Peptidyl Transferase Center. *Antimicrob Agents Chemother*. 2008;52(5):1737–42.
360. Nabriva Pharmaceuticals. Developing a New Class of Antibiotics. Available at: <http://www.nabriva.com/programs/development/>. Accessed December 20 2013.
361. Drugs.com. Nabriva Reports Positive Results from Phase II Trial of Pleuromutilin Antibiotic BC-3781 in ABSSSI. Available at: [http://www.drugs.com/clinical\\_trials/nabriva-reports-positive-results-phase-ii-trial-pleuromutilin-antibiotic-bc-3781-abssi-11577.html](http://www.drugs.com/clinical_trials/nabriva-reports-positive-results-phase-ii-trial-pleuromutilin-antibiotic-bc-3781-abssi-11577.html). Accessed December 20 2013.
362. Srivastava A, Talaue M, Liu S, et al. New Target for Inhibition of Bacterial RNA Polymerase: 'Switch Region'. *Curr Opin Microbiol*. 2011;14(5):532–43.
363. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. OPT-80 Eliminates Clostridium difficile and is Sparing of Bacteroides Species During Treatment of C. difficile Infection. *Antimicrob Agents Chemother*. 2009;53(1):261–3.
364. Andries K, Verhasselt P, Guillemont J, et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis. *Science* 2005;307(5707):223–7.
365. Avorn J. Approval of a Tuberculosis Drug Based on a Paradoxical Surrogate Measure. *JAMA*. 2013;309(13):1349–50.
366. Ejim L, Farha MA, Falconer SB, et al. Combinations of Antibiotics and Nonantibiotic Drugs Enhance Antimicrobial Efficacy. *Nat Chem Biol*. 2011;7(6):348–50.
367. Challis GL, Hopwood DA. Synergy and Contingency as Driving Forces for the Evolution of Multiple Secondary Metabolite Production by Streptomyces Species. *Proc Natl Acad Sci U.S.A.* 2003;100(Suppl(2)):14555–61.
368. Rashid MU, Lozano HM, Weintraub A, Nord CE. In vitro Activity of Cadazolid Against Clostridium difficile Strains Isolated from Primary and Recurrent Infections in Stockholm, Sweden. *Anaerobe*. 2013;20:32–5.
369. Blais J, Lewis SR, Krause KM, Benton BM. Antistaphylococcal Activity of TD-1792, a Multivalent Glycopeptide-cephalosporin Antibiotic. *Antimicrob Agents Chemother*. 2012;56(3):1584–7.
370. Tyrrell KL, Citron DM, Warren YA, Goldstein EJ. In vitro Activity of TD-1792, a Multivalent Glycopeptide-cephalosporin Antibiotic, Against 377 Strains of Anaerobic Bacteria and 34 Strains of Corynebacterium Species. *Antimicrob Agents Chemother*. 2012;56(4):2194–7.
371. Pokrovskaya V, Baasov T. Dual-acting Hybrid Antibiotics: A Promising Strategy to Combat Bacterial Resistance. *Expert Opin Drug Discov*. 2010;5(9):883–902.
372. Panchal RG, Lane D, Boshoff HI, et al. Bis-imidazolinyliindoles are Active against Methicillin-resistant Staphylococcus aureus and Multidrug-resistant Mycobacterium tuberculosis. *J Antibiotics (Japan)*. 2013;66:47–9.
373. Butler MM, Williams JD, Peet NP, et al. Comparative *in vitro* Activity Profiles of Novel Bis-Indole Antibacterials against Gram-Positive and Gram-Negative Clinical Isolates. *Antimicrob Agents Chemother*. 2010;54(9):3974–7.
374. Huang Q, Kirikae F, Kirikae T, et al. Targeting FtsZ for Antituberculosis Drug Discovery: Nontoxic Taxanes as Novel Antituberculosis Agents. *J Med Chem*. 2006;49(2):463–6.
375. Kumar K, Awasthi D, Lee SY, et al. Novel Trisubstituted Benzimidazoles, Targeting Mtb FtsZ, as a New Class of Antitubercular Agents. *J Med Chem*. 2011;54(1):374–81.
376. Reynolds RC, Srivastava S, Ross LJ, Suling WJ, White EL. A New 2-Carbomoyl Pteridine that Inhibits Mycobacterial FtsZ. *Bioorg Med Chem Lett*. 2004;14(12):3161–4.
377. White EL, Suling WJ, Ross LJ, Seitz LE, Reynolds RC. 2-Alkoxy-carbonylaminopyridines: Inhibitors of Mycobacterium tuberculosis FtsZ. *J Antimicrob Chemother*. 2002;50(1):111–4.
378. Matthew B, Ross L, Reynolds RC. A Novel Quinoline Derivative that Inhibits Mycobacterial FtsZ. *Tuberculosis (Oxford, United Kingdom)*. 2013;93(4):398–400.
379. Adams DW, Wu LJ, Czaplowski LG, Errington J. Multiple Effects of Benzamide Antibiotics on FtsZ Function. *Mol Microbiol*. 2011;80(1):68–84.
380. Haydon DJ, Stokes NR, Ure R, et al. An Inhibitor of FtsZ with Potent and Selective Anti-staphylococcal Activity. *Science*. 2008;321(5896):1673–5.
381. Parhi AK, Zhang Y, Saionz KW, et al. Antibacterial Activity of Quinoxalines, Quinazolines, and 1,5-Naphthyridines. *Bioorg Med Chem Lett*. 2013;23:4968–74.
382. Kelley C, Zhang Y, Parhi A, Kaul M, Pilch DS, LaVoie EJ. 3-Phenyl Substituted 6,7-Dimethoxyisoquinoline Derivatives as FtsZ-targeting Antibacterial Agents. *Bioorg Med Chem Lett*. 2012;20(24):7012–29.
383. Kelley C, Lu S, Parhi A, Kaul M, Pilch DS, LaVoie EJ. Antimicrobial Activity of Various 4- and 5-substituted 1-Phenylnaphthalenes. *Eur J Med Chem*. 2013;60:395–409.
384. Zhang Y, Giurleo D, Parhi A, Kaul M, Pilch DS, LaVoie EJ. Substituted 1,6-Diphenylnaphthalenes as FtsZ-targeting Antibacterial Agents. *Bioorg Med Chem Lett*. 2013;23(7):2001–6.
385. Margalit DN, Romberg L, Mets RB, et al. Targeting Cell Division: Small-molecule Inhibitors of FtsZ GTPase Perturb Cytokinetic Ring Assembly and Induce Bacterial Lethality. *Proc Natl Acad Sci (USA)*. 2004;101(32):11821–6.
386. Haydon DJ, Bennett JM, Brown D, et al. Creating an Antibacterial with *in vivo* Efficacy: Synthesis and Characterization of Potent Inhibitors of the Bacterial Cell Division Protein FtsZ with Improved Pharmaceutical Properties. *J Med Chem*. 2010;53(10):3927–36.
387. Plaza A, Keffer JL, Bifulco G, Lloyd JR, Bewley CA. Chrysophantins A-H, Antibacterial Bisdiarylbutene Macrocycles that Inhibit the Bacterial Cell Division Protein FtsZ. *J Am Chem Soc*. 2010;132(26):9069–77.
388. Urgaonkar S, La Pierre HS, Meir I, Lund H, Raychaudhuri D, Shaw JT. Synthesis of Antimicrobial Natural Products Targeting FtsZ: (+/-)-Dichamanetin and (+/-)-2'-hydroxy-5'-Benzylisouvarinol-B. *Org Lett*. 2005;7(25):5609–12.
389. Parhi A, Kelley C, Kaul M, Pilch DS, LaVoie EJ. Antibacterial Activity of Substituted 5-Methylbenzo[c]phenanthridinium Derivatives. *Bioorg Med Chem Lett*. 2012;22(23):7080–3.
390. Wang J, Galgoci A, Kodali S, et al. Discovery of a Small Molecule that Inhibits Cell Division by Blocking FtsZ, a Novel Therapeutic Target of Antibiotics. *J Biol Chem*. 2003;278(45):44424–44428.
391. Paradis-Bleau C, Beaumont M, Sanschagrín F, Voyer N, Levesque RC. Parallel Solid Synthesis of Inhibitors of the Essential Cell Division FtsZ Enzyme as a New Potential Class of Antibacterials. *Bioorg Med Chem*. 2007;15(3):1330–40.
392. Sass P, Josten M, Famulla K, et al. Antibiotic Acyldepsipeptides Activate ClpP Peptidase to Degrade the Cell Division Protein FtsZ. *Proc Natl Acad Sci (USA)*. 2011;42(108):17474–9.
393. Brötz-Oesterhelt H, Beyer D, Kroll HP, et al. Dysregulation of Bacterial Proteolytic Machinery by a New Class of Antibiotics. *Nat Med*. 2005;11(10):1082–7.
394. Hinzen B, Raddatz S, Paulsen H, et al. Medicinal Chemistry Optimization of Acyldepsipeptides of the Enopeptin Class Antibiotics. *Chem Med Chem*. 2006;1(7):689–93.
395. Johnson KW, Lofland D, Moser HE. PDF Inhibitors: An Emerging Class of Antibacterial Drugs. *Curr Drug Targets Infect Disord*. 2005;5(1):39–52.
396. Aubart K, Zalacain M. Peptide Deformylase Inhibitors. *Prog Med Chem*. 2006;44:109–143.
397. Lofland D, Difuntorum S, Waller A, et al. *In vitro* Antibacterial Activity of the Peptide Deformylase Inhibitor BB-83698. *J Antimicrob Chemother*. 2004;53(4):664–8.





398. Fritsche TR, Sader HS, Cleland R, Jones RN. Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance. *Antimicrob Agents Chemother.* 2005;49(4):1468–76.
399. O'Dwyer K, Hackel M, Hightower S, et al. Comparative Analysis of the Antibacterial Activity of a Novel Peptide Deformylase Inhibitor, GSK1322322. *Antimicrob Agents Chemother.* 2013;57(5):2333–42.
400. Bister B, Bischoff D, Ströbele M, et al. Abyssomicin C-A Polycyclic Antibiotic from a Marine *Verrucospora* Strain as an Inhibitor of the p-Aminobenzoic acid/Tetrahydrofolate Biosynthesis Pathway. *Angew Chem Int Ed.* 2004;43(19):2574–2576.
401. Riedlinger J, Reicke A, Zähler H, et al. Abyssomicins, Inhibitors of the Para-aminobenzoic Acid Pathway Produced by the Marine *Verrucospora* Strain AB-18-032. *J Antibiot (Tokyo).* 2004;57(4):271–9.
402. Keller S, Schadt HS, Ortel I, Süßmuth RD. Action of Atrop-abyssomicin C as an Inhibitor of 4-Amino-4-deoxychorismate Synthase PabB. *Angew Chem Int Ed.* 2007;46(43):8284–6.
403. Fisher M, Basak R, Kalverda AP, Fishwick CW, Turnbull WB, Nelson A. Discovery of Novel FabF Ligands Inspired by Platensimycin by Integrating Structure-based Design with Diversity-oriented Synthetic Accessibility. *Org Biomol Chem.* 2014;12(3):486–94.
404. Ghosh AK, Xi K. A Symmetry-based Concise Formal Synthesis of Platencin, a Novel Lead against "Superbugs". *Angew Chem Int Ed.* 2009;48(29):5372–5.
405. Martens E, Demain AL. Platensimycin and Platencin: Promising Antibiotics for Future Application in Human Medicine. *J Antibiot (Tokyo).* 2011;64(11):705–10.
406. Wang J, Lee V, Sintim HO. Efforts Towards the Identification of Simpler Platensimycin Analogues: The Total Synthesis of Oxazinidiny Platensimycin. *Chemistry.* 2009;15(12):2747–50.
407. Nicolaou KC, Stepan AF, Lister T, et al. Design, Synthesis, and Biological Evaluation of Platensimycin Analogues with Varying Degrees of Molecular Complexity. *J Am Chem Soc.* 2008;130(39):13110–9.
408. Shen HC, Ding FX, Singh SB, et al. Synthesis and Biological Evaluation of Platensimycin Analogs. *Bioorg Med Chem Lett.* 2009;19(6):1623–7.
409. Nicolaou KC, Tang Y, Wang J, Stepan AF, Li A, Montero A. Total Synthesis and Antibacterial Properties of Carbaplatensimycin. *J Am Chem Soc.* 2007;129(48):14850–1.
410. Nicolaou KC, Lister T, Denton RM, Montero A, Edmonds DJ. Adamantaplatensimycin: A Bioactive Analogue of Platensimycin. *Angew Chem Int Ed.* 2007;46(25):4712–4.
411. Young K, Jayasuriya H, Ondeyka JG, et al. Discovery of FabH/FabF Inhibitors from Natural Products. *Antimicrob Agents Chemother.* 2006; 50(2):519–26.
412. Wang J, Soisson SM, Young K, et al. Platensimycin is a Selective FabF Inhibitor with Potent Antibiotic Properties. *Nature.* 2006;441(7091): 358–61.
413. Singh SB, Jayasuriya H, Ondeyka JG, et al. Isolation, Structure, and Absolute Stereochemistry of Platensimycin, a Broad Spectrum Antibiotic Discovered using an Antisense Differential Sensitivity Strategy. *J Am Chem Soc.* 2006;128(36):11916–20.
414. Wang J, Kodali S, Lee SH, et al. Discovery of Platencin, a Dual FabF and FabH Inhibitor with *in vivo* Antibiotic Properties. *Proc Natl Acad Sci.* 2007;104(18):7612–16.
415. Jayasuriya H, Herath KB, Zhang C, et al. Isolation and Structure of Platencin: a FabH and FabF Dual Inhibitor with Potent Broad-spectrum Antibiotic Activity. *Angew Chem Int Ed* 2007;46(25): 4684–8.
416. Allahverdiyev AM, Bagirova M, Abamor ES, et al. The use of Platensimycin and Platencin to Fight Antibiotic Resistance. *Infect Drug Res.* 2013;6:99–114.
417. Claesson A, Jansson AM, Pring BG, Hammond SM, Ekström B. Design and Synthesis of Peptide Derivatives of a 3-Deoxy-D-manno-2-octulosonic acid (KDO) Analogue as Novel Antibacterial Agents Acting upon Lipopolysaccharide Biosynthesis. *J Med Chem.* 1987;30(12):2309–13.
418. Cipolla L, Polissi A, Airoidi C, Galliani P, Sperandio P, Nicotra F. The Kdo Biosynthetic Pathway toward OM Biogenesis as Target in Antibacterial Drug Design and Development. *Curr Drug Discov Technol.* 2009;6(1):19–33.
419. Cipolla L, Polissi A, Airoidi C, Gabrielli L, Merlo S, Nicotra F. New Targets for Antibacterial Design: Kdo Biosynthesis and LPS Machinery Transport to the Cell Surface. *Curr Med Chem.* 2011;18(6):830–52.
420. Kaustov L, Kababya S, Belakhov V, Baasov T, Shoham Y, Schmidt A. Inhibition Mode of a Bisubstrate Inhibitor of KDO8P Synthase: A Frequency-selective REDOR Solid-state and Solution NMR Characterization. *J Am Chem Soc.* 2003;125(15):4662–9.
421. Belakhov V, Dovgolevsky E, Rabkin E, Shulami S, Shoham Y, Baasov T. Synthesis and Evaluation of a Mechanism-based Inhibitor of KDO8P Synthase. *Carbohydr Res.* 2004;339(2):385–92.
422. Coutrot P, Dumarçay S, Finance C, Tabyaoui M, Tabyaoui B, Grison C. Investigation of New Potent KDO-8-phosphate Synthetase Inhibitors. *Bioorg Med Chem Lett.* 1999;9(7):949–52.
423. Baasov T, Sheffer-Dee-Noor S, Kohen A, Jakob A, Belakhov V. Catalytic Mechanism of 3-Deoxy-D-manno-2-octulosonate-8-phosphate Synthase. The use of Synthetic Analogues to Probe the Structure of the Putative Reaction Intermediate. *Eur J Biochem.* 1993;217(3):991–9.
424. Adachi H, Kondo K, Kojima F, et al. Synthesis and Inhibitory Activity of 8-Substituted 2-Deoxy-beta-KDO against CMP-KDO Synthetase. *Nat Prod Res.* 2006;20(4):361–370.
425. Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. Comparative *in vitro* Activities of GSK2251052, a Novel Boron-containing Leucyl-tRNA Synthetase Inhibitor, against 916 Anaerobic Organisms. *Antimicrob Agents Chemother.* 2013;57(5):2401–4.
426. Mendez RE, Biedenbach DJ, Alley MRK, Sader HS, Jones RN, 2011. Potency and Spectrum of Activity of AN3365, a Novel Boron-containing Protein Synthetase Inhibitor, Tested against *Enterobacteriaceae*, abstr F1-1638. Fifty-first Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, 17 to 20 September 2011.
427. Robertson JG. Enzymes as a Special Class of Therapeutic Target: Clinical Drugs and Modes of Action. *Curr Opin Struct Biol.* 2007;17:674–9.